Assessment
and
Treatment
of
Patients
with
Coexisting
Mental
llness
and
Alcohol
or
Other
Drug
Abuse
Treatment
Improvement
Series
TIP#9
Table of
Contents
Chapter 1 --Introduction
Chapter 2 -- Dual Disorders: Concepts
and Definitions
Chapter 3 -- Mental Health And
Addiction Treatment Systems: Phil...
Chapter 4 -- Linkages For Mental
Health and AOD Treatment
Chapter 5 -- Mood Disorders
Chapter 6 -- Anxiety Disorders
Chapter 7 -- Personality Disorders
Chapter 8 -- Psychotic Disorders
Chapter 9 -- Pharmacologic Management
Appendix A -- Bibliography
Appendix B -- Treatment of Patients
With Dual Disorders: Sample ...
Appendix C -- Federal Resource
Panel
Appendix D -- Field Reviewers
Exhibits
Chapter 1 --Introduction
Overview
The treatment needs of patients who have a psychiatric disorder in combination
with an alcohol and other drug (AOD) use disorder differ significantly
from the treatment needs of patients with either an AOD use disorder or
a psychiatric disorder by itself. This Treatment Improvement Protocol (TIP)
consists of recommendations for the treatment of patients with dual disorders.
This TIP was developed by a multidisciplinary consensus panel that included
addiction counselors, social workers, psychologists, psychiatrists, other
physicians, nurses, and program administrators with active clinical involvement
in the treatment of patients with dual disorders. Consumers also participated
on the panel.
This TIP was written principally for addiction treatment staff. However,
it contains information and treatment recommendations that can be used
by healthcare providers in a variety of treatment settings. For example,
it will be useful to people who work in primary care clinics, hospitals,
and various mental health settings. In addition, there are recommendations
that are targeted to administrators and planners of healthcare services.
A thoughtful attempt has been made to include information that the consensus
panel felt was clinically relevant. While many clinical topics are explored
in depth, some are only briefly mentioned, and a few are avoided altogether.
It is not the goal of this TIP to provide an exhaustive description
of all of the possible issues that relate to the treatment of patients
with dual disorders. Rather, the primary goal is to provide treatment recommendations
that are practical and useful.
Indeed, the usefulness of this TIP can be enhanced by blending these
recommendations with those of another TIP such as Intensive Outpatient
Treatment for Alcohol and Other Drug (AOD) Abuse.
By doing so, treatment
protocols can be developed which will meet very specific treatment needs.
Contents
Definitions and Models
Chapter 2 --
Dual
Disorders: Concepts and Definitions -- provides descriptions and diagnostic
criteria for AOD abuse and dependence. There is also a description of the
possible interactions between AOD use and psychiatric symptoms and disorders.
Chapter 3
-- Mental Health and Addiction Treatment Systems: Philosophical and
Treatment Approach Issue -- describes the similarities, differences,
strengths, and weaknesses of the treatment systems used by patients with
dual disorders: the mental health system, the addiction treatment system,
and the medical system. Similarly, there is a description of treatment
models most frequently used: sequential treatment of each disorder, parallel
treatment of each disorder, and integrated treatment of both disorders.
The chapter includes a discussion of critical treatment issues and general
assessment issues in providing care to patients with dual disorders.
Linkages
Chapter 4 --
Linkages
for Mental Health and AOD Treatment -- describes several areas of critical
concern for programs that provide services to patients with dual disorders.
There are discussions regarding policy and planning; funding and reimbursement;
data collection and needs assessment; program development; screening, assessment,
and referral; case management; staffing and training; and linkages with
social service, health care, and the criminal justice systems.
This chapter should be particularly useful for administrators and political
planners who address the potential administrative overlaps and gaps that
exist between the mental health and addiction treatment systems. The semi-outline
format of the chapter will allow planners of services a rapid checkup of
specific areas such as funding and reimbursement, program development,
and case management.
Specific Psychiatric Disorders
While entire books can be written regarding specific psychiatric disorders,
this TIP describes the disorders that account for the majority of psychiatric
problems seen in patients with dual disorders. TIP chapters that address
specific psychiatric problems include Chapter
5, Mood Disorders; Chapter
6, Anxiety Disorders; Chapter
7, Personality Disorders; and Chapter
8, Psychotic Disorders.
By combining chapters, strategies for treating patients with complex
disorders may be developed. For example, by combining techniques recommended
for the treatment of personality and mood disorders, borderline syndrome
treatment strategies can be developed.
Both content and stylistic approaches vary markedly among these chapters,
reflecting the differences of consensus panel members who composed them.
Since these differences in stylistic approaches may be useful to the reader,
they have been retained.
Psychopharmacology
Chapter 9 --
Pharmacologic
Management -- is a brief overview of the types of medications used
in psychiatry and addiction medicine and for patients with dual disorders.
A stepwise treatment model that can minimize medication abuse risks is
discussed, and cautions about drug interactions are reviewed.
Addiction treatment program staff are increasingly encountering patients
who require prescribed medications in order to participate in recovery.
For this reason, it is important for clinical staff to have an understanding
of the principle medications used in psychiatry and how they are used.
In addition, agencies that hire a consulting psychiatrist may want to review
with the psychiatrist the prescribing issues raised in this chapter.
A bibliography is provided for further study in Appendix
A. A brief overview of sample cost data for the treatment of dual disorders
is in Appendix
B. It compares three treatment programs on features such as salary
ranges and administrative costs.
Chapter 2 -- Dual Disorders: Concepts and Definitions
The Relationships Between AOD Use and Psychiatric Symptoms
and Disorders
Establishing an accurate diagnosis for patients in addiction and mental
health settings is an important and multifaceted aspect of the treatment
process. Clinicians must discriminate between acute primary psychiatric
disorders and psychiatric symptoms caused by alcohol and other drugs (AODs).
To do so, clinicians must obtain a thorough history of AOD use and psychiatric
symptoms and disorders.
There are several possible relationships between AOD use and psychiatric
symptoms and disorders. AODs may induce, worsen, or diminish psychiatric
symptoms, complicating the diagnostic process.
The primary relationships between AOD use and psychiatric symptoms or
disorders are described in the following classification model (Landry
et al., 1991a; Lehman
et al., 1989; Meyer,
1986). All of these possible relationships must be considered during
the screening and assessment process.
-
AOD use can cause psychiatric symptoms and mimic psychiatric disorders.
Acute and chronic AOD use can cause symptoms associated with almost any
psychiatric disorder. The type, duration, and severity of these symptoms
are usually related to the type, dose, and chronicity of the AOD use.
-
Acute and chronic AOD use can prompt the development, provoke the reemergence,
or worsen the severity of psychiatric disorders.
-
AOD use can mask psychiatric symptoms and disorders. Individuals may use
AODs to purposely dampen unwanted psychiatric symptoms and to ameliorate
the unwanted side effects of medications. AOD use may inadvertently hide
or change the character of psychiatric symptoms and disorders.
-
AOD withdrawal can cause psychiatric symptoms and mimic psychiatric syndromes.
Cessation of AOD use following the development of tolerance and physical
dependence causes an abstinence phenomenon with clusters of psychiatric
symptoms that can also resemble psychiatric disorders.
-
Psychiatric and AOD disorders can coexist. One disorder may prompt the
emergence of the other, or the two disorders may exist independently. Determining
whether the disorders are related may be difficult, and may not be of great
significance, when a patient has long-standing, combined disorders. Consider
a 32-year-old patient with bipolar disorder whose first symptoms of alcohol
abuse and mania started at age 18, who continues to experience alcoholism
in addition to manic and depressive episodes. At this point, the patient
has two well-developed independent disorders that both require treatment.
-
Psychiatric behaviors can mimic behaviors associated with AOD problems.
Dysfunctional and maladaptive behaviors that are consistent with AOD abuse
and addiction may have other causes, such as psychiatric, emotional, or
social problems. Multidisciplinary assessment tools, drug testing, and
information from family members are critical to confirm AOD disorders.
The symptoms of a coexisting psychiatric disorder may be misinterpreted
as poor or incomplete "recovery" from AOD addiction. Psychiatric disorders
may interfere with patients' ability and motivation to participate in addiction
treatment, as well as their compliance with treatment guidelines.
For example, patients with anxiety and phobias may fear and resist attending
Alcoholics Anonymous or group meetings. Depressed people may be too unmotivated
and lethargic to participate in treatment. Patients with psychotic or manic
symptoms may exhibit bizarre behavior and poor interpersonal relations
during treatment, especially during group-oriented activities. Such behaviors
may be misinterpreted as signs of treatment resistance or symptoms of addiction
relapse.
AOD Use and Psychiatric Symptoms
-
AOD use can cause psychiatric symptoms and mimic psychiatric syndromes.
-
AOD use can initiate or exacerbate a psychiatric disorder.
-
AOD use can mask psychiatric symptoms and syndromes.
-
AOD withdrawal can cause psychiatric symptoms and mimic psychiatric syndromes.
-
Psychiatric and AOD use disorders can independently coexist.
-
Psychiatric behaviors can mimic AOD use problems.
The Terminology of Dual Disorders
The term dual diagnosis is a common, broad term that indicates the
simultaneous presence of two independent medical disorders. Recently, within
the fields of mental health, psychiatry, and addiction medicine, the term
has been popularly used to describe the coexistence of a mental health
disorder and AOD problems. The equivalent phrase dual disorders also
denotes the coexistence of two independent (but invariably interactive)
disorders, and is the preferred term used in this Treatment Improvement
Protocol (TIP).
The acronym MICA, which represents the phrase mentally ill
chemical abusers, is occasionally used to designate people who have
an AOD disorder and a markedly severe and persistent mental disorder such
as schizophrenia or bipolar disorder. A preferred definition is mentally
ill chemically affected people, since the word affected better
describes their condition and is not pejorative. Other acronyms are also
used: MISA (mentally ill substance abusers), CAMI (chemical
abuse and mental illness), and SAMI (substance abuse and mental
illness).
Common examples of dual disorders include the combinations of major
depression with cocaine addiction, alcohol addiction with panic disorder,
alcoholism and polydrug addiction with schizophrenia, and borderline personality
disorder with episodic polydrug abuse. Although the focus of this volume
is on dual disorders, some patients have more than two disorders, such
as cocaine addiction, personality disorder, and AIDS. The principles that
apply to dual disorders generally apply also to multiple disorders.
The combinations of AOD problems and psychiatric disorders vary along
important dimensions, such as severity, chronicity, disability, and degree
of impairment in functioning. For example, the two disorders may each be
severe or mild, or one may be more severe than the other. Indeed, the severity
of both disorders may change over time. Levels of disability and impairment
in functioning may also vary.
Thus, there is no single combination of dual disorders; in fact, there
is great variability among them. However, patients with similar combinations
of dual disorders are often encountered in certain treatment settings.
For instance, some methadone treatment programs treat a high percentage
of opiate-addicted patients with personality disorders. Patients with schizophrenia
and alcohol addiction are frequently encountered in psychiatric units,
mental health centers, and programs that provide treatment to homeless
patients.
Patients with mental disorders have an increased risk for AOD disorders,
and patients with AOD disorders have an increased risk for mental disorders.
For example, about one-third of patients who have a psychiatric disorder
also experience AOD abuse at some point (Regier
et al., 1990), which is about twice the rate among people without psychiatric
disorders. Also, more than half of the people who use or abuse AODs have
experienced psychiatric symptoms significant enough to fulfill diagnostic
criteria for a psychiatric disorder (Regier
et al., 1990; Ross
et al., 1988), although many of these symptoms may be AOD related and
might not represent an independent condition.
Compared with patients who have a mental health disorder or an AOD use
problem alone, patients with dual disorders often experience more severe
and chronic medical, social, and emotional problems. Because they have
two disorders, they are vulnerable to both AOD relapse and a worsening
of the psychiatric disorder. Further, addiction relapse often leads to
psychiatric decompensation, and worsening of psychiatric problems often
leads to addiction relapse. Thus, relapse prevention must be specially
designed for patients with dual disorders. Compared with patients who have
a single disorder, patients with dual disorders often require longer treatment,
have more crises, and progress more gradually in treatment.
Psychiatric disorders most prevalent among dually diagnosed patients
include mood disorders, anxiety disorders, personality disorders, and psychotic
disorders. Each of these clusters of disorders and symptoms is dealt with
in more detail in separate chapters.
AOD Abuse, Addiction, Dependence, Misuse
The characteristic feature of AOD abuse is the presence of dysfunction
related to the person's AOD use. The Diagnostic and Statistical Manual
of Mental Disorders (DSM-III-R), produced by the American Psychiatric
Association and updated periodically, is used throughout the medical and
mental health fields for diagnosing psychiatric and AOD use disorders.
It provides clinicians with a common language for communicating about these
disorders and for making clinical decisions based on current knowledge.
For each diagnosis, the manual lists symptom criteria, a minimum number
of which must be met before a definitive diagnosis can be given to a patient.
Criteria for AOD abuse hinge on the individual's continued use of a
drug despite his or her knowledge of "persistent or recurrent social, occupational,
psychologic, or physical problems caused or exacerbated by the use of the
[drug]" (American
Psychiatric Association, 1987). Alternately, there can be "recurrent
use in situations in which use is physically hazardous." The DSM-IV draft
continues this emphasis (American
Psychiatric Association, 1993).
Thus, AOD abuse is defined as the use of a psychoactive drug to such
an extent that its effects seriously interfere with health or occupational
and social functioning. AOD abuse may or may not involve physiologic dependence
or tolerance. Importantly, evidence of physiologic dependence and tolerance
is not sufficient for diagnosis of AOD abuse. For example, use of AODs
in weekend binge patterns may not involve physiologic dependence, although
it has adverse effects on a person's life.
AOD Abuse
-
Significant impairment or distress resulting from use
-
Failure to fulfill roles at work, home, or school
-
Persistent use in physically hazardous situations
-
Recurrent legal problems related to use
-
Continued use despite interpersonal problems
Therefore, screening questions should relate to life problems that result
from AOD use, taking into consideration that patients may not have the
insight to perceive that their life problems are caused by AOD abuse.
The phrase AOD addiction (called "psychoactive substance dependence"
in the DSM-III-R and "substance dependence" in the DSM-IV draft) is an
often progressive process that typically includes the following aspects:
1) compulsion to acquire and use AODs and preoccupation with their acquisition
and use, 2) loss of control over AOD use or AOD-induced behavior, 3) continued
AOD use despite adverse consequences, 4) a tendency toward relapse following
periods of abstinence, and 5) tolerance and/or withdrawal symptoms.
AOD Addiction or Dependence
-
Pathologic, often progressive and chronic process
-
Compulsion and preoccupation with obtaining a drug or drugs
-
Loss of control over use or AOD-induced behavior
-
Continued use despite adverse consequences
-
Tendency for relapse after period of abstinence
-
Increased tolerance and characteristic withdrawal (but not necessary or
sufficient for diagnosis).
The DSM-III-R describes nine diagnostic criteria (shown
in Exhibit 2-1), of which three or more must be present for a month
or more to establish a diagnosis of dependence. Screening questions can
be based on these criteria. The DSM-IV draft committee deleted DSM-III-R
criterion 4 and the requirement of symptoms being present for at least
1 month. The DSM-IV draft emphasizes the symptoms of tolerance and withdrawal,
which the draft committee placed at the top of the list of criteria.
In the DSM-III-R, criteria 1 and 2 deal with loss of control; criterion
3 addresses time involvement; criteria 4 and 5 relate to social dysfunction;
criterion 6 relates to continued use despite adverse consequences;and criteria
7, 8, and 9 relate to the development of tolerance and withdrawal. It is
important to note that tolerance, physiologic dependence, and withdrawal
are neither necessary nor sufficient for the establishment of a diagnosis
of AOD addiction.
The term AOD dependence can be confusing because it has multiple
meanings. The DSM-III-R uses the phrase "psychoactive substance dependence"
to describe the process of addiction, while many pharmacologists use the
term "dependence" exclusively for describing the biologic aspects of physical
tolerance and/or withdrawal. The American Society of Addiction Medicine
describes drug dependence as having two possible components: 1) psychologic
dependence and 2) physical dependence.
Psychologic dependence centers on the user's need of a drug to
reach a level of functioning or feeling of well-being. Because this term
is particularly subjective and almost impossible to quantify, it is of
limited usefulness in making a diagnosis.
Physical dependence refers to the issues of physiologic dependence,
establishment of tolerance, and evidence of an abstinence syndrome or withdrawal
upon cessation of AOD use. In this case, AOD type, volume, and chronicity
are the important variables: Given a certain substance, the higher the
dose and longer the period of consumption, the more likely is the development
of tolerance, dependence, and subsequent withdrawal symptoms. Physical
dependence and tolerance are best understood as two of many possible consequences
(which may or may not include addiction and abuse) of chronic exposure
to psychoactive substances.
Among patients with a psychiatric problem, any AOD use -- whether abuse
or not -- can have adverse consequences. This is especially true for patients
with severe psychiatric disorders and patients who are taking prescribed
medications for psychiatric disorders. For patients with psychiatric disorders,
the infrequent consumption of alcohol can lead to serious problems such
as adverse medication interactions, decreased medication compliance, and
AOD abuse. Screening questions can relate to evidence of any use of alcohol
and other drugs, as well as frequency, dose, and duration.
Medication misuse describes the use of prescription medications
outside of medical supervision or in a manner inconsistent with medical
advice. While medication misuse is not an abuse problem per se, it is a
high-risk behavior that: 1) may or may not involve AOD abuse, 2) may or
may not lead to AOD abuse, 3) may represent medication noncompliance and
promote the reemergence of psychiatric symptoms, and 4) may cause toxic
effects and psychiatric symptoms if it involves overdose.
Thus, some patients may consume medications at higher or lower doses
than recommended or in combination with AODs. Also, certain patients may
respond to prescribed psychoactive medications by developing compulsive
use and loss of control over their use.
Chapter 3 -- Mental Health And Addiction Treatment Systems:
Philosophical and Treatment Approach Issues
Introduction
For people with dual disorders, the attempt to obtain professional help
can be bewildering and confusing. They may have problems arising within
themselves as a result of their psychiatric and AOD use disorders as well
as problems of external origin that derive from the conflicts, limitations,
and clashing philosophies of the mental health and addiction treatment
systems. For example, internal problems such as frustration, denial, or
depression may hinder their ability to recognize the need for help and
diminish their ability to ask for help. A typical external problem might
be the confusion experienced when individuals need services but lack knowledge
about the different goals and processes of various types of available services.
Other problems of external origin may be very fundamental, such as the
inability to pay for child care services or the lack of transportation
to the only available outpatient program.
Historically, when patients in AOD treatment exhibited vivid and acute
psychiatric symptoms, the symptoms were either: 1) unrecognized, 2) observed
but misdescribed as toxicity or "acting-out behavior," or 3) accurately
identified, prompting the patients to be discharged or referred to a mental
health program. Virtually the same process occurred for patients in mental
health treatment who exhibited vivid and acute symptoms of AOD use disorders.
Mislabeling, rejecting, failing to recognize, or automatically transferring
patients with dual disorders can result in inadequate treatment, with patients
falling between the cracks of treatment systems. The symptoms of psychiatric
and AOD use disorders often fluctuate in intensity and frequency. Current
symptom presentation may reflect a short-term change in the course of long-term
dual disorders. Thus, even when patients receive traditional professional
help, treatment may address only selected aspects of their overall problem
unless treatment is coordinated among services including AOD, mental health,
social, and medical programs.
As a result, the treatment system itself may be a stumbling block for
some people attempting to receive ongoing, appropriate, and comprehensive
treatment for combined psychiatric and AOD use disorders. Thus, treatment
services for patients with dual disorders must be sensitive to both the
individual's and the treatment system's impediments to the initiation and
continuation of treatment.
Treatment Systems: Mental Health, Addiction, And Medical
People with dual disorders who want to engage in the treatment process
(or who need to do so) frequently encounter not one but several treatment
systems, each having its own strengths and weaknesses. These treatment
systems have different clinical approaches.
The Mental Health System
Actually, there is no single mental health system, although most States
have a set of public mental health centers. Rather, mental health services
are provided by a variety of mental health professionals including psychiatrists;
psychologists; clinical social workers; clinical nurse specialists; other
therapists and counselors including marriage, family, and child counselors
(MFCCs); and paraprofessionals.
These mental health personnel work in a variety of settings, using a
variety of theories about the treatment of specific psychiatric disorders.
Different types of mental health professionals (for example, social workers
and MFCCs) have differing perspectives; moreover, practitioners within
a given group often use different approaches.
A major strength of the mental health system is the comprehensive array
of services offered, including counseling, case management, partial hospitalization,
inpatient treatment, vocational rehabilitation, and a variety of residential
programs. The mental health system has a relatively large variety of treatment
settings. These settings are designed to provide treatment services for
patients with acute, subacute, and long-term symptoms. Acute services are
provided by personnel in emergency rooms and hospital units of several
types and by crisis-line personnel, outreach teams, and mental health law
commitment specialists. Subacute services are provided by hospitals, day
treatment programs, mental health center programs, and several types of
individual practitioners. Long-term settings include mental health centers,
residential units, and practitioners' offices. Clinicians vary with regard
to academic degrees, styles, expertise, and training. Another strength
of the mental health system is the growing recognition at all system levels
of the role of case management as a means to individualize and coordinate
services and secure entitlements.
Medication is more often used in psychiatric treatment than in addiction
treatment, especially for severe disorders. Medications used to treat psychiatric
symptoms include psychoactive and nonpsychoactive medications. Psychoactive
medications cause an acute change in mood, thinking, or behavior, such
as sedation, stimulation, or euphoria.
Psychoactive medications (such as benzodiazepines) prescribed to the
average patient with psychiatric problems are generally taken in an appropriate
fashion and pose little or no risk of abuse or addiction. In contrast,
the use of psychoactive medications by patients with a personal or family
history of an AOD use disorder is associated with a high risk of abuse
or addiction.
Some medications used in psychiatry that have mild psychoactive effects
(such as some tricyclic antidepressants with mild sedative effects) appear
to be misused more by patients with an AOD disorder than by others. Thus,
a potential pitfall is prescribing psychoactive medications to a patient
with psychiatric problems without first determining whether the individual
also has an AOD use disorder.
While most clinicians in the mental health system generally have expertise
in a biopsychosocial approach to the identification, diagnosis, and treatment
of psychiatric disorders, some lack similar skills and knowledge about
the specific drugs of abuse, the biopsychosocial processes of abuse and
addiction, and AOD treatment, recovery, and relapse. Similarly, AOD treatment
professionals may have a thorough understanding of AOD abuse treatment
but not psychiatric treatment.
The Addiction Treatment System
As with mental health treatment, no single addiction treatment system exists.
Rather, there is a collection of different types of services such as social
and medical model detoxification programs, short- and long-term treatment
programs, methadone detoxification and maintenance programs, long-term
therapeutic communities, and self-help adjuncts such as the 12-step programs.
These programs can vary greatly with respect to treatment goals and philosophies.
For example, abstinence is a prerequisite for entry into some programs,
while it is a long-term goal in other programs. Some AOD treatment programs
are not abstinence oriented. For example, some methadone maintenance programs
have the overt goal of eventual abstinence for all patients, while others
promote continued methadone use to encourage psychosocial stabilization.
As with mental health treatment, addiction treatment is provided by
a diverse group of practitioners, including physicians, psychiatrists,
psychologists, certified addiction counselors, MFCCs, and other therapists,
counselors, and recovering paraprofessionals. There can be a wide difference
in experience, expertise, and knowledge among these diverse providers.
As with mental health treatment, most States have public and private AOD
treatment systems.
The strengths of addiction treatment services include the multidisciplinary
team approach with a biopsychosocial emphasis, and an understanding of
the addictive process combined with knowledge of the drugs of abuse and
the 12-step programs. In typical addiction treatment, medications are used
to treat the complications of addiction, such as overdose and withdrawal.
However, few medications that directly treat or interrupt the addictive
process, such as disulfiram and naltrexone, have been identified or regularly
used. Maintenance medications such as methadone are crucial for certain
patients. However, most addiction treatment professionals attempt to eliminate
patients' use of all drugs.
Similarities of Mental Health and Addiction Treatment Systems
-
Variety of treatment settings and program types
-
Public and private settings
-
Multiple levels of care
-
Biopsychosocial models
-
Increasing use of case and care management
-
Value of self-help adjuncts.
Many who work in the addiction treatment field have only a limited understanding
of medications used for psychiatric disorders. Historically, some people
have mistakenly assumed that all or most psychiatric medications are psychoactive
or potentially addictive. Many addiction treatment staff tend to avoid
the use of any medication with their patients, probably in reaction to
those whose addiction included prescription medications such as diazepam
(Valium). Many staff have a lack of training and experience in the use
of such medications. In the treatment of dual disorders, a balance must
be made between behavioral interventions and the appropriate use of nonaddicting
psychiatric medications for those who need them to participate in the recovery
process. Withholding medications from such individuals increases their
chances of AOD relapse.
An important adjunct to addiction treatment services is the massive
system of consumer-developed groups, such as the 12-step program of Alcoholics
Anonymous (AA). Participants in AA and other self-help groups (Narcotics
Anonymous [NA], Cocaine Anonymous [CA], etc.) can provide needed support
and encouragement for patients in treatment. Importantly, these services
are widespread nationally and internationally. While self-help programs
are not considered treatment per se, they are integral adjuncts to professional
treatment services.
However, patients in self-help groups may give others inappropriate
advice regarding medication compliance, based on personal experience, fears
of medication, or incomplete knowledge about the role of medication in
dual disorders. In many urban areas, there are specialized 12-step groups
for people with dual disorders. In these so-called "Double Trouble" meetings,
medication compliance is a part of "working the program."
The Medical System
Primary health care providers (physicians and nurses) have historically
been the largest single point of contact for patients seeking help with
psychiatric and AOD use disorders. Physicians and nurses are uniquely qualified
to manage life-threatening crises and to treat medical problems related
and unrelated to psychiatric and substance use disorders. And because they
are in contact with such large numbers of patients, they have an exceptional
opportunity to screen and identify patients with psychiatric and AOD disorders.
However, physicians -- especially primary care physicians -- are able
to devote very little time to each patient. Pressured for time, these physicians
may prescribe such psychiatric medications as antidepressants or anxiolytics
or medication such as disulfiram or naltrexone as a primary approach, rather
than as an adjunctive approach. Indeed, primary care physicians are the
largest single prescriber of antianxiety medications. Some of these medications,
such as the benzodiazepines, are psychoactive and can be abused.
Also, physicians and nurses have historically been trained to focus
on the medical consequences of addiction, such as withdrawal, overdose,
or hepatitis, without assessing, treating, or actively referring the individual
for treatment of the addiction itself. The role of physicians with regard
to addiction is changing through the leadership of national organizations
such as the American Society of Addiction Medicine, the American Academy
of Psychiatrists on Alcohol and Addiction, and the Association of Medical
Education and Research on Substance Abuse. Similar groups exist for nurses
and allied health care professionals. Such groups can provide medical professionals
with important information and education about the biopsychosocial nature
of addiction and treatment, especially regarding patients with dual disorders.
Differing Approaches: Individual Responsibility and
Treatment Focus
Traditionally, patients in mental health settings have had the responsibility
of getting themselves to treatment services and appointments as a sign
of treatment motivation. More recently, and in recognition that many severely
mentally ill patients are unwilling or unable to use traditional community-based
services, the mental health field has emphasized the role of case management.
Case management (also called care management) can help to engage, link,
and support patients in needed community services. Case management can
help to reduce the negative consequences to the individual from lack of
followup and participation in treatment. Without case management, many
severely ill patients would decompensate, need to be hospitalized, or become
homeless.
The case management model identifies individual limitations, deficits,
and strengths and aggressively attempts to provide patients with what they
need. When a patient rejects professional assistance, the case manager
assumes the responsibility for finding a different way to get the individual
to accept assistance. The case manager may minimize the negative consequences
to the individual in order to engage or maintain the patient in treatment.
This activity might be seen as "enabling" by traditional addiction treatment
personnel.
In contrast, the addiction treatment system focuses on individual responsibility,
including the responsibility of accepting help. Motivation for recovery
is enhanced through confrontation of the adverse consequences of addiction.
Further, addiction intervention and treatment involve diminishing the individual's
denial about the presence and severity of the addiction through direct
but therapeutic confrontation of examples of addiction-related behaviors.
Thus, traditionally, patients in the addiction treatment system who did
not want help or could not tolerate confrontation might not get help. Mental
health personnel might regard this situation as an abandonment of the most
needy. More recently, the addiction treatment system has been developing
case management models to better address treatment-resistant patients.
Treatment of patients with dual disorders must blend both mental health
and AOD treatment models, with each applied at appropriate times and in
appropriate situations according to patients' needs. There should be a
balance between clinician and patient acceptance of responsibility for
treatment and recovery from dual disorders.
For example, in AOD treatment, clinical staff and fellow patients often
aggressively confront patients who deny that they have an AOD problem or
who minimize the severity of their problem. However, treatment of individuals
with dual disorders first requires innovative approaches to engage them
in treatment as a prerequisite to confrontation. The role of confrontation
may need to be substantially modified, particularly in the treatment of
disorganized or psychotic patients, who may tolerate confrontation only
in later stages of treatment (when their symptoms are stable and they are
engaged in the treatment process).
In addiction treatment, the focus is often on the "here and now," while
in mental health treatment, the focus is often on past developmental issues.
Mental health practitioners may identify AOD abuse as a symptom of a prior
trauma rather than an illness in its own right. The focus of treatment
may be on the developmental issues, with the assumption that the AOD use
disorder will improve automatically once these issues are treated. Inadvertently,
the mental health therapist can enable AOD use to continue.
The Role of Abstinence
Within parts of the addiction treatment system, abstinence from psychoactive
drugs is a precondition to participate in treatment. For the more severely
ill patients with dual disorders (such as patients with schizophrenia),
abstinence from AODs is often considered a goal, possibly a long-term goal,
similar to the approach at some methadone maintenance programs. On the
other hand, treatment of less severe dual psychiatric conditions, such
as depression or panic disorder, should require AOD abstinence, since AOD
use compromises both diagnosis and treatment (see individual chapters).
For some patients with dual disorders, requiring abstinence as a condition
of entering treatment may hinder or discourage engagement in the treatment
process. For these patients, abstinence may be redefined as a goal, with
encouragement provided for incremental steps in the reduction of amount
and frequency of drug use. For example, patients who experience homelessness
and housing instability likely do not live in drug-free environments. For
such patients, it may be unrealistic to mandate abstinence as a requirement
for treatment. Exhibit
3-1 describes some of the treatment strategy differences for managing
patients in mental health, addiction, and dual disorder treatment approaches.
Treatment Models: Sequential, Parallel, Or Integrated
As the mental health and AOD abuse treatment fields have become increasingly
aware of the existence of patients with dual disorders, various attempts
have been made to adapt treatment to the special needs of these patients
(Baker,
1991;
Lehman
et al., 1989; Minkoff,
1989; Minkoff
and Drake, 1991; Ries,
1993a). These attempts have reflected philosophical differences about
the nature of dual disorders, as well as differing opinions regarding the
best way to treat them. These attempts also reflect the limitations of
available resources, as well as differences in treatment responses for
different types and severities of dual disorders. Three approaches have
been taken to treatment.
Sequential Treatment
The first and historically most common model of dual disorder treatment
is sequential treatment. In this model of treatment, the patient is treated
by one system (addiction or mental health) and then by the other. Indeed,
some clinicians believe that addiction treatment must always be initiated
first, and that the individual must be in a stage of abstinent recovery
from addiction before treatment for the psychiatric disorder can begin.
On the other hand, other clinicians believe that treatment for the psychiatric
disorder should begin prior to the initiation of abstinence and addiction
treatment. Still other clinicians believe that symptom severity at the
time of entry to treatment should dictate whether the individual is treated
in a mental health setting or an addiction treatment setting or that the
disorder that emerged first should be treated first.
The term sequential treatment describes the serial or nonsimultaneous
participation in both mental health and addiction treatment settings. For
example, a person with dual disorders may receive treatment at a community
mental health center program during occasional periods of depression and
attend a local AOD treatment program following infrequent alcoholic binges.
Systems that have developed serial treatment approaches generally incorporate
one of the above orientations toward the treatment of patients with dual
disorders.
Parallel Treatment
A related approach involves parallel treatment: the simultaneous
involvement of the patient in both mental health and addiction treatment
settings. For example, an individual may participate in AOD education and
drug refusal classes at an addiction treatment program, participate in
a 12-step group such as AA, and attend group therapy and medication education
classes at a mental health center. Both parallel and sequential treatment
involve the utilization of existing treatment programs and settings. Thus,
mental health treatment is provided by mental health clinicians, and addiction
treatment is provided by addiction treatment clinicians. Coordination between
settings is quite variable.
Integrated Treatment
A third model, called integrated treatment, is an approach that
combines elements of both mental health and addiction treatment into a
unified and comprehensive treatment program for patients with dual disorders.
Ideally, integrated treatment involves clinicians cross-trained in both
mental health and addiction, as well as a unified case management approach,
making it possible to monitor and treat patients through various psychiatric
and AOD crises.
There are advantages and disadvantages in sequential, parallel, and
integrated treatment approaches. Differences in dual disorder combinations,
symptom severity, and degree of impairment greatly affect the appropriateness
of a treatment model for a specific individual. For example, sequential
and parallel treatment may be most appropriate for patients who have a
very severe problem with one disorder, but a mild problem with the other.
However, patients with dual disorders who obtain treatment from two separate
systems frequently receive conflicting therapeutic messages; in addition,
financial coverage and even confidentiality laws vary between the two systems.
Treatment Models
-
Sequential: The patient participates in one system, then the other.
-
Parallel: The patient participates in two systems simultaneously.
-
Integrated: The patient participates in a single unified and comprehensive
treatment program for dual disorders.
In contrast, integrated treatment places the burden of treatment continuity
on a case manager who is expert in both psychiatric and AOD use disorders.
Further, integrated treatment involves simultaneous treatment of both disorders
in a setting designed to accommodate both problems.
Critical Treatment Issues For Dual Disorders
Mental health and addiction treatment programs that are being designed
to accommodate patients with dual disorders should be modified to address
the specific needs of these patients. Although there are different dual
disorder treatment models, all such programs must address several key issues
that are critical for successful treatment. These issues include: 1) treatment
engagement, 2) treatment continuity and comprehensiveness, 3) treatment
phases, and 4) continual reassessment and rediagnosis.
Treatment Engagement
In general, treatment engagement refers to the process of initiating and
sustaining the patient's participation in the ongoing treatment process.
Engagement can involve such enticements as providing help with the procurement
of social services, such as food, shelter, and medical services. Engagement
can also involve removing barriers to treatment and making treatment more
accessible and acceptable, for example, by providing day and evening treatment
services. Engagement can be enhanced by providing adjunctive services that
may appear to be indirectly related to the disorders, such as child care
services, job skills counseling, and recreational activities. It may also
be coercive, such as through involuntary commitment or a designated payee.
Engagement begins with efforts that are designed to enlist people into
treatment, but it is a long-term process with the goals of keeping patients
in treatment and helping them manage ongoing problems and crises. Essential
to the engagement process is: 1) a personalized relationship with the individual,
2) over an extended period of time, with 3) a focus on the stated needs
of the individual.
For patients with dual disorders, engagement in the treatment process
is essential, although the techniques used will depend upon the nature,
severity, and disability caused by an individual's dual disorders. An employed
person with panic disorder and episodic alcohol abuse will require a different
type of engagement than a homeless person with schizophrenia and polysubstance
dependence. With respect to severe conditions such as psychosis and violent
behaviors, therapeutic coercive engagement techniques may include involuntary
detoxification, involuntary psychiatric treatment, or court-mandated acute
treatment.
Treatment Continuity
To treat patients with dual disorders, it is critical to develop continuity
between treatment programs and treatment components, as well as treatment
continuity over time. In practice, many patients participate in treatment
at different sites. Even in integrated treatment programs, many patients
require different treatment services during different phases of treatment.
For this reason, treatment should include an integrated dual disorder case
management program, which can be located within a mental health setting,
an addiction treatment setting, or a collaborative program.
Treatment Comprehensiveness
An overall system for treating dual disorders includes mental health and
addiction treatment programs, as well as collaborative integrated programs.
Programs should be designed to: 1) engage clients, 2) accommodate various
levels of severity and disability, 3) accommodate various levels of motivation
and compliance, and 4) accommodate patients in different phases of treatment.
There should be access to abstinence-mandated programs and abstinence-oriented
programs, as well as to drug maintenance programs. Different levels of
care, ranging from more to less intense treatment, should be available.
Phases of Treatment
In general, the medical term acute describes phenomena that begin
quickly and require rapid response. Acute problems are contrasted with
chronic problems. Most commonly, acute stabilization of patients with dual
disorders refers to the management of physical, psychiatric, or drug toxicity
crises. These include injury, illness, AOD-induced toxic or withdrawal
states, and behavior that is suicidal, violent, impulsive, or psychotic.
The acute stabilization of AOD use disorders typically begins with detoxification,
such as inpatient detoxification for patients with significant withdrawal
or outpatient detoxification for mild to moderate withdrawal, as well as
nonmedical withdrawal, such as occurs in social-model detoxification programs.
Also, initiation of methadone maintenance can provide outpatient acute
stabilization for patients addicted to opioids.
Acute stabilization of psychiatric symptoms more frequently occurs within
a mental health or emergency medical setting, but involves a range of treatment
intensity. Patients with severe symptoms, especially psychotic, violent,
or impulsive behaviors, usually require acute psychiatric inpatient treatment
and psychiatric medications, while patients with less severe symptoms can
be treated in outpatient or day treatment settings.
Dual disorder programs that provide stabilization to patients with acute
needs should have the capability to:
-
Identify medical, psychiatric, and AOD use disorders
-
Treat a range of illness severity
-
Provide drug detoxification, psychiatric medications, and other biopsychosocial
levels of treatment
-
Provide a range of intensities of service.
These programs should be capable of promoting the patient's engagement
with the treatment system. They should be able to aggressively provide
linkages to other programs that will provide ongoing treatment and engagement.
Subacute Stabilization
The medical term subacute describes the status of a medical disorder
at points between the acute condition and either resolution or chronic
state. The subacute phase of a medical problem occurs as the acute course
of the problem begins to diminish, or when symptoms emerge or reemerge
but are not yet severe enough to be described as acute.
For example, patients recently detoxified from AODs frequently experience
subacute symptoms such as insomnia and anxiety that may linger for a few
days or weeks. On the other hand, recently detoxified patients with dual
disorders may experience subacute symptoms of insomnia and anxiety either
as subacute withdrawal symptoms or as a prelude to relapse with depression.
Although the subacute phase is not generally regarded as a period of crisis,
ignoring these symptoms and failing to assess and treat them may lead to
symptom escalation, decompensation, and relapse.
As AOD-induced toxic or withdrawal symptoms resolve, constant reassessment
and rediagnosis is required. During this phase, a psychoeducational and
behavioral approach should be used to educate patients about their disorders
and symptomatology. During this phase, treatment providers should provide
assessment and planning for dealing with long-term issues such as housing,
long-term treatment, and financial stability.
Biopsychosocial Assessment Issues From the AOD and Psychiatric Perspectives
|
AOD |
Psychiatric |
| Biological: |
Alcohol on breath
Positive drug tests
Abnormal laboratory tests
Injuries and trauma
Toxicity and withdrawal
Impaired cognition |
Abnormal laboratory tests
Neurological exams
Using psychiatric medications
Other medications, conditions |
| Psychological: |
Intoxicated behavior
Withdrawal symptoms
Denial and manipulation
Responses to AOD assessments
AOD use history |
Mental status exam: Affect mood, psychosis, etc.
Stress, situational factors
Self-image, defenses, etc. |
| Social: |
Collateral information from others
Social interactions and lifestyle
Involvement with other AOD groups
Family history of AOD use disorders
Family history
Housing and employment histories |
Support systems: Family, friends, others
Current psychiatric therapy
Hospitalization |
ABC Model for Psychiatric Screening
-
Appearance, alertness, affect, and anxiety:
-
Appearance:
-
General appearance, hygiene, and dress.
-
Alertness:
-
What is the level of consciousness?
-
Affect:
-
Elation or depression: gestures, facial expression, and speech.
-
Anxiety:
-
Is the individual nervous, phobic, or panicky?
-
Behavior:
-
Movements:
-
Rate (Hyperactive, hypoactive, abrupt, or constant?).
-
Organization:
-
Coherent and goal-oriented?
-
Purpose:
-
Bizarre, stereotypical, dangerous, or impulsive?
-
Speech:
-
Rate, organization, coherence, and content.
-
Cognition:
-
Orientation:
-
Person, place, time, and condition.
-
Calculation:
-
Memory and simple tasks.
-
Reasoning:
-
Insight, judgment, problem solving.
-
Coherence:
-
Incoherent ideas, delusions, and hallucinations?
Long-Term Stabilization
The treatment settings for long-term treatment, rehabilitation, and recovery
from dual disorders include outpatient, day treatment, and residential
settings. Ideally, treatment intensity is dictated by disorder severity
and motivation for treatment, as well as by personal and local treatment
resources. In more severe conditions, ongoing dual disorder case management
is essential. The management of long-term severe conditions is described
in more detail in the chapter on psychotic disorders (Chapter
8).
With regard to the initiation and maintenance of sobriety in patients
with dual disorders, another way of looking at acute, subacute, and long-term
phases involves a four-step approach that leads to abstinence. This approach
is particularly important for patients with severe psychiatric problems
and an AOD use disorder (Minkoff
and Drake, 1991; Ries,
1993a).
Individual case management.
Individual case management provides an initial introduction to treatment
goals and concepts and may provide assistance with regard to crises, housing,
and entitlements. An individual treatment plan is developed.
Persuasion groups.
Patients who display strong denial about their AOD use disorder and lack
motivation can attend persuasion groups, which provide basic AOD education
and treatment engagement. Premature, potent, and direct confrontation and
an insistence on abstinence should be avoided since these approaches may
prompt more fragile patients to leave treatment.
Active treatment groups.
Active treatment groups consist of patients who have accepted the goal
of abstinence and are relatively mentally stable. These groups use supervised
peer confrontation and a psychoeducational-behavioral approach to AOD abuse.
Abstinence support groups.
Finally, abstinence support groups consist of patients who are essentially
committed to abstinence and are relatively stable mentally, who require
ongoing education and support for sobriety and the development of relapse
prevention skills.
Psychiatric and AOD abuse treatment issues are woven into the groups
in such a way that concrete issues (such as medication compliance) are
addressed in persuasion groups, while abstract concepts (such as self-image)
are addressed in active treatment or abstinence support groups. Some patients
-- such as severely psychotic patients -- may not be able to advance beyond
persuasion groups or active treatment groups.
General Assessment Issues
Each of the following chapters will address assessment and evaluation issues
relative to specific psychiatric disorders. Specific assessment tools may
be recommended for certain interventions and certain settings. Irrespective
of the treatment or intervention setting, and notwithstanding the crisis
that may have initiated the treatment contact, all treatment contacts with
patients who may have dual disorders should include a basic screening for
psychiatric and AOD use disorders. These issues are addressed in detail
in the chapters on mood, personality, and psychotic disorders. With respect
to both psychiatric and AOD use disorders, the assessment process should
be sensitive to biological, psychological, and social issues.
Full assessments of patients with dual disorders should be performed
by clinicians who have certified training in the areas that they assess.
However, clinicians who are not certified can learn to perform screening
tests. Assessments of patients who may have dual disorders should include
at least a brief mental status exam to assess for the presence and severity
of psychiatric problems, as well as a screening for AOD use disorders.
The "ABC" model described on the previous page is a simple screening
technique for the presence of psychiatric disorders. The CAGE questionnaire
and the CAGE questionnaire modified for other drugs (CAGEAID) are rapid
and accurate screening tools for AOD use disorders (Exhibit
3-2). The substances used most often by patients with dual disorders
are the same as those used by society in general: alcohol, marijuana, cocaine,
and more rarely, opioids. It is recommended that all front-line AOD and
mental health staff receive detailed training in the use of a mental status
exam and AOD screening tests.
Chapter 4 -- Linkages For Mental Health and AOD Treatment
Overview
Conventional boundaries between single-focus agencies have impeded the
clinical progress of patients who have psychiatric disorders and alcohol
and other drug (AOD) use disorders (Baker,
1991;
Schorske
and Bedard, 1988).
The treatment of patients with dual disorders is a clinical challenge,
as well as a systems challenge, requiring innovation and coordination.
The goal of this chapter is to help State and local administrators consider
strategies for linkages across systems in order to improve service delivery
and treatment outcomes.
Profiles of patients with dual disorders demonstrate that they are more
or differently disabled and require more services than patients with a
single disorder. They have higher rates of homelessness and legal and medical
problems. They have more frequent and longer hospitalizations and higher
acute care utilization rates. For example, among patients with schizophrenia,
episodes of violence and suicide are twice as likely to occur among those
who abuse street drugs as among those who do not.
Treatment and social needs of patients with dual disorders differ depending
on the type and severity of the disorders. Patients with dual disorders
are generally less able to navigate between, engage in, and remain engaged
in treatment services. Focusing on linkages highlights the fact that treatment
providers, rather than patients and their families, have the responsibility
for coordinating diverse and often conflicting treatment services.
Treatment must be suited to patients' personal needs and characteristics,
linking services across several different systems of care. Instead of blaming
patients for poor treatment outcomes as they fall through the cracks of
separate service systems, patients can be empowered and better treated
when given effective options.
Collaboration across multiple systems and philosophies of care is needed
to treat patients with dual disorders effectively. The systems often affected
include:
-
Alcohol prevention and treatment services
-
Drug prevention and treatment services
-
Mental health treatment services
-
Criminal justice systems
-
Legal services
-
Social and welfare services
-
General health care services
-
Child and adult protective services
-
Vocational rehabilitation programs
-
Housing agencies
-
Agencies for homeless people
-
Educational systems
-
HIV/AIDS prevention and treatment services.
For the treatment of patients with dual disorders, the primary systems
involved are AOD and mental health treatment. Programs that focus on dual
disorders operate in both the mental health and AOD systems. Staff and
administrative initiative is required to collaborate across systems. At
a minimum, both systems should be involved when developing initiatives
to improve linkages. This TIP is focused on the linkages between these
systems.
In order to work effectively together, AOD treatment providers and mental
health professionals need to understand and respect the different historical
and philosophical underpinnings of both systems. As explained in the third
chapter, the systems developed separately. There are inherent stresses
and strengths among medical, psychoanalytic, psychosocial, and self-help
care orientations, as well as between AOD treatment and mental health treatment.
These differences have frequently been a source of conflict and have
caused problems for some patients. For example, if a patient with a dual
disorder is told by his psychiatrist that he needs psychotropic medication
to treat his psychiatric disorder, but members of his self-help AA group
tell him to give up all mood-altering drugs to recover from his AOD abuse,
to whom does he listen?
Patients with dual disorders challenge the treatment systems. Their
involvement in treatment can become an opportunity for providers to examine
the philosophical and practical aspects of treatment.
-
Providers should acknowledge that no single field has all the answers and
that a need exists to integrate treatment by building upon and adapting
from experience. Clinicians who work with dual disorder patients must add
to their existing clinical skills. The development of a dual disorders
program is an evolutionary process that requires agreed-upon outcome measures
and program evaluation.
-
Providers should review admission criteria. These criteria should be inclusive,
not exclusionary. Admission and placement criteria should be based on behaviors
and skills required to participate in and benefit from a program rather
than based solely on diagnosis.
-
Providers should find creative ways to bridge the differing funding streams,
target populations, legal and regulatory mandates, and professional backgrounds
and expertise.
-
Providers should accept the responsibility to provide integrated treatment
-- not parallel or concurrent treatment efforts that require the patient
to integrate and adapt to different and sometimes conflicting treatment
models.
In spite of the historical and philosophical differences that have separated
the fields, the consensus panel identified several shared treatment concepts
that administrators can use to help move toward integration.
-
Treatment should be provided in the least restrictive and most clinically
appropriate setting within a continuum of care.
-
Treatment should be individualized for each patient.
-
The patient should be seen from a holistic, biopsychosocial perspective.
-
Self-help and peer support are valuable in the recovery process.
-
Families need education and support.
-
Case management plays a key role in effective treatment.
-
Multidisciplinary teams and approaches are necessary.
-
Group education and group process are valuable elements of the treatment
process.
-
Ongoing support, relapse management, and prevention are necessary strategies.
-
Understanding that relapse and recovery are processes, not single events,
and that relapse is not synonymous with failure is essential.
-
Cultural competence in programs and staff is required.
-
Gender-specific approaches to treatment are necessary.
Areas of Primary Concern
To establish and maintain linkages among the various systems working with
patients who have dual disorders, several primary administrative areas
need to be examined.
It is beyond the scope of this document to provide detailed discussion
of each area, but the following discussion of problems and solutions will
help readers in their problem solving. The areas to be discussed in this
chapter include:
-
Policy and planning structures
-
Funding and reimbursement
-
Data collection and needs assessment
-
Program development
-
Screening, assessment, and referral
-
Case management
-
Staffing issues
-
Training and staffing
-
Linkages with social services agencies
-
Linkages with the medical health care system
-
Linkages with the criminal justice system.
Policy and Planning Structures
Problems
Often there is little or no communication or collaboration among various
departments and levels of government that have separate administrative
structures, constituencies, mandates, and target groups. There are also
different Federal, State, and local planning cycles within the AOD use
and mental health treatment systems.
The Federal Government requires two separate planning processes for
programs receiving Federal funds: A State mental health plan and a State
substance abuse plan. The federally mandated State planning processes required
under the Public Health Service Act for mental health treatment and AOD
abuse treatment are separate and have no requirements for coordination.
Solutions
Amendments are needed to the Public Health Service Act to encourage coordinated
long-term planning between the State mental health and AOD abuse treatment
systems for patients with dual disorders.
The development and use of long-term structural mechanisms (such as
coordinating bodies, task forces, memoranda of understanding, and letters
of agreement) can help improve planning for and integration of services
for patients who have dual disorders.
To accomplish this goal, States might create a joint planning mechanism
-- an officially organized planning group -- that would: 1) have diverse
composition, 2) carry out specific types of tasks, and 3) maintain specific
foci.
1. The planning organization should have diverse composition.
-
There should be dedicated policy-level staff from different agencies to
work on the joint planning body.
-
The planning group should be culturally competent and include a culturally
diverse cross-section of the population.
-
The planning group should include a significant percentage of direct recipients
of the services.
-
The planning group should include family members of patients.
-
The planning group should include providers.
-
The planning group should include academic representation from schools
of medicine, nursing, psychology, social work, and public health.
2. The planning group should accomplish the following tasks:
-
The group should set yearly objectives that are practical and outcome oriented,
and that can be tied to observable results on the service level.
-
The group should examine existing licensing requirements and regulations
that affect programs that treat patients who have dual disorders. The goal
should be to make the programs compatible and to reduce duplication of
licensing reviews where possible.
-
The group should alert AOD and mental health programs that provide treatment
for patients with dual disorders to existing Federal and State patient
protection and confidentiality laws that may be applicable for both fields.
-
The results, findings, and recommendations of the joint planning body should
be formally structured to feed back into the system and ensure that the
initiatives are implemented and maintained.
-
The group should recommend model policies regarding dual disorders, and
stimulate initiatives in program development and training.
-
There should be collaboration with universities and colleges to develop
and integrate coursework, field placements, and treatment research specific
to patients with dual disorders.
-
There should be a linkage with vocational rehabilitation and employment
services.
3. The planning group should maintain the following foci:
-
Define a needed array of services to address the needs of the full spectrum
of patients with dual disorders.
-
Encourage county and other joint or collaborative planning with similar
objectives for treating patients with dual disorders.
-
Encourage the use of funding and contracting mechanisms as incentives to
ensure that services for patients with dual disorders are included.
-
Ensure that competitive contract bids to operate treatment services specify
services for patients with dual disorders.
-
Award additional points to proposals for programs that address the needs
of patients with dual disorders.
-
Require that local and county program plans submitted for State funds address
services for dually diagnosed patients as a special population.
-
Promote training and staff development strategies to encourage acquisition
of and recognition for skills in treating patients with dual disorders.
The planning group should identify and disseminate information regarding
the availability of Federal grants.
Funding and Reimbursement
Problems
Because of diminishing fiscal resources and competition among many interest
groups for particular types of treatment, those who seek funds for the
treatment of patients with dual disorders have an increasingly difficult
task. In many areas, patients with dual disorders may not be recognized
as a priority group for funding. No specific monies are set aside for patients
with dual disorders under the block grants. The amount of funds that the
Federal Government allocates to States for the AOD and mental health block
grant programs changes from year to year and often includes mandated set-asides
for specific groups (for example, needle users, women, etc.). Set-asides
tend to be different for mental health and AOD abuse treatment and limit
the amount available for special groups not specifically targeted.
States often do not take advantage of Federal monies that can be used
for patients with dual disorders. It is difficult to identify Federal grants
that can be used for dual disorders, since grants and announcements are
scattered across many agencies such as the Substance Abuse and Mental Health
Services Administration (SAMHSA), CSAT, the Center for Substance Abuse
Prevention (CSAP), the National Institute on Drug Abuse (NIDA), the National
Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute
of Mental Health (NIMH), and the Center for Mental Health Services (CMHS),
to name a few.
Current reimbursement practices inhibit integration of services and
effective treatment, and there are several problems related to reimbursement
from both public and private third-party payers. These problems include
the following:
-
There are separate monies for AOD abuse and mental health treatment.
-
The span of coverage limits the types of services that can be provided
in each setting.
-
Few standards exist that define minimum benefits for either AOD abuse or
mental health services.
-
Depending on the type of treatment program in which patients participate,
the separation of AOD abuse services and mental health services often drives
the: 1) primary diagnosis, 2) type of treatment, 3) level of treatment,
and 4) level of reimbursement. This causes competition for benefits rather
than cooperation.
-
Benefit funding levels vary dramatically.
Solutions
1. Facilitate the aggressive pursuit of Federal funds by the following
actions:
-
Assign an individual to search for Federal grant programs serving patients
with dual disorders. This can be done at the State, local, and agency levels.
-
A lead Federal agency should be identified to screen grants applicable
to patients with dual disorders, and to encourage States to take advantage
of potential Federal funding. (CSAT might be the lead agency.)
-
At the State level, technical assistance should be provided to screen for
and assist local agencies to pursue Federal mental health and AOD funding.
2. Facilitate the use of block grant funds for treating patients with dual
disorders.
-
Work to create joint funding of programs. For example, New Jersey's Division
on Alcoholism and Drug Abuse and Mental Health cofunded a number of model
programs for patients with dual disorders.
-
Strive to share staff resources in programs, thus spreading out monies.
For example, mental health staff can cofacilitate a dual disorders group
in an AOD treatment program, and vice versa. Similarly, a mental health
program can provide staff to monitor medications to avoid duplication of
effort by the AOD treatment program.
-
Coordinate the provision of services and the expenditure of funds within
each block grant area.
-
Encourage the allocation of more Federal dollars for block grants and set-asides
that include treatment for dual disorders.
-
There may be some innovative mechanisms other than set-asides to encourage
use of block grant funds for patients with dual disorders.
3. Promote Requests for Proposals (RFPs) for treating patients with dual
disorders.
-
States should promote the development of RFPs specifying programs and services
for patients with dual disorders.
-
State grants might give extra points for demonstrating linkages among the
systems.
4. Encourage initiatives within third-party reimbursement mechanisms to
cover treatment for patients with dual disorders.
-
Play an active role in keeping dual disorders a priority in health care
reform efforts.
-
Encourage providers and payers to more effectively communicate with each
other.
-
Encourage State-mandated benefit minimums that recognize that a more intense
level of case management than usual is needed for treating patients with
dual disorders.
-
Educate third-party providers that treatment for patients with dual disorders
may be not only more intense but also more lengthy.
-
Consolidate and coordinate reimbursement rules for AOD abuse and mental
health treatment.
-
Negotiate with local health maintenance organizations and other providers
of health and mental health services to contract services for patients
with dual disorders.
-
Encourage managed care companies to cover and facilitate treatment for
dual disorders.
-
Encourage States to establish standards for different levels of care and
requirements for staffing. Encourage the development or adoption of criteria
such as those developed by the American Society of Addiction Medicine with
regard to dual disorder typologies, levels of care, and reimbursement.
Reimbursement should be linked to the use of criteria.
Data Collection and Needs Assessment
Problems
Only limited treatment and research data are available, and those that
are available are not in a standardized format. Existing data also tend
to be general and not useful to local planners for developing a continuum
of care. Data collection systems are mandated to be separate from each
other. It is difficult to gather prevalence data on patients with dual
disorders because many of them interact with several treatment agencies
or systems, while others do not interact with any.
There are systemic disincentives to gathering data on patients with
dual disorders. For example, Medicaid may cover a patient who makes a suicide
attempt as a result of major depression, but may not cover a patient who
makes a drug-induced suicide attempt.
Solutions
At least on the State level, common identifiers in data collection should
exist for both AOD abuse and mental health treatment systems. Research
should be in a form that allows for evaluation of cost-effectiveness and
outcome. Outcomes should be measured across several categories encompassing
biopsychosocial issues. Examples might be 1) severity of AOD and psychiatric
symptomatology, 2) housing, 3) service involvement and utilization, and
4) vocational involvement. Collaboration with local colleges and universities
to conduct such research should be encouraged.
State planning bodies should encourage or require local needs and resource
assessment and data collection. Local planners should collect data from
various systems, examining and comparing data from different groups, programs,
and locations. The State could gather all the data and compile them for
use in improved planning and in evaluating outcomes.
Confidentiality laws must protect the patient, but also must allow for
inclusion of anonymous case number data in pools to promote better assessment
and treatment outcome studies.
There should be aggressive efforts to examine cost-effectiveness and
outcomes of specific models of treatment services for patients with dual
disorders. These research efforts can be incorporated into State and local
initiatives, perhaps involving local colleges and universities.
Program Development
Problems
Linkages in the development of programs for treating patients with dual
disorders are impeded by several factors:
-
Rigid models, resistance to changing programs, and turf battles
-
Regulations and reimbursement rules
-
Clinical assumptions about dual disorders
-
Program development driven by reimbursement rules rather than by patients'
needs
-
Limited knowledge about what is effective; absence of outcome research
for program models
-
Absence of good processes for disseminating information about existing
programs throughout the country
-
Lack of standards for comprehensive dual disorders programs
-
Lack of incentives for good program development on the State and local
levels
-
Absence of State licensing criteria specific to dual disorders
-
Lack of appropriately trained staff and other resources
-
Lack of ownership. Dual disorder treatment systems are not "owned" by the
AOD abuse or mental health treatment systems. Therefore, development of
dual disorder treatment programs is not a priority in either system.
Solutions
-
Provide financial incentives for integrated dual disorder treatment programs.
-
Provide grants for model program development.
-
Identify State and county dual disorder experts.
-
Publish a State bulletin to facilitate information exchange.
-
Encourage research on existing programs from both AOD abuse and mental
health fields by collaborative grants between States and universities.
-
Determine how existing services can be adapted (such as with special tracks
or staff training to serve the dually diagnosed population) and help define
which services need to be developed and which are special and unique to
groups (for example, detoxification, longer-term residential programs,
halfway houses). For example, the State of New Jersey issued guidelines
for a continuum of care that describe how to adapt existing AOD abuse and
mental health services and what services need to be specialized to care
for dual disorder patients. The guidelines serve as a blueprint for systems
integration.
-
Publish a State glossary of terms to encourage communication across systems.
-
Make sure programs have integrated expertise from both AOD abuse and mental
health treatment fields through a joint review process for RFPs as well
as joint ongoing monitoring processes.
-
Review programs for gender and cultural competency.
-
Establish a consumer feedback process to modify programs.
-
Encourage the involvement of providers, patients, and their families in
educating the public on the needs of dual disorder patients and advocating
for resources.
Screening, Assessment, And Referral
Problems
The screening process amplifies the tendency to look for a single diagnosis.
Staff in single-focus screening services are not trained to assess patients
for dual disorders.
There is no "gold standard" instrument to diagnose dual disorders. Some
of the instruments that are used often yield false positive results.
Screeners are not adequately trained to make effective referrals across
systems, which can result in denial of treatment services.
Screening for dual disorders may take longer than screening for a single
disorder. For example, psychiatric symptoms can appear or disappear as
the AOD-induced symptoms clear.
Solutions
-
State policies should lengthen the time frames in which screening and assessments
are done for patients thought to have dual disorders. State policies should
recognize that screening and assessment are ongoing processes.
-
The Federal Government should encourage research to develop standardized
screening and assessment tools for dual disorders. These tools should be
appropriate for people with severe and moderate AOD and psychiatric problems.
-
There should be systems-wide training of gatekeepers on the proper way
to screen for dual disorders and on effective ways to make referrals.
-
There should be widespread encouragement of the multidisciplinary approach
through joint staffing of screening centers or on-call backup support.
Case Management
Problems
There frequently is no single person or agency responsible for following
up on referrals and ensuring that patients are linked to treatment and
that services are coordinated. People with dual disorders need others to
help them obtain the services that they require, which are often fragmented.
The Public Health Service Act requires that State mental health agencies
that receive Federal funds provide case management services to patients
with severe mental illness. However, a comparable requirement is not built
into the Federal mandate for AOD abuse treatment services. AOD abuse treatment
agencies usually do not have enough social service staff to handle the
case management functions of linkage or followup for many dual disorder
patients.
Solutions
-
States and agencies need to define criteria for patients who need and do
not need case management. Case management should be targeted to those who
need it, while less severely ill persons should receive other services.
-
Develop multidisciplinary teams with expertise in dual disorders within
AOD and mental health treatment settings. Also, encourage the use of peer
counselors to help engage patients with dual disorders into appropriate
treatment.
-
Encourage a continuum of case management, defining who should get what
level of case management. Levels may range from treatment plan coordination
while the patient is in treatment to coordinating services within the community
(such as Social Security Income [SSI] and housing). Assertive mobile outreach
teams can encourage out-of-treatment individuals to become engaged in treatment.
These efforts can help potential patients who are reluctant to participate
in treatment or who are unable to get to treatment.
-
States should help increase the case management function within the AOD
abuse treatment field. Ways to develop collaboration by including AOD treatment
experts in a mental health facility and in outreach operations should be
found.
Staffing
Problems
All too often, treatment staff are knowledgeable about either mental health
or AOD treatment. They lack thorough training and education about dual
disorder patients.
There is often insufficient staff time available for the level of case
management required for dual disorder patients.
Staff selection is often driven more by clinicians' academic degree
and their ability to provide reimbursable services than by clinicians'
expertise in dual disorders.
Solutions
-
Standards for staffing dual disorders programs should be developed. These
standards should include expertise in meeting the emotional, social, psychological,
biological, vocational, and recreational needs of the patient.
-
A certification process should be established for certifying clinicians
who have expertise in treating dual disorders. Third-party payers should
be encouraged to reimburse based on clinicians' knowledge, competence,
and expertise rather than on academic degree.
Training and Staffing
Problems
Clinicians in AOD abuse treatment and mental health treatment usually are
not trained in the other discipline. The availability of staff trained
in both fields is limited. Agencies frequently lack the resources to recruit
and retain staff who have sufficient education and experience. There is
both a shortage of qualified staff and an inability to financially compensate
qualified staff for their specialized abilities.
The diagnosis and treatment of dual disorders are not generally understood
by staff, administrators, and legislators, let alone the general public.
Agency directors and supervisors often assign whom they believe to be the
most appropriate staff member to work with dual disorder patients without
a clear idea of the knowledge and skills required.
Professionals in AOD abuse and mental health treatment have accumulated
biases against the other discipline, as well as negative stereotypes of
both patients and staff.
There are no structured incentives for individuals or programs to develop
or take part in training, such as pay differentials and career opportunities
specific to dual disorders. Opportunities and incentives for cross-training
are lacking.
Consumers are not adequately involved in the training process.
Relatively few academic programs involve training or research in this
field.
Solutions
Cross-training is one of the most effective tools administrators have for
bridging gaps between clinicians and services from different fields. Training
programs that provide knowledge about local networking can greatly improve
linkages for patients with dual disorders.
Solutions for administrators:
-
Hire administrators with clinical backgrounds in dual disorders.
-
Expose administrators to what is currently being done in the field of dual
disorders through conferences, literature, visits to facilities, and visits
to other States.
-
Develop clear education and experience guidelines for different levels
of staff members who treat dual disorder patients. These guidelines should
be used to establish training goals with staff and to establish opportunities
for advancement.
-
Develop standards for State, local, and facility training for various levels
of staff.
-
Ensure that continuing education credits are available for both AOD abuse
and mental health staff.
-
Provide certification or credentialing for training in the other discipline
to promote sensitivity in AOD and mental health treatment.
-
Discuss with State certification board members their willingness to develop
associate credentialing on AOD treatment targeted to social welfare, mental
health, and criminal justice personnel.
-
Increase awareness of dual disorders for State legislative and networking
systems through appropriately detailed curricula on patients with dual
disorders.
-
Prepare a training plan for new staff and plan ongoing training for existing
staff.
-
Provide ample time to have staff fully trained (2 to 3 years).
-
Coordinate with local universities and colleges to create a dual disorders
training track.
Solutions for staff:
-
Create an individualized plan for each staff person, defining strengths
as well as deficits and areas of needed growth; identify areas of greatest
needs; define a training plan with a timetable and components.
-
Receive training at an established dual disorders treatment program.
-
Attend workshops on treating patients with dual disorders.
-
Include on-the-job training:
-
AOD abuse and mental health jointly facilitated groups
-
Mental health workers on an AOD abuse service
-
AOD abuse workers on a mental health service
-
Staff sharing.
-
Provide didactic inservice training:
-
Train mental health workers in AOD abuse treatment
-
Train AOD treatment staff about mental health treatment
-
Train staff in dual disorders.
-
Provide staff with important articles from the field by providing subscriptions
to appropriate peer-reviewed journals. Purchase textbooks on dual disorders.
-
Work with local universities, colleges, and community college programs
to create a dual disorders training track.
Solutions for the community:
-
Disseminate information to the general population through newspapers, television,
and radio shows. Recovering people with dual disorders are good models.
-
Make presentations to community interest groups through speakers and speakers'
bureaus.
Solutions for consumers and their families:
-
Consumers of treatment services should be offered a role in the training
process for staff in the AOD abuse and mental health fields.
-
Consumers should be included on advisory boards for nonprofit and government
treatment programs.
-
Consumers should be offered the opportunity to receive training in both
fields to enhance their skills as peer counselors and group cofacilitators,
and to help start AA and NA meetings that are sensitive to people with
dual disorders, sometimes called "Double Trouble" meetings. Organizations
that can help provide education to the public and patients include the
National Alliance for the Mentally Ill, the National Association of Psychiatric
Survivors, the National Association of Right Protection and Advocacy, and
groups such as the Manic Depressive Association.
-
Families of patients should participate in Al-Anon and other support groups.
Linkages With Social Service Systems
Problems
A large proportion of patients with dual disorders require social services.
The scope of social services is extremely broad, encompassing public and
private multisystems.
Federally mandated income support programs are notoriously complex,
each with its own set of regulations. Some, such as the Social Security
Income (SSI) maintenance program, are administered by the Federal Government,
while others are administered by the State and vary from State to State.
Income support programs include SSI, Medicaid, Medicare, welfare, Aid
to Families With Dependent Children (AFDC), and food stamps.
Regulations for each program are often not understood by professionals
and others who provide services to potential recipients. This makes it
even more difficult for the potential recipient to get and retain benefits.
Some programs, such as SSI, require proof of a permanent and total disability.
Mental health problems often do not neatly fit into categories, making
it difficult to obtain this support.
Income support programs for single individuals have been cut drastically
in recent years.
Applications for these income support programs are often taken at a
site other than where either mental health or AOD services are provided
for the patient.
The complexity of the application and appeal process adds to the stress
of a person with a dual disorder.
Overburdened staff who are processing income support applications often
do not understand dual disorders.
Federally mandated services for children, youth, and families include
services that fall under the child welfare system (for example, child protective
services and foster care placement).
Child welfare system staff are overburdened and understaffed. A large
percentage of caseloads involve family AOD use problems.
Most child welfare staff are not trained in recognizing or treating
dual disorder problems. Mental health and AOD abuse staff are not trained
in child welfare. There is a lack of knowledge of each other's systems
and resources.
Other social service programs serve a wide range of special needs populations,
including the homeless and victims of domestic violence or sexual abuse,
who require a broad array of support services. Although many users of these
services have mental health and AOD abuse problems, these services are
often not available on site. Social service staff often lack knowledge
of how to refer people with such problems into these systems.
Solutions
-
Train SSI maintenance staff about patients with dual disorders.
-
Train AOD abuse and mental health staff in a range of social service areas,
including income support, child welfare, and special populations.
-
Encourage an on-site application process for income support programs at
AOD abuse and mental health treatment facilities. Mental health and AOD
abuse treatment programs can request training and support from Federal,
State, or local administrators of various income support programs.
-
Develop mobile outreach approaches to assist patients with dual disorders
in gaining access to income support programs and other needed social service
programs.
-
Encourage an ongoing exchange among policy-level staff of AOD abuse, mental
health, and Social Security agencies on Federal, State, and local levels.
-
Encourage a designated policy-level social services staff to create and
maintain links with AOD abuse and mental health treatment systems.
-
Allocate sufficient social service staff time to assist patients who need
a range of supports and services.
Linkages With the Health Care System
Problems
The medical system is vast, covering a wide range of public and private
programs including primary, secondary, and tertiary care.
Public primary care clinics are often overburdened, understaffed, and
underfinanced. They are often oriented to treating presenting physical
problems, and staff may not be trained in screening for either AOD abuse
or mental health problems. The same problems often exist in nonprofit primary
care facilities. Staff are often not knowledgeable about how and where
to refer patients.
Historically, physicians have not received any education about AOD treatment
and little education about mental health problems in medical school. Primary
care physicians are often unaware of the signs and symptoms of AOD use
disorders, and may have only a basic understanding of a few psychiatric
problems such as depression and anxiety. For example, persons who experience
physical trauma, such as burn injuries or falls, often have AOD use disorders.
Yet, when presented with injured patients, primary care physicians may
not screen for AOD use disorders.
At hospital discharge, personnel often have difficulty dealing with
AOD abuse and mental health concerns. Patients are sometimes discharged
inappropriately with inadequate discharge planning and linkage with aftercare
services.
Staff in mental health and AOD abuse treatment systems often do not
know how to gain access to medical systems and therefore are ineffective
in providing information and ongoing education.
Solutions
-
AOD abuse and mental health staff should take the initiative to conduct
training sessions through established medical organizations such as medical
societies, hospital associations, nurses' associations, and other professional
organizations.
-
AOD and mental health planning groups should publish materials that provide
tips on linkage techniques for patients with dual disorders, and target
such materials to the medical community.
-
Many public health clinics operated by the local health department are
under the same administrative umbrella as the AOD programs. The local public
health director can encourage the development of interagency training sessions,
protocols, and policies and procedures to facilitate linkages between the
clinics and AOD abuse treatment services and network with the mental health
treatment services. Also, the local health director can help to establish
stronger linkages between AOD and mental health providers with HIV/AIDS
prevention and treatment systems.
Linkages With the Criminal Justice System
Problems
The criminal justice is a top-down system. There is often no mandated joint
planning.
The mental health system has no formal responsibility for inmates with
dual disorders.
Incarceration is often a substitute for AOD abuse and mental health
treatment. Treatment may not begin until shortly prior to release.
Medical services for the incarcerated are not reimbursable under Medicaid
or any third-party payer. There is often an interagency debate regarding
who should pay for care.
Offenders who should be committed are often released. Prerelease assessments
are often inadequate. There usually is no coordinated plan for release.
No systemic funding incentives to provide care exist. There is a range
of custody status.
Criminal justice staff often have AOD abuse or mental health problems.
There are many inadequate employee assistance programs within the criminal
justice system.
The criminal justice system and community AOD abuse and mental health
treatment agencies may compete for the same AOD abuse and mental health
treatment dollars.
Solutions
1. State
-
Establish joint top-level planning by the AOD abuse, mental health, and
criminal justice fields.
-
Encourage funding that supports linkage at the service delivery level.
-
Work with AOD abuse and mental health treatment monitoring and licensing
regulations to require and encourage cooperation with the criminal justice
system.
-
Encourage funding for research and gathering data on persons with dual
disorders in the criminal justice system.
-
Formally identify the responsibility of each system for providing specific
services within the criminal justice system.
2. County and locality
-
Include representatives from the criminal justice system in local AOD abuse
and mental health treatment planning groups.
-
Identify patients in each system who have an interest in cooperation.
3. Consumers
-
Educate consumer groups and the general public about the need for treatment
of persons with dual disorders in the criminal justice system.
-
Encourage consumer groups to influence policy makers regarding linkages.
4. Pretrial process
-
Monitor and assess cases that involve AOD treatment and mental health treatment
issues.
-
Advise and train judges regarding AOD treatment and mental health treatment
options.
5. During incarceration
-
Conduct assessment for dual disorders at admission.
-
Provide treatment early in the incarceration.
-
Consider AOD abuse and mental health treatment issues during the parole
hearing.
6. During the probation-parole period
-
Conduct joint assessment by AOD, mental health, and criminal justice staff
prior to release.
-
Develop a release plan that addresses AOD and mental health issues.
-
Develop a clear contingency plan to address noncompliance.
-
Establish prompt and consistent graduated sanctions of custody status.
-
Establish joint supervision of problem cases.
7. Criminal justice staff
-
Provide EAP services that assess, identify, and treat AOD and mental health
problems of staff.
-
Cooperate with unions.
-
Provide training on screening and assessment.
-
Provide training to address negative attitudes of criminal justice personnel
regarding AOD abuse and mental health treatment and patients with dual
disorders.
Chapter 5 -- Mood Disorders
Definitions and Diagnoses
The term mood describes a pervasive and sustained emotional state
that may affect all aspects of an individual's life and perceptions.
Mood
disorders are pathologically elevated or depressed disturbances of
mood, and include full or partial episodes of depression or mania. A mood
episode (for example, major depression) is a cluster of symptoms that
occur together for a discrete period of time.
A major depressive episode involves a depression in mood with
an accompanying loss of pleasure or indifference to most activities, most
of the time for at least 2 weeks. These deviations from normal mood may
include significant changes in energy, sleep patterns, concentration, and
weight. Symptoms may include psychomotor agitation or retardation, persistent
feelings of worthlessness or inappropriate guilt, or recurrent thoughts
of death or suicide. The diagnosis of major depression requires
evidence of one or more major depressive episodes occurring without clearly
being related to another psychiatric, AOD use, or medical disorder. Major
depression is subclassified as major depressive disorder, single episode
and
recurrent.
There are nine symptoms of a major depressive episode listed in the DSM-IV
draft, and diagnosis of this disorder requires at least five of them to
be present for 2 weeks.
Dysthymia is a chronic mood disturbance characterized by a loss
of interest or pleasure in most activities of daily life but not meeting
the full criteria for a major depressive episode. The diagnosis of dysthymia
requires mild to moderate mood depression most of the time for a duration
of at least 2 years.
A manic episode is a discrete period (at least 1 week) of persistently
elevated, euphoric, irritable, or expansive mood. Symptoms may include
hyperactivity, grandiosity, flight of ideas, talkativeness, a decreased
need for sleep, and distractibility. Manic episodes, often having a rapid
onset and symptom progression over a few days, generally impair occupational
or social functioning, and may require hospitalization to prevent harm
to self or others. In an extreme form, people with mania frequently have
psychotic hallucinations or delusions. This form of mania may be difficult
to differentiate from schizophrenia or stimulant intoxication.
A hypomanic episode is a period (weeks or months) of pathologically
elevated mood that resembles but is less severe than a manic episode. Hypomanic
episodes are not severe enough to cause marked impairment in social or
occupational functioning or to require hospitalization.
A bipolar disorder is diagnosed upon evidence of one or more
manic episodes, often in an individual with a history of one or more major
depressive episodes. Bipolar disorder is subclassified as manic, depressed,
or mixed, depending upon the clinical features of the current or most recent
episodes. Major depressive or manic episodes may be followed by a brief
episode of the other.
Cyclothymia can be described as a mild form of bipolar disorder,
but with more frequent and chronic mood variability. Cyclothymia includes
multiple hypomanic episodes and periods of depressed mood insufficient
to meet the criteria for either a manic or a major depressive episode.
The revised third edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-III-R) states that for a diagnosis of cyclothymia
to be made, there must be a 2-year period during which the patient is never
without hypomanic or dysthymic symptoms for more than 2 months.
Substance-induced mood disorder is described in the DSM-IV draft
according to the following criteria:
-
A. A prominent and persistent disturbance in mood characterized by either
(or both) of the following:
-
1) depressed mood or markedly diminished interest or pleasure in all, or
almost all, activities,
-
2) elevated, expansive, or irritable mood.
-
B. There is evidence from the history, physical examination, or laboratory
findings of substance intoxication or withdrawal, and the symptoms in criterion
A developed during, or within a month of, significant substance intoxication
or withdrawal.
-
C. The disturbance is not better accounted for by a mood disorder that
is not substance induced. Evidence that the symptoms are better accounted
for by a mood disorder that is not substance induced might include: the
symptoms precede the onset of the substance abuse or dependence; they persist
for a substantial period of time (e.g., about a month) after the cessation
of acute withdrawal or severe intoxication; they are substantially in excess
of what would be expected given the character, duration, or amount of the
substance used; or there is other evidence suggesting the existence of
an independent non-substance-induced mood disorder (e.g., a history of
recurrent non-substance-related major depressive episodes) .
-
D. The symptoms cause clinically significant distress or impairment in
social, occupational, or other important areas of functioning.
-
E. The disturbance does not occur exclusively during the course of delirium.
Substance-induced mood disorder can be specified as having 1) manic features,
2) depressive features, or 3) mixed features. Also, it can be described
as having an onset during intoxication or withdrawal. For most of the major
mental illnesses, the DSM-IV draft includes the alternative of a substance-induced
disorder within that diagnosis.
Prevalence
Using structured interviews, the Epidemiologic Catchment Area (ECA) studies
found that nearly 40 percent of people with an alcohol disorder also fulfilled
criteria for a psychiatric disorder. Among people with other drug disorders,
more than half reported symptoms of a psychiatric disorder (Regier
et al., 1990).
The most common psychiatric diagnoses among patients with an AOD disorder
are anxiety and mood disorders. Among those with a mood disorder, a significant
proportion has major depression. Mood disorders may be more prevalent among
patients using methadone and heroin than among other drug users. In an
addiction treatment setting, the proportion of patients diagnosed with
major depression is lower than in a mental health setting.
The prevalence rates of mood disorders in the general population can
be estimated from the results of the ECA studies (Regier
et al., 1988; Robins
et al., 1988). These studies indicate that:
-
The lifetime prevalence rates for any mood disorder ranged from 6.1 to
9.5 percent in the ECA study of New Haven, Baltimore, and St. Louis.
-
The lifetime prevalence rates for major depressive episode ranged from
3.7 to 6.7 percent.
-
The lifetime prevalence rates for dysthymia ranged from 2.1 to 3.8 percent.
-
The lifetime prevalence rates for manic episode ranged from 0.6 to 1.1
percent.
Some studies demonstrate that the prevalence of mood and anxiety disorders
is no greater among AOD abusers than in the general population. Other studies
show elevated rates of these disorders among people with AOD disorders.
Many patients receiving treatment for addiction appear depressed, but only
a small percent receive a formal diagnosis of major depression as a concurrent
illness.
During the first months of sobriety, many AOD abusers may exhibit symptoms
of depression that fade over time and that are related to acute withdrawal.
Thus, depressive symptoms during withdrawal and early recovery may result
from AOD disorders, not an underlying depression. A period of time should
elapse before depression is diagnosed.
Among women with an AOD disorder, the prevalence of mood disorders may
be high. The prevalence rate for depression among alcoholic women is greater
than the rate among men. Counselors should be reminded that women in both
addiction and nonaddiction treatment settings are more likely than men
to be clinically depressed.
In addition to women, other populations require special consideration.
Native Americans, patients with HIV, patients maintained on methadone,
and elderly people may all have a higher risk for depression. The elderly
may be the group at highest risk for combined mood disorder and AOD problems.
Episodes of mood disturbance generally increase in frequency with age.
Elderly people with concurrent mood and AOD disorders tend to have more
mood episodes as they get older even when their AOD use is controlled.
Differential Diagnosis
Diagnostic Process
Diagnoses of psychiatric disorders should be provisional and constantly
reevaluated. In addiction treatment populations, many psychiatric disorders
are substance-induced disorders that are caused by AOD use. Treatment of
the AOD disorder and an abstinent period of weeks or months may be required
for a definitive diagnosis of an independent psychiatric disorder. Unfortunately,
the severely depressed person may drop out of treatment or even commit
suicide while the clinician is trying to sort things out (see section on
"Assessing Danger to Self or Others.")
Acute manic symptoms may be induced or mimicked by intoxication with
stimulants, steroids, hallucinogens, or polydrug combinations. They may
also be caused by withdrawal from depressants such as alcohol and by medical
disorders such as AIDS and thyroid problems. Acute mania with its hyperactivity,
psychosis, and often aggressive and impulsive behavior is an emergency
and should be referred to emergency mental health professionals. This is
true whatever the causes may appear to be.
Other psychiatric conditions can mimic mood disorders. The predominant
condition that mimics a mood disorder is addiction, which is frequently
undiagnosed or misdiagnosed. Disorders that can complicate diagnosis include
schizophrenia, brief reactive psychosis, and anxiety disorders.
Patients with personality disorders, especially of the borderline, narcissistic,
and antisocial types, frequently manifest symptoms of mood disorders. These
symptoms are often fluid and may not meet the diagnostic criterion of persistence
over time. In addition, all of the psychiatric disorders noted here can
coexist with AOD and mood disorders.
Case Examples: George and Mary
George is a 37-year-old divorced male who was brought into the emergency
room intoxicated. His blood alcohol level was 152, and the toxicology screen
was positive for cocaine. He was also suicidal ("I'm going to do it right
this time! I've got a gun."). He has a history of three psychiatric hospitalizations
and two inpatient AOD treatments. Each psychiatric admission was preceded
by AOD use. George has never followed through with psychiatric treatment.
He has intermittently attended AA, but not recently.
Mary is a 37-year-old divorced female who was brought into a detoxification
unit with a blood alcohol level of 150 and was noted to be depressed and
withdrawn. She has never used drugs (other than alcohol), and began drinking
alcohol only 3 years ago. However, she has had several alcohol-related
problems since then. She has a history of three psychiatric hospitalizations
for depression, at ages 19, 23, and 32. She reports a positive response
to antidepressants. She is currently not receiving AOD or psychiatric treatment.
Differential diagnostic issues for case examples.
Many factors must be examined when making initial diagnostic and treatment
decisions. For example, what if George's psychiatric admissions were 2
or 3 days long -- usually with discharges related to leaving against medical
advice? Decisions about diagnosis and treatment would be quite different
if two of his psychiatric admissions were 4 to 6 weeks long with clearly
defined manic and psychotic symptoms continuing throughout the course,
despite aggressive use of psychiatric treatment and medication.
Similarly, what if Mary had abstained from alcohol for 6 months "on
her own," but over the past 3 months, she had become increasingly depressed,
tired, and withdrawn, with disordered sleep and poor concentration, as
well as suicidal thoughts? In addition, last night, while planning to kill
herself, she relapsed. A different diagnostic picture would emerge in this
case if Mary had been using antidepressants for the past year and, during
the past month, she had experienced an increase in heavy drinking, losing
her job yesterday because of alcohol use.
AOD-Induced Mood Disorders
It is important to distinguish between mood disorders and AOD intoxication,
withdrawal, and/or chronic effects. These distinctions are especially important
following the chronic use of drugs that cause physiologic dependence.
All psychoactive drugs cause alterations in normal mood. The severity
and manner of these alterations are regulated by preexisting mood states,
type and amount of drug used, chronicity of drug use, route of drug administration,
current psychiatric status, and history of mood disorders.
AOD-induced mood alterations can result from acute and chronic drug
use as well as from drug withdrawal. AOD-induced mood disorders, most notably
acute depression lasting from hours to days, can result from sedative-hypnotic
intoxication. Similarly, prolonged or subacute withdrawal, lasting from
weeks to months, can cause episodes of depression, sometimes accompanied
by suicidal ideation or attempts.
Also, stimulant withdrawal may provoke episodes of depression lasting
from hours to days, especially following high-dose, chronic use. Stimulant-induced
episodes of mania may include symptoms of paranoia lasting from hours to
days. Overall, the process of addiction per se can result in biopsychosocial
disintegration, leading to chronic dysthymia or depression often lasting
from months to years.
Since symptoms of mood disorders that accompany acute withdrawal syndromes
are often the result of the withdrawal, adequate time should elapse before
a definitive diagnosis of an independent mood disorder is made.
Conditions that most frequently cause and mimic mood disorders and symptoms
must be differentiated from AOD-induced conditions. When symptoms persist
or intensify, they may represent AOD-induced mental disorders. Transient
dysphoria following the cessation of stimulants can mimic a depressive
episode. According to the DSM-IV draft, if symptoms are intense and persist
for more than a month after acute withdrawal, a depressive episode can
be diagnosed. Symptoms of shorter duration can be diagnosed as a substance-induced
mood disorder.
It is difficult to generalize about specific drugs causing specific
behavioral syndromes. There is tremendous variability, as demonstrated
in Exhibit 5-1.
Multiple drug use further complicates the differential diagnosis. Diagnostic
procedures such as urinalysis and toxicology screens should be used if
possible. It should also be emphasized that addicted patients may experience
withdrawal from one drug despite using another drug.
Stimulants
Stimulants such as cocaine and the amphetamines cause potent psychomotor
stimulation. Stimulant intoxication generally includes increased
mental and physical energy, feelings of well-being and grandiosity, and
rapid pressured speech. Chronic, high-dose stimulant intoxication, especially
when combined with sleep deprivation, may prompt an episode of mania. Symptoms
may include euphoric, expansive, or irritable mood, often with flight of
ideas, severe impairment of social functioning, and insomnia.
Acute stimulant withdrawal generally lasts from several hours
to 1 week and is characterized by depressed mood, agitation, fatigue, voracious
appetite, and insomnia or hypersomnia. Depression resulting from stimulant
withdrawal may be severe and can be worsened by the individual's awareness
of addiction-related adverse consequences. Symptoms of craving for stimulants
are likely and suicide is possible.
Protracted stimulant withdrawal often includes sustained episodes
of anhedonia and lethargy with frequent ruminations and dreams about stimulant
use. There may be bursts of dysphoria, intense depression, insomnia, and
agitation for several months following stimulant cessation. These symptoms
may be either worsened or lessened by the quality of the patient's recovery
program.
Depressants
The general effect of the central nervous system depressants such as alcohol,
the benzodiazepines, and the opioids is a slowing down of an individual's
psychomotor processes. However, acute alcohol intoxication and opioid
intoxication often include two phases: an initial period of euphoria
followed by a longer period of relaxation, sedation, lethargy, apathy,
and drowsiness.
Alcohol, barbiturates, and the benzodiazepines can cause sedative-hypnotic
intoxication, especially when taken in high doses. Psychomotor symptoms
include mood lability, mental impairment, impaired memory and attention,
loss of coordination, unsteady gait, slurred speech, and confusion.
Hallucinogens, Marijuana, and PCP
The hallucinogens can cause a state of intoxication called hallucinosis,
which has several features in common with psychotic disorders and a few
in common with mood disorders. Hallucinogens such as LSD and drugs such
as MDMA (methylenedioxy-methamphetamine, or Ecstasy) and MDA (methylenedioxyamphetamine)
may precipitate intense emotional experiences that may be perceived as
positive or negative mood states by the drug user.
These experiences are affected greatly by personality, preexisting mood
state, personal expectations, drug dosage, and environmental surroundings.
While many users will experience sensory and perceptual distortions, some
will experience euphoric religious or spiritual experiences that may resemble
aspects of a manic or psychotic episode. Others may have a deeply troubling
introspective experience, causing symptoms of depression.
Marijuana, which has sedative and psychedelic properties, can cause
a variety of mood-related effects. In the individual who has not developed
tolerance for the drug's effects, high doses of marijuana can cause acute
marijuana intoxication with euphoria or agitation, grandiosity, and
"profound thoughts." Together, these symptoms can mimic mania. Because
marijuana is only slowly eliminated from the body, chronic use results
in relatively constant marijuana levels. Thus, daily marijuana use can
be, in effect, a chronic marijuana intoxication. This state may
include symptoms of chronic, low-grade lethargy and depression, perhaps
accompanied by anxiety and memory loss. Phencyclidine (PCP) intoxication
can
include symptoms of euphoria, mania, or depression, in addition to sensory
dissociation, hallucinations, delusions, psychotic thinking, altered body
image, and disorientation.
Mood Disorders Due to A Medical Condition
The DSM-IV draft describes diagnostic criteria for mood disorder due
to a general medical condition. The five criteria are:
-
A. A prominent and persistent mood disturbance is characterized by either
(or both) of the following:
-
1) depressed mood or markedly diminished interest or pleasure in all, or
almost all, activities,
-
2) elevated, expansive, or irritable mood.
-
B. There is evidence from the history, physical examination, or laboratory
findings of a general medical condition judged to be etiologically related
to the disturbance.
-
C. The disturbance is not better accounted for by another mental disorder
(e.g., adjustment disorder with depressed mood, in response to the stress
of having a general medical condition).
-
D. The symptoms cause clinically significant distress or impairment in
social, occupational, or other important areas of functioning.
-
E. The disturbance does not occur exclusively during the course of delirium
or dementia.
Mood disorder due to a general medical condition can be described as having
1) manic features, 2) depressive features, or 3) mixed features in which
symptoms of both mania and depression are present and neither predominates.
Medical conditions that can either precipitate or mimic mood disorders
include the following:
-
Malnutrition
-
Anemia
-
Hyper- and hypothyroidism
-
Dementia
-
Brain disease
-
Lupus
-
HIV/AIDS
-
Postcardiac condition
-
Stroke, especially among elderly people.
Medications, including reserpine and other medications that treat hypertension
and hypotension, can cause conditions that may be confused with psychiatric
or AOD disorders. Both prescribed and over-the-counter (OTC) medications
can precipitate depression. Diet pills and other OTC medications can lead
to mania. Patients treated with neuroleptic (antipsychotic) drugs may have
a marked constriction of affect that can be misinterpreted as a symptom
of depression.
Stages of Assessment
The patient with coexisting AOD and mood disorders requires a thorough
assessment and treatment for both disorders. The assessment process can
be divided into three clinical phases: acute, subacute, and long term.
Acute and subacute assessment may not be applicable to certain patients
seen in some clinical settings. For instance, AOD treatment program staff
in outpatient settings may see fewer patients with acute psychiatric symptoms
than are seen in detoxification settings.
Acute Evaluation
Assessing Danger to Self or Others
It is critical to assess whether patients are threats to themselves or
others. This evaluation helps to determine if there is a duty to protect
patients from self-harm, interrupt intentions of violence toward others,
and/or warn intended victims of patients' announced violent intent.
The responsibility to protect some patients from suicide or violence
due to mental illness is not mitigated by confidentiality laws with respect
to AOD addiction. Imminent risk, according to the laws of most States,
justifies and requires commitment of patients or the warning of potential
victims.
Generally, AOD confidentiality laws are very stringent. While some States
protect against involuntary commitment for AOD abuse, they do not protect
against commitment for AOD-induced psychiatric states which involve danger
to oneself or others.
Screening personnel should assess whether suicidal feelings are transitory
or reflect a chronic condition. Consider: Do patients have a suicide plan
or serious intentions? Have they made past attempts? Whether the patients
have had prior psychiatric hospitalization or are in current treatment
should be determined. If patients are acutely dangerous to themselves or
others, either voluntary or involuntary methods such as commitment should
be pursued through local resources. AOD staff should have a thorough knowledge
of local resources prior to and in anticipation of crises.
Placement in a safe holding environment can have a positive effect on
patients with AOD problems and apparent suicidal intentions. If an intake
facility cannot hold such patients, referral to an appropriate facility
is recommended. For example, if someone walks into a program at 8:00 a.m.
on Monday saying he wants to hurt himself, there should be time to talk
the person down, assess treatment needs, and begin treatment or make assessment
referrals. When necessary, an assessment should include a rapid triage.
See the sections on the assessment of high-risk conditions in Chapter
7 (Personality Disorders) and Chapter
8 (Psychotic Disorders).
In virtually every recent study of successful or attempted suicide,
AOD use and major depression are among the top associated conditions. Having
both conditions simultaneously leads to even greater risk of suicide.
Patients with manic symptoms that approach psychotic proportions require
thorough evaluation and require urgent care. Evaluation of mania should
be done on a priority basis and should be monitored during subacute assessments.
Patients who have manic and hypomanic symptoms often minimize AOD and
psychiatric disorders. Because of the symptom of grandiosity, manic patients
may have poor insight into their AOD disorder, their mania, and their social
situation. Manic patients may not see themselves as ill. They are usually
hyperactive and irritable, and often become a danger to themselves or others
through impulsivity, irritability, and poor judgment. When such people
are also intoxicated, most will require involuntary commitment. See Chapter
8 for a discussion of assessment of patients with psychosis.
Medical Assessment
Patients, particularly the elderly, with mood disorders may have life-threatening
medical conditions, including hypoglycemia (insulin overdose), stroke,
or infections. These conditions, as well as withdrawal and toxic drug reactions,
must always be considered and require a thorough physical examination and
laboratory assessment. Assessment personnel should make appropriate referrals
for medical assessment and treatment. Facilities that have no medical component
should train assessment staff in triage and referral.
A plan should be developed to assess and treat medical conditions that
precipitate or complicate mood disturbances. Endocrine disorders (such
as thyroid problems), neurological disorders (such as multiple sclerosis),
and HIV infection should be considered. In addition to obvious medical
problems, it can be assumed that basic medical needs of patients with dual
disorders are not being met, and a plan should be developed to address
these deficits.
Initial Addiction Assessment Using the CAGE Questions
Clinicians can easily use the CAGE questions for screening (see
Chapter 3) as well as adapt them for use with patients who may have
mood disorders. For example, consider the following questions adapted from
the CAGE questionnaire. "Have you ever cut down or increased your
AOD use related to being severely depressed (or manic, etc.)?" "Do you
ever get more irritable, angry, depressed, or annoyed when using
AODs?" "Do you drink or use other drugs to deal with guilt feelings?"
"Do you feel more moody in the morning or evening?" "Have you ever been
suicidal when intoxicated?"
Initial AOD assessment should focus on recent use of alcohol and other
drugs and a behavioral history. The assessor needs to know what drug has
been used, in what quantity, with what frequency, and how recently. Past
treatments, past episodes of delirium tremens, hallucinosis, blackouts,
and destructive behavior should be recorded.
Social Assessment
The social assessment should evaluate the patient's social environment,
especially in relation to AOD and psychiatric disorders. It is important
to assess whether the patient experiences housing instability or homelessness.
Where does the patient live? Does the patient live in a home? With whom
does the patient live? With whom does the patient have regular social contact?
Are the social and home environments stable?
In the patient's social life, is there a precipitating crisis occurring?
What is the patient's existing support structure in the home and community?
What role do others have? Is the home free of AODs? Are the home and social
environments safe and free from violence? Do the home and social environments
support an abstinent lifestyle? If not, it should be assessed whether the
patient has the support necessary to overcome the adverse effect of home
and social environments that do not support abstinence and recovery.
Violence by Others
During the screening interview, it is important to determine whether the
patient's family members are physically abusive. It should be determined
whether the patient is in danger. Physical and behavioral observation can
be an important aspect of evaluation. The best predictor of future violence
is previous violence.
Assessing Mood Symptomatology
During AOD use history taking and psychiatric screening and assessment
sessions, patients with AOD disorders may overemphasize or underemphasize
their psychiatric symptoms. For instance, patients who feel depressed during
the assessment may distort their past psychiatric experiences and unwittingly
exaggerate the intensity or frequency of past depressive episodes.
In contrast, patients who are profoundly depressed during the assessment
may minimize their depressive illness because they think it represents
a normal state. Indeed, some patients may believe that they "deserve" to
be depressed, rather than recognizing that depression is a deviation from
normal mood states.
Some patients experience feelings of guilt that are excessive and inappropriate.
Other patients do not accurately label their depression and fail to remember
that they have experienced depression before. Since patients frequently
confuse depression with sadness and other emotions, it is important during
the assessment to ask such questions as: "Have you ever seen a psychiatrist
or therapist?" (If yes: "Why?") "Are you able to get out of bed in the
morning or do you feel chronically tired?" "Have there been any recent
changes in your sleeping patterns or in your appetite?"
Patients may select details from their psychiatric history consistent
with their current mood. Those who are depressed may give a generally negative
self-report. Addicted patients tend to emphasize psychiatric symptoms;
psychiatric patients often underemphasize them. Unhappy addicted patients
in a transient disturbance of mood will often rationalize their histories
as lifelong depression. Thus, it is important to obtain collateral information
from other people and from documents such as medical and psychiatric records.
It is critical to continue the process of evaluation past the period of
drug withdrawal.
Tips for Assessment
The following are sample questions to ask during the assessment process.
For depression:
-
"During the past month, has there been a period of time during which you
felt depressed most of the day nearly every day?"
-
"During this period of time, did you gain or lose any weight?"
-
"Did you have trouble concentrating?"
-
"Did you have problems sleeping or did you sleep too much?"
-
"Did you try to hurt yourself?"
For mania:
-
"During the past month, have you experienced times during which you felt
so hyperactive that you got into trouble or were told by others that your
behavior was not normal for you?"
-
"Have you recently experienced bouts of irritability during which you would
yell or fight with others?"
-
"During this period, did you feel more self-confident than usual?"
-
"Did you feel pressured to talk a great deal or feel that your thoughts
were racing?"
-
"Did you feel restless and irritable?"
-
"How much sleep do you need?"
Patients' responses to questions are often influenced by the way questions
are asked. Most patients being interviewed tend to say what they believe
the interviewer wants to hear. Therefore, the manner in which the interview
is conducted is important. The interviewer should not lead the patient
or make suggestions regarding the "correct" answer.
Because of the subjective nature of mood disturbances, the way in which
questions are asked is important. Subjective and quantifiable questions
should be asked in an objective way. Neutral, open-ended questions can
be effective. Questions should be asked about impairment and disturbance
of sleep, appetite, and sexual function, as well as other disturbances
in functional impairment. Interviewers must be alert to contradictory responses
and recognize that AOD-dependent patients have a tendency to distort information.
Subacute and Longer-Term Assessment
Settings for subacute assessment include the following:
-
Medical clinics
-
Mental health clinics
-
Sexually transmitted disease (STD) clinics
-
Hospitals
-
Emergency rooms
-
Welfare and social services offices
-
Other nontreatment settings
-
Doctors' offices
-
Psychotherapists' offices.
This section will focus on patients who likely have coexisting AOD use
and mood disorders, are not imminently dangerous, and are candidates for
treatment. Their functional levels, liabilities, and strengths should be
assessed. The goal of subacute assessment is to develop treatment plans
with less need for the focus on acute protection (as in the case of acute
assessment). Treatment planning is based on a full assessment of treatment
needs.
Assessments can be considered part of the treatment process since the
assessment process often facilitates breaking through the addicted person's
denial mechanisms. By asking specific questions (about work, relationships,
health, or legal problems), the clinician calls attention to the consequences
of AOD use. Toxicology screens and/or abnormal liver function tests such
as the GGT should be obtained when symptoms and AOD use reports don't match.
Such results can be identified as "consequences" of AOD use. Diagnostic
and assessment sessions can be the first intervention. The boundary between
assessment and treatment is fluid.
Medical Assessment
A plan should be developed to assess and treat medical conditions that
can precipitate or complicate mood disturbances. Such conditions include
endocrine disorders (such as thyroid problems), neurological disorders
(such as multiple sclerosis), and HIV infection.
Some medical problems may have a heightened visibility because of their
more obvious need for ongoing treatment. However, frequently the primary
health care needs of patients with combined AOD and mood disorders are
not pursued. For this reason, a plan to assess and meet these treatment
needs should be developed.
Psychiatric and Addiction Screening
A subacute nonemergency setting is appropriate for screening and in depth
diagnostic interviews for AOD and psychiatric disorders. The following
sources can provide valuable information for screening and assessment:
psychiatric history, previous medical and psychiatric records, and information
from collateral sources such as employers, family members, and laboratory
data.
A diagnostic interview, unlike a screening interview, can be done over
the course of several sessions. Collateral sources, especially family members,
can help clarify diagnostic issues and to help patients recognize the denial
that may accompany their disorders.
A thorough history of AOD use, problems, patterns, and treatments should
be obtained at this stage. Such information should be collected in a supportive
nonjudgmental manner and over multiple interviews when possible. As with
the psychiatric assessment, interviews with family and collateral sources
are important.
Assessment Instruments
The diagnostic evaluation can include the clinical application of the DSM-III-R
(or DSM-IV), perhaps in the form of the Structured Clinical Interview from
DSM-III-R (SCID). The Brief Psychiatric Rating Scale, the Hamilton Scale,
the Addiction Severity Index (ASI), and the Beck Scale can also be used
to assess patients with dual disorders.
The SCID and the ASI are research instruments, but their demonstrated
reliability and the advantages of consistent, standardized tools make it
reasonable to administer them. Facilities that use these instruments should
provide training in their use.
Psychosocial Assessment
A comprehensive psychosocial and vocational assessment can be an important
aspect of the overall assessment. Evaluation of the patient's ongoing support
system is important: What is the patient's support network, including friends
and family? What patterns of interpersonal and family relationships exist
within the nuclear family, the extended family, and the family of choice?
What means of financial support does the patient have? What job skills
does the patient have? Also, both ethnic and cultural backgrounds may alter
a person's experience of both AOD and psychiatric conditions.
Treatment Strategies, Issues, and Goals
Acute Treatment Strategies
Management of Intoxication And Withdrawal
Management of withdrawal is often crucial to patients' safety and comfort.
Withdrawal management can foster patient engagement in an ongoing treatment
and recovery process. Although withdrawal management does not in itself
produce enduring abstinence, it can help to increase retention in the treatment
process, which improves long-term outcome.
Treatment strategies for intoxication range from letting patients "sleep
it off" to confinement in a medical or psychiatric unit. Treatment for
acute sedative-hypnotic withdrawal should include medically managed detoxification.
Hospital settings are preferable, especially for depressed patients. Opiate
withdrawal, while not life threatening, should also be treated medically
and on an inpatient basis when possible. When such hospital-based settings
are unavailable, residential or outpatient support with or without medication
should be attempted.
Since unassisted withdrawal can cause seizure, psychosis, depression,
and suicidal thoughts, it can be dangerous. Thus, successful detoxification
is often a lifesaving process. Also, the medical management of withdrawal
alleviates patients' suffering. It can provide a safe, supportive, and
nonthreatening environment for depressed patients.
Medical Treatment
Acute treatment may be required for medical conditions identified in the
medical assessment. For example, thyrotoxicosis (thyroid storm) is a life-threatening
imitator of mania. Also, low blood sugar resulting from insulin overdose
can resemble intoxication and depression.
Psychiatric Treatment
Patients who are imminently dangerous to themselves or others due to a
psychiatric disturbance require emergency psychiatric treatment. Such treatment
may involve voluntary or involuntary confinement.
The presence of a coexisting AOD use disorder or the suspicion that
the psychiatric disturbance is AOD induced does not mitigate requirements
for confinement. Rather, it may necessitate addiction-specific emergency
treatment such as detoxification.
Patients not requiring confinement after evaluation may benefit from
the support of existing family networks, existing programs, or when available,
a rapid referral to a dual disorders treatment program.
Medical management of acute psychiatric symptoms is a treatment strategy
during the acute phase regardless of long-term diagnostic results. Patients
who experience hallucinations, delusions, mania, or significant disorganization
of thought can benefit from medical treatment with antipsychotic medication
(such as haloperidol or thioridazine) whether or not their symptoms are
AOD induced. If potentially abusable medications are required (such as
benzodiazepines for acute mania), a period of tapering or reduction of
the medication within 1 or 2 weeks should be built into the original treatment
plan.
Subacute Treatment Issues
Matching Patients and Treatment
During subacute treatment, the first decision to be made is whether patients
should receive treatment in a psychiatric or addiction setting. In some
locations, a third alternative is available: the dual disorders treatment
setting. When realistic, both types of treatment should be provided simultaneously;
integrated treatment generally is preferable.
Criteria for determining placement include the patient's treatment needs
and potential for loss of control, as well as program features such as
intensity, structure, and limitations. There are also considerations specific
to mood disorders.
For example, if patients are experiencing mania or psychotic depression
with disordered thinking, it must be determined whether the program is
capable of handling and treating patients with these problems. While psychotic
depression or mania is being managed, patients may then be shifted to an
addiction or dual disorder setting. Appropriate matching of patients to
facilities is important.
Some patients with dual disorders require rare or minimal psychiatric
intervention, such as AOD patients whose bipolar disorder is successfully
managed with lithium and regular blood level monitoring. Patients who require
a strong recovery-oriented AOD abuse treatment program should also receive
treatment for their psychiatric disorder (parallel treatment), with an
emphasis on AOD treatment.
In contrast, patients who experience chronic and severe psychiatric
disturbances and who episodically use AODs in a markedly destructive fashion
will be better treated in a psychiatric program that has staff with expertise
in addiction treatment. The optimal match for the patient with two active
disorders that require treatment is the integrated facility. The intensity
of each disorder dictates the relative intensity of each treatment component
required.
Referral to an appropriate facility should be based on practical clinical
criteria rather than on diagnosis alone. For example, patients' ability
to understand, interpret, and tolerate the level of care being provided
is most important. Some patients can participate in standard 12-step groups.
Others will require 12-step groups that are intended for people with dual
disorders (Double Trouble groups). Still others will require professionally
run therapy groups that include patients with similar problems.
Effective treatment is based on what patients can understand and tolerate,
which is not always predicted by diagnosis. Some psychotic patients function
well in traditional programs, while others require special settings. An
individual plan and a flexible ongoing reassessment of effectiveness are
the best ways to ensure fit.
Psychiatric Medications
The judicious use of antidepressant and mood-regulating medication is appropriate
for AOD patients with mood disorders. For example, patients who experience
debilitating, misery-provoking, and incapacitating depressive symptoms
may require antidepressant medication to participate in addiction recovery.
(See Chapter 9 for
further discussions of psychiatric medications.)
When depressive symptoms interfere with functioning, antidepressant
medication can provide symptom relief and allow participation in recovery
activities and activities of daily living. Relief from depression and anxiety
can be significant motivating factors in recovery. Left untreated, symptoms
can keep patients from taking part in recovery activities.
Patients who have difficulty engaging in Alcoholics Anonymous and other
support groups and who do not exhibit evidence of a personality disorder
may be depressed. Depression may manifest as social withdrawal, reclusiveness,
or inability to complete activities of daily living such as going to work.
Regularly spending many hours a day in bed or having serious insomnia may
be cardinal signs of depression but are often seen among patients with
AOD disorders during the first weeks and months of abstinence.
When prescribing antidepressants for people participating in addiction
treatment, the acronym MASST is a reminder for clinicians of the areas
of AOD recovery that need to be continually assessed. MASST is an acronym
that reminds clinicians to assess patients' treatment needs regarding:
1) Meetings, 2) Abstinence from all psychoactive drugs, 3) Sponsor (or
other helping people), 4) Social support systems, and 5) overall Treatment
efforts. (See the discussion on the use of 12-step programs in Chapter
6.)
MASST Areas of Recovery
-
M:
-
Meetings (12-step or other recovery-oriented self-help)
-
A:
-
Abstinence from all psychoactive drugs
-
S:
-
Sponsor and other helping people
-
S:
-
Social support systems
-
T:
-
Treatment efforts.
Case Management
Case management is crucial when patients are receiving simultaneous AOD
and psychiatric care at separate settings (parallel treatment). There must
be good linkages between the two treatment programs or providers. For example,
patients might see their mental health counselor three times a week, go
to both AOD self-help group meetings and mental health support group meetings,
and receive AOD counseling. This level and mix of treatment can be overwhelming
and confusing for the patient. An effective case manager can help with
planning sensible treatment. Case managers can also facilitate the use
of self-help groups. (See the discussion on the use of 12-step programs
and other self-help groups in Chapter
6).
The separate disorders, their distinct treatment needs, and the divergent
treatment approaches can cause staff splitting and turf problems that exacerbate
the patient's denial and can cause other treatment problems. These problems
can be avoided in almost all cases by effective communication and coordinated
treatment planning. Good psychiatric and addiction treatment efforts are
rarely truly conflicting.
Counseling and Psychotherapy For Depression
It is beyond the scope of this TIP to provide comprehensive details on
the use of psychotherapeutic treatment. However, there are numerous resources
regarding counseling and psychotherapy and depression. Recent publications
written for both counselors and patients include The Good News About
Depression by M.S. Gold and When Self-Help Fails by P. Quinnet.
Levels of Care
Once psychiatric and addiction severity has been determined, the treatment
intensity, structure, and level of care required must be decided. From
the least to the greatest intensity, the levels of care are:
-
Individual treatment with a psychotherapist or counselor. This is the least
intensive level of care and includes few, if any, additional treatment
services such as education.
-
Outpatient treatment. Within this level of care are services that vary
greatly in structure and intensity. They include weekly to daily individual
or group counseling, often in combination with additional treatment services
such as detoxification, education, medical services, and specially focused
groups. A multidisciplinary treatment team that includes assertive and
intensive case management services may be needed for patients with severe
and persistent mood disorders coexisting with AOD disorders.
-
Intensive outpatient treatment. This level of care includes treatment models
such as partial hospitalization (which includes day treatment, evening,
and weekend programs). For example, patients in day treatment generally
participate in a full day of treatment for 5 or more days per week. Intensive
outpatient treatment represents a range of treatment intensities. The level
of intensity of a given program is based primarily on the number of treatment
services offered. Generally, intensive outpatient treatment programs offer
several treatment components such as group therapy, educational sessions,
and social support services.
-
Halfway houses. These are settings that serve as safe AOD-free homes for
people who can manage independent daily activities and can benefit from
a structured and recovery-oriented group living arrangement. They vary
widely in style and purpose.
-
Residential rehabilitation setting. Participation can vary from 30 days
to 3 months or more, with patients removed from familiar surroundings and
separated from AODs. In residential settings, patients receive education
about dual disorders and learn important recovery skills such as utilizing
groups, building trust, and talking about feelings. Therapy and support
groups provide socialization and support and are the core of treatment.
They prepare the patient for increased reliance on group support systems
after discharge.
-
Therapeutic communities. Long-term therapeutic communities often require
patient participation lasting from 6 months to 2 years. They are generally
considered to be appropriate for patients with severe AOD disorders who
have significant social and vocational deficits and who require long-term
and intensive support, skill building, interpersonal abilities refinement,
and trauma resolution.
-
Hospitals. Psychiatric or AOD hospitalization may be required for acute
and subacute stabilization. In this age of managed care, hospitalization
episodes have become much shorter and more acute than a few years ago.
This puts more responsibility and risk on outpatient treatment providers.
Patients with severe and persistent mood and AOD disorders frequently require
intensive and assertive treatment approaches as outlined in Chapter
8 on psychotic disorders. These patients will benefit from programs
that can provide concurrent, integrated dually focused treatment. Also,
these patients may require assertive case management to encourage medication
compliance and to help them secure all psychiatric, addiction, and social
services that they may need.
While some programs for dual disorders exist at all levels of care and
in several program models, few AOD or mental health residential programs
are dually focused, and many AOD programs refuse to accept patients who
have histories of psychiatric disorders or who currently are prescribed
medication for psychiatric disorders.
Traditional biases in the addiction field against psychiatric medication
should be shed in light of the evidence that medicating existing disorders
is humane, can be provided safely, and is necessary for some patients to
engage in treatment. It is helpful to use psychiatrists who are skilled
and are perhaps specialists in the treatment of coexisting psychiatric
and AOD disorders.
Similarly, traditional psychiatric biases regarding rapid medication
intervention and some clinicians' emphases on "getting in touch with feelings"
can impede or reverse the AOD recovery process. Encouraging emotional expression
without regard for the patient's stage of AOD recovery and stability can
aggravate AOD disorders. Many residential facilities in the mental health
system are inadequately controlled for the presence of AODs, are not abstinence
based, and are not safe environments for AOD users.
Family Involvement In Treatment Settings
In all of the above settings, patients should receive family therapy and
education, addiction and recovery counseling, and psychiatric counseling.
Special attention must be focused on the chronic and cyclical nature of
addiction and mood disorders and the likelihood of relapse.
Manic patients' uncontrolled grandiose behaviors have frequently caused
their families great stress. Thus, family members need education about
the nature of addiction, mania, and recovery. It is necessary for staff
to ally with family members to ensure cooperation with treatment and reduce
collusion between family members and the patient.
Similarly, the depressed patient is frequently seen as a family burden.
Families need assistance to engage the depressed patient. The combination
of depression and addiction can be very difficult for family members, and
the challenges for the family must be considered.
Family and friends are often mistakenly afraid that they might exacerbate
or aggravate depression or mania if they confront the dangerous and maladaptive
behaviors and denial that result from addiction and mood disorders. Such
fears are ungrounded. In fact, supportive intervention by the patient's
social network is helpful with respect to both disorders.
The patient's family should be encouraged to confront the patient rather
than remain reticent, and they should be coached to confront the patient
in a supportive way. Support for and education of family members are necessary
to encourage their constructive involvement and to help them avoid collusion
in the patient's drug-using behavior or denial of psychiatric disturbance.
Professional and Vocational Planning
While some patients with dual disorders have severe and poorly remitting
mood and AOD disorders, most patients improve, especially with careful
psychiatric treatment. Since these disorders are generally well controlled,
patients can experience very high levels of vocational, social, and creative
functioning. As a result, vocational planning should be long term and accentuate
patient strengths.
AIDS and HIV Risk Reduction
Studies demonstrate that HIV/AIDS risk reduction measures can make a difference
in the rate of HIV infection. Potential and actual risk behaviors that
are identified in evaluation should be addressed by referral to specific
educational, training, and intervention programs.
Staff at these programs should be sensitive to patients' cultural and
ethnic backgrounds, and understand how these can influence AOD use, sexual
behaviors, and patients' receptivity to risk reduction measures. Programs
should be proficient in communicating with patients using culturally sensitive
language. However, the most culturally insensitive position is to avoid
raising these issues out of fear or hesitancy.
With respect to risk reduction, special attention should be paid to
the fact that, while depressed, many patients may be sexually abstinent,
but this behavior may not reflect their typical behavior patterns. If patients
are assessed while they are depressed, they should be asked to describe
their sexual behavior during times when not depressed, or perhaps they
should be assessed when they are not depressed. Mania and active AOD use
markedly elevate the potential for high-risk behaviors and should be seen
as extremely dangerous situations for the transmission of HIV and other
sexually transmitted diseases.
HIV counseling and testing is appropriate and advisable for patients
with coexisting AOD and mood disorders. There is no evidence that people
with mood disorders become suicidal or experience thought disorganization
in response to HIV testing.
Long-Term Treatment Goals
Treatment goals should include consolidating the AOD-free lifestyle, establishing
psychiatric stability, achieving social independence and stability, and
enhancing vocational choices and goals. Long-term treatment can be viewed
as a maintenance period -- a time for personal growth and development and
consolidation of long-term, satisfying patterns of social adaptation.
Addiction Treatment
The long-term management of addiction includes participation in 12-step
programs and other support groups, individual and group counseling, and
in some cases, continued participation in a treatment program. The severity
of a patient's illness should be matched with the appropriate treatment
intensity and level of care.
Patients with dual disorders who experience low levels of psychiatric
impairment require a level of care that can be provided in traditional
low-structure abstinence-oriented addiction treatment programs. Dual disorder
patients who experience severe psychiatric symptoms or cognitive impairment
require a more intense level of care such as that provided by a highly
structured dual disorders treatment program. Matching patients to the appropriate
treatment and level of care can help achieve desired outcomes.
Psychiatric Treatment
The majority of patients receiving treatment for combined mood disorders
and addiction improve in response to treatment. When they don't improve,
there should be a reevaluation of the treatment plan. For example, a patient
receiving antidepressant medication who is abstinent from AODs but anhedonic
(unable to feel pleasure or happiness) requires a careful evaluation and
assessment to identify resistant psychiatric conditions that require treatment.
In this example, based on assessment, an additional treatment service such
as psychotherapy may be added. Indeed, psychotherapy has been shown to
improve the efficacy of addiction treatment and of psychiatric treatment
that involves antidepressant medication.
When patients do not improve as expected, it is not necessarily because
of treatment failure or patient noncompliance. Patients may be compliant
and plans may be adequate, but disease processes remain resistant. Persistent
attention to the addictive process and its complications as well as meticulous
attention to psychiatric therapy usually leads to improvement. However,
patients with severe and persistent AOD and mood disorders should not be
seen as resistant, manipulative, or unmotivated but as extremely ill and
requiring intensive treatment.
Long-Term Treatment Needs
Patients who have experienced sexual, physical, or psychological abuse
may have problems that surface during acute treatment or that are identified
during long-term treatment evaluations. Treatment needs resulting from
these types of abuse should be addressed in the long-term treatment plan.
The resolution of problems related to sexual, physical, and psychological
abuse usually requires specialized, long-term treatment. However, these
problems should be addressed whenever they surface in any phase of treatment
for AOD and mood disorders.
For example, addressing these problems during early recovery should
be viewed from the perspective of anxiety reduction and consolidation of
abstinence. At that phase of recovery, the treatment goal is to have patients
contain or express their potent and surfacing feelings without using alcohol
and other drugs. Later in recovery, these problems can be dealt with in
terms of long-term stabilization and psychological resolution.
Continuing addiction counseling and participation in group support activities
are useful to help consolidate abstinence. These recovery maintenance activities
include participation in social clubs, 12-step programs, religious organizations,
and other cultural institutions. Community-based activities can provide
long-term stability to these patients.
At this stage of treatment, special treatment needs can be identified
through targeted testing in such areas as neurologic, cognitive, and personality
disorders. Special treatment needs should be specifically addressed by
the appropriate treatment strategy. STD and HIV risk reduction, evaluated
throughout the progression of illness, should now address the importance
of long-term stable changes in behavior.
Family Issues
Family members should be evaluated for AOD problems in acute and subacute
stages when the family members begin to become involved in the patient's
treatment. There is usually adequate time to deal with family issues in
the subacute phase, when personnel and family members become acquainted.
Family members include household members as well as members of the patient's
support system.
The family often needs and should receive treatment. After careful evaluation
of family dynamics, the presence of addictive disorders or codependent
behavior in the family should be evaluated. The presence of AOD and mood
disorders in the patient is the best predictor of AOD and mood disorders
in the family. A family history of one disease increases the risk for the
other; a family history of both disorders multiplies the risk factor.
Family therapy can be provided on site. Individual family members should
be referred for the treatment of specific problems when required. It is
often necessary to help families "mop up the rage" that has accumulated.
It is important to determine when to deal with the family as a group to
resolve conflicts and when members need to work with a therapist alone
to develop independence from dysfunctional reliance. Participation in Al-Anon
and related self-help groups for family members should be encouraged and
incorporated in the treatment schedule for family members.
Eating Disorders and Gambling
Other conditions that coexist with dual disorders include eating disorders
and pathologic gambling. It may be helpful to refer patients to support
groups that deal with these conditions. Eating disorders are more commonly
diagnosed in women, and pathologic gambling is more commonly diagnosed
in men.
Reassessment and Reassessment...
The purposes of ongoing reassessments are: 1) to continue to refine prior
diagnostic assessments, 2) to evaluate life adjustment in general, 3) to
evaluate the effectiveness of treatment efforts for the dual disorders,
and 4) to evaluate the discontinuation or continued use of medication and
other treatments.
Persistently emerging and remitting problems should be addressed. For
example, patients who chronically exhibit a negative disposition should
be assessed for a personality disorder. Such patients may have a personality
disorder with depressive features rather than a mood disorder.
Testing
Specific neuropsychological, psychological, educational, and vocational
testing assessments should be performed when necessary and appropriate.
These include testing for learning disorders, cognitive or literacy impairments,
and personality disorders. These tests are more reliable and accurate when
performed following several months of sobriety.
Chapter 6 -- Anxiety Disorders
Definitions and Diagnoses
The anxiety disorders are the most common group of psychiatric disorders.
The term anxiety refers to the sensations of nervousness, tension,
apprehension, and fear that emanate from the anticipation of danger, which
may be internal or external. Anxiety disorders describe different
clusters of signs and symptoms of anxiety, panic, and phobias.
A panic attack is a distinct period of intense fear or discomfort
that develops abruptly, usually reaching a crescendo within a few minutes
or less. Physical symptoms may include hyperventilation, palpitations,
trembling, sweating, dizziness, hot flashes or chills, numbness or tingling,
and the sensation or fear of nausea or choking. Psychologic symptoms may
include depersonalization and derealization and fear of fainting, dying,
doing something uncontrolled, or losing one's mind. A panic disorder
consists
of episodes of panic attacks followed by a period of persistent fear of
the recurrence of more panic attacks.
When the focus of anxiety is an activity, person, or situation that
is dreaded, feared, and probably avoided, the anxiety disorder is called
a phobia. Phobia-inspired avoidance behavior as well as travel and
activity restrictions may become intense and incapacitating. The phobias
include agoraphobia, social phobia, and simple or specific phobia; panic
attacks and panic disorders are often but not necessarily involved.
Specific phobia, also called single or simple phobia, describes
the onset of intense, excessive, or unreasonable fear, stimulated by the
presence or anticipation of a specific object or situation. The causes
may be naturally occurring (for example, animals, insects, thunder, water),
situational (such as heights or riding in elevators), or related to receiving
injections or giving blood. Social phobia describes the persistent
and recognizably irrational fear of embarrassment and humiliation in social
situations. The social phobia may be quite specific (for example, public
speaking) or may become generalized to all social situations. Agoraphobia
is the fear of being caught in a situation from which a graceful and speedy
escape would be impossible, difficult, or embarrassing. Examples of feared
situations include attendance in an auditorium, being stuck in traffic,
and being outside the house.
In generalized anxiety disorder, there is no specific focus to
the anxiety; symptoms are free-floating. Generalized anxiety disorder involves
excessive anxiety, worry, and apprehensive expectations focused on many
life circumstances, more days than not, for a period of at least 6 months.
The intensity, duration, and frequency of symptoms are out of proportion
to the probability or consequences of the feared event. Somatic symptom
clusters often involve: 1) motor tension (such as trembling, restlessness,
and fatigue), 2) autonomic hyperactivity (for example, shortness of breath,
palpitations, sweating, dry mouth, dizziness, and abdominal distress),
and 3) hyperarousal (such as exaggerated startle response, irritability,
insomnia, and poor concentration).
Obsessive-compulsive disorder (OCD) is an anxiety disorder involving
obsessions or compulsive rituals or both. Obsessions are repetitive
and intrusive thoughts, impulses, or images that cause marked anxiety.
They often involve transgressing social norms, harming others, and becoming
contaminated, but they are more intense than excessive worries about real
problems. Compulsions are repetitive rituals and acts that people
are driven to perform and which they perform reluctantly to prevent or
reduce distress. The frequency and duration of their repetition make them
inconvenient and often incapacitating. Examples include ritualistic behaviors
(such as hand-washing and rechecking) and mental acts (for example, counting
and repeating words silently); they are time-consuming and interfere significantly
with daily functioning.
Post-traumatic stress disorder (PTSD) involves an individual's
experiencing a psychologically traumatic stressor such as witnessing death,
being threatened with death or injury, or being sexually abused. At the
time of the stressor event, the individual experiences intense fear, helplessness,
or horror. PTSD entails a persistent reexperiencing of the trauma in the
form of recurrent and intrusive images and thoughts, or recurrent dreams,
or experiencing episodes during which the trauma is relived (perhaps with
hallucinations). People with PTSD experience persistent symptoms of increased
arousal such as insomnia, irritability, hypervigilance, and exaggerated
startle response. They persistently avoid stimuli related to the trauma
such as activities, feelings, and thoughts associated with the traumatic
event.
Interest in the role of sexual abuse and incest in PTSD and other psychiatric
and AOD disorders has increased. Clinicians note that long-term responses
to childhood and adult sexual abuse often include symptoms associated with
PTSD and other psychiatric problems, including an increased risk for AOD
disorders. Many such problems are addressed in treatment efforts popular
in adult children of alcoholic (ACOA) programs, some of which are controversial
and unsubstantiated by research or long-term observation. Such treatment
approaches may exacerbate AOD use and psychiatric disorders and should
be cautiously undertaken. Amnesic periods have to be carefully evaluated
both as blackout phenomena and as possible dissociated states. Such differentiation
can be extremely complicated. While a clinician's immediate response may
be to identify these patients as being intoxicated, they may be experiencing
independent psychiatric phenomena.
Prevalence
Prevalence rates for anxiety disorders in the general population can be
estimated from the Epidemiologic Catchment Area (ECA) studies. According
to the ECA studies, anxiety disorders affect more than 7 percent of adults
(Regier
et al., 1988). (In the general population, the lifetime prevalence
rate of anxiety disorders is 14.6 percent.) Women, individuals under age
45, those who are separated or divorced, and those in low socioeconomic
groups all have a higher rate of anxiety disorders than individuals in
other groups.
The ECA studies indicate that in the general population:
-
The 1-month prevalence rate for any anxiety disorder is 7.3 percent (4.7
percent for males and 9.7 percent for females), and the 6-month rate is
8.9 percent.
-
The 1-month prevalence rate for phobia is about 6.2 percent (3.8 percent
for males and 8.4 percent for females).
-
The 1-month prevalence rate for panic disorder is about 0.5 percent (0.3
percent for males and 0.7 percent for females).
-
The 1-month prevalence rate for obsessive-compulsive disorder is 1.3 percent
(1.1 percent for males and 1.5 percent for females).
-
Lifetime prevalence of post-traumatic stress syndrome in the general population
is estimated to be less than 1 percent. The prevalence among individuals
who have experienced a psychologically traumatic stressor and then developed
psychiatric symptoms is poorly understood.
Among patients with AOD problems, there is a significant likelihood for
having a coexisting anxiety disorder. One study noted that more than 60
percent of patients being treated for AOD disorders had a lifetime diagnosis
of an anxiety disorder, and about 45 percent experienced an anxiety disorder
within the past month (Ross
et al., 1988). Other studies have demonstrated that most anxiety disorders
among patients in addiction treatment are AOD induced (Anthenelli
and Schuckit, 1993).
Differential Diagnosis
Anxiety sometimes has value as a signal of danger. In the same way that
being sad is an appropriate response to some situations, experiencing anxiety
can be an appropriate response. When manifestations of anxiety occur without
apparent triggers or are out of proportion to the situation, they can be
considered anxiety symptoms. If the symptoms are persisting, maladaptive,
and meet certain diagnostic criteria, then the symptoms can be described
as a syndrome. Further, if specific criteria are met in terms of
consistency, repetitiveness, and duration, then the symptoms can be considered
an anxiety disorder.
Anxiety symptoms are the most common psychiatric symptoms seen in AOD
abusers. AOD-induced or withdrawal-related anxiety symptoms usually resolve
within a few days or weeks. Most anxiety symptoms seen in AOD abusers resolve
with AOD treatment; such conditions would be diagnosed according to the
DSM-IV draft as substance-induced anxiety disorders. However, some people
with AOD disorders have coexisting anxiety disorders that can be mildly
to seriously debilitating.
Medical problems that may produce symptoms of anxiety include those
affecting the cardiovascular and respiratory symptoms; neurological, hematological,
and immunological disorders; and endocrine dysfunction. Several disease
states can resemble generalized anxiety or panic, including acute cardiac
disorders, cardiac arrhythmia, hyperthyroid conditions, brain disease,
and HIV infection and AIDS. However, the most frequent imitator is addiction.
Medications that can cause anxiety symptoms include antispasmodics,
cold medicines, thyroid supplements, digitalis, prescribed or over-the-counter
diet medications, antidepressant medications, and, paradoxically, some
antianxiety drugs such as benzodiazepines. Methylphenidate (Ritalin) and
neuroleptic drugs can also cause anxiety. Withdrawal from depressants,
opioids, and stimulants invariably includes potent anxiety symptoms. Steroids
can make people hyperactive and anxious. Idiosyncratic reactions to medications,
caffeine use, and nicotine withdrawal all can cause states similar to panic.
Similarly, some medications cause acathisia, which is a feeling
of restlessness and the urgent need to move about. Acathisia can be confused
with anxiety.
The differential diagnosis of agoraphobia and social phobia includes
avoidance behaviors that occur as a part of depression, schizophrenia,
paranoia, other anxiety disorders, and some organic mental disorders. Many
features of OCD can emerge as secondary complications of major depression,
and obsessions may appear in the context of either depression or schizophrenia;
distinctions between delusions and obsessions can be difficult to make.
Like PTSD, adjustment disorder is a maladaptive reaction to a psychosocial
stressor but involves a broader range of less extreme experiences. Adjustment
disorder may result in a few of the symptoms seen in PTSD, but intense
reexperiencing is less common.
PTSD and dissociative disorders such as multiple personality disorder
(MPD) are often diagnosed among individuals with AOD disorders. Although
the relationship has not been systematically examined, it is one to consider
in differential diagnosis. MPD is receiving renewed attention and may occur
frequently with AOD use disorders. Addiction treatment personnel should
be trained that patients in a blackout or altered state may appear to be
sober, and may in fact be sober. Recent studies indicate evidence of overdiagnosis
of MPD. It is not necessary to assess all AOD patients for this disorder.
Rather, training clinical staff to be alert for the signs and symptoms
of MPD is a worthwhile goal. Mental health staff who treat patients with
MPD should be alert for the signs and symptoms of AOD use disorders.
Many of these individuals need treatment provided by professionals who
have specialized training in trauma resolution. Such patients need stability
in their primary therapeutic relationship; hence, this work should not
be undertaken in settings with high staff turnover. In most settings, the
AOD abuse counselor should not try to treat patients who have experienced
trauma.
Traditional long-term psychotherapy can cause patients anxiety, especially
patients who were traumatized during some part of their lives. During acute
treatment it may be best to teach patients the skills to express conflicts
in socially appropriate ways, such as in self-help and therapeutic groups.
Later, psychotherapy can help patients to resolve the underlying conflicts.
AODs and Anxiety Disorders
Psychoactive drugs can markedly arouse intense psychomotor stimulation
and numerous manifestations of anxiety, including generalized anxiety and
panic attacks. Stimulant and marijuana use and depressant withdrawal can
prompt the emergence of anxiety symptoms. Hallucinogenic drugs can cause
intense emotional excitement and subsequent anxiety.
Stimulants
Stimulants, such as cocaine and the amphetamines, cause potent psychomotor
stimulation. Stimulant intoxication, including caffeine intoxication, can
cause motor tension, autonomic hyperactivity, hyperarousal, and panic attacks.
Chronic and high-dose stimulant use can provoke the onset of obsessions
and compulsive behaviors. Acute stimulant withdrawal typically involves
an agitated depression, often with anxiety and sometimes with panic attacks.
Subacute stimulant withdrawal, although characterized by sustained episodes
of anhedonia and lethargy, frequently involves intense ruminations and
dreams about stimulant use. These may prompt symptoms of anxiety and panic.
Depressants
Cessation of chronic use of sedative-hypnotics, such as alcohol and the
benzodiazepines, can cause an acute sedative-hypnotic withdrawal. Cessation
of chronic use of opioids, such as heroin and methadone, can cause an acute
opioid withdrawal. Acute withdrawal from depressants can include intense
anxiety symptoms, including motor tension, autonomic hyperactivity, and
hyperarousal, depending on the degree of tolerance. Panic attacks are common.
Anxiety symptoms are often self-medicated with depressants.
Following acute withdrawal, some patients experience a subacute withdrawal
syndrome,
also called "prolonged" or "protracted" withdrawal. Subacute withdrawal
may begin shortly after acute withdrawal or may emerge weeks or months
later, often in discrete episodes that last one or more days. Subacute
withdrawal syndromes have been identified for alcohol, benzodiazepines,
opioids, and stimulants. For example, sedative-hypnotic subacute withdrawal
often includes such symptoms as bursts of anxiety, insomnia, and irritability.
Benzodiazepine-related subacute withdrawal may also cause muscle spasm,
tinnitus (ringing in the ear), and parasthesias (unusual physical sensations
often described as burning, pricking, tickling, or tingling).
Hallucinogens
Most hallucinogenic drugs exert stimulant effects in addition to causing
perceptual and sensory alterations. Some drugs, such as MDMA (Ecstasy),
MDA, and mescaline are related to the amphetamines. At low doses, perceptual
and sensory distortions predominate; at high doses, stimulant effects prevail.
Thus, high doses of hallucinogens can prompt symptoms of anxiety and panic
much like other stimulants.
While the effects of hallucinogens are pleasant at times to many users,
some individuals may respond with intense anxiety and panic. Some may fear
the sensory distortions and others may fear that the experiences will be
permanent. In such cases, a soothing interaction in a quiet, comfortable
room with minimal distractions can often allay distress. In these circumstances,
individuals are often suggestible and respond well to a calm discussion
that includes reassurance that the experience is drug induced, time limited,
and not likely to result in permanent damage.
Marijuana, which has sedative and hallucinogenic properties, can cause
a variety of mood-related effects. Acute marijuana intoxication
can include periods of anxiety and panic, usually seen in persons who have
not acquired a tolerance to the effects of the drug.
Case Example
While Molly and a group of her friends were preparing to attend a rock
concert, they each consumed a tablet that was described as Ecstasy (methylenedioxymethamphetamine
or MDMA). About an hour later, Molly began to experience potent emotional
sensations, and felt an internal pressure to talk about her feelings. Once
inside the coliseum, Molly gravitated toward the stage. At some point,
she became increasingly aware of the loudness of the music, the brightness
of the stage lights, and the intense crowding of concert attendees. Molly
began to sweat heavily, tremble, and feel dizzy. She turned to escape the
overstimulation, but the crowd of people made her passage difficult. She
became fearful and nauseous, and her hands and feet tingled and became
somewhat numb. By the time she reached the first-aid tent, she felt that
she was losing her mind.
By taking a history from Molly and speaking with her friends, the emergency
medical technician determined that she had taken MDMA, which along with
the explosion of sight, sound, and crowding, prompted a severe panic attack.
Molly was treated by moving her to a quiet room without bright lights,
letting her walk off some of the nervousness, and using "talkdown" techniques.
The acute panic symptoms resolved within minutes, although she was anxious
for the next hour. About 3 hours after taking the MDMA, the stimulant effects
diminished, and Molly felt only a sense of mild anxiety and frustration
for having missed much of the concert.
AOD-Induced Conditions
The addiction counselor should not assume that anxiety symptoms, especially
those emerging or persisting after 30 days in treatment, or depersonalization
are related to AOD abuse. Staff in mental health programs, on the other
hand, may fail to recognize that the symptoms of anxiety, caused by AOD
use, may resemble a psychiatric disorder. Addiction counselors have historically
been encouraged more than psychiatric personnel to seek referrals for the
patient who requires treatment beyond their clinical skills. Both groups
should view increased cross-referral and consultation as beneficial.
Panic.
Panic attacks can occur in individuals who are chronic users of alcohol,
cannabis, inhalants, hallucinogens, organic solvents, and especially stimulants
such as cocaine and the amphetamines. Use or withdrawal from these drugs
can produce panic effects. For example, panic attacks can occur during
acute and subacute withdrawal from sedative-hypnotics and opioids.
Phobias.
What appears to be a phobia may be the result of the chronic use of alcohol,
benzodiazepines, or hallucinogens. For example, patients may avoid leaving
the house not because of agoraphobia but because of the desire to have
ready access to an AOD supply. Apparent phobias are not likely to occur
following the acute use of these drugs.
Post-traumatic stress disorder.
Some effects of hallucinogens, marijuana, PCP, alcohol, and benzodiazepines
may be dissociative. However, PTSD, MPD, and dissociative disorders seem
to cluster with chemical dependency. PTSD is difficult to accurately diagnose
and is often misdiagnosed. It is necessary to differentiate between PTSD
and acute dissociative states due to drug use.
Dissociative disorders.
Some drugs, including hallucinogens, phencyclidine (PCP), and marijuana,
can cause dissociation while they are being used. People who are experiencing
withdrawal from alcohol, benzodiazepines, barbiturates, and opiates can
manifest symptoms of dissociation. The differentiation between blackouts
and dissociation can be extremely complicated. The initial response may
be to describe dissociated people as inebriated, often because they are
glassy eyed and poorly responsive. In response to questions about situations
or events that are not recalled because of memory impairment, some people
will fabricate facts or events. This process is called confabulation.
It differs from lying in that the person is not consciously attempting
to deceive.
Acute withdrawal and dissociative disorder often appear similar. Dissociated
people require an immediate toxicological screen and should be admitted
for continued observation. Attempts to establish reality-based grounding
are necessary with these patients before medications are given or other
interventions are attempted. The clinician should establish a soothing
atmosphere, establish eye contact with the patient, and keep the patient
grounded. It is often helpful to encourage agitated patients to focus externally
on things they can see and describe, instead of focusing on their internal
states. This shift in attention is often effective in allaying distress.
People in outpatient treatment may be verifiably abstinent and participating
in recovery but may be experiencing dissociative symptoms. Patients with
these disorders may have great difficulty in establishing and maintaining
abstinence. Thus, integrated (rather than parallel) treatment is especially
important for this group.
The evaluation of anxiety disorders and dissociative disorders, including
PTSD and MPD, should include a careful history of recent and remote traumas.
An assessment of trauma should include physical, sexual, and psychological
abuse, and catastrophic stresses such as combat or hostage situations.
For example, a rape experience within the last year and early childhood
incest both could lead to the development of anxiety disorders. People
living in violent situations, such as prostitutes who have been raped,
can manifest anxiety symptoms. It is a mistake to ignore violence such
as rape and look solely at early traumas. Recent traumas can be the trigger
for PTSD or an MPD event. Early childhood abuse of males as well as females
must be considered.
Obsessive-compulsive disorder.
With chronic use, several types of drugs (alcohol, benzodiazepines, and
stimulants) can produce signs and symptoms similar to those of obsessive-compulsive
disorder.
Assessment of the Anxious Person
Anxiety is one of the most common symptoms of people with AOD disorders.
During acute assessments, many patients who are anxious and/or depressed
are experiencing the effects of AOD use. As is the case with depression,
time must pass before it is possible to make a definitive differential
diagnosis of either AOD abuse, anxiety, depression, or a combination thereof.
Most symptoms related to AOD use usually clear within 2-4 weeks, although
the generally less severe subacute withdrawal symptoms may emerge after
this time.
Patients with panic disorder are more likely to give a better history
and description of panic attacks than the depressed patient can give regarding
episodes of depression. Many people with a history of panic or anxiety
disorders will be able to describe them with impressive accuracy. Also,
patients with anxiety disorders are more likely to perceive them as abnormal
conditions or "illnesses" that they don't deserve, compared with depressed
patients who often feel that they deserve to be depressed or may feel that
being depressed is a normal condition. Both depressed and anxious patients
tend to ignore the connection with AOD use.
Various states may be mistakenly called anxiety, and people often use
terms such as "panic attack" to describe nonpsychiatric states. Thus, clinicians
should clarify the nature of the experience described by the patient. For
example, many people consider any fear as anxiety or panic: "You really
scared me. I almost had a panic attack." Careful inquiry along the lines
of DSM-III-R criteria will distinguish definitive characteristics of anxiety
disorders from commonplace distress described with popular terms.
Anxiety can be dangerous. In combination with depression (which is frequent),
the risk for suicide is markedly increased. In the emergency room or clinic,
people may exhibit panic, dissociation, or PTSD; they can be very difficult
to handle. Anxiety can mimic signs of heart disease such as angina, arrhythmias,
heart attacks, cardiac ischemia, and congestive heart failure; it can also
accompany these conditions.
In the medical examination of the anxious person, there should be a
high index of suspicion of AOD use, especially withdrawal from depressants
and intoxication with stimulants and hallucinogens. The seemingly dissociated
individual should receive immediate toxicologic screens. AOD-induced anxiety
symptoms can signal serious medical crises; for example, benzodiazepine
withdrawal can cause seizures.
In cases where medications cause depression, caretakers have time to
deal with them. In contrast, anxiety caused by drug use may signal a medical
emergency. Nonmedical people should be familiar with warning signs and
have rapid access to medical screening.
Acute Assessment Issues
The medical management of withdrawal is driven by the drug(s) to which
a patient has developed tolerance; it does not vary significantly if the
patient is anxious or depressed. Whatever the drug involved, the management
of withdrawal-related anxiety involves issues similar to those associated
with depression. Psychiatric support, confinement, and medication may all
be needed.
People with simple anxiety are less likely to need to be hospitalized
involuntarily. Since coexisting anxiety and depression constitute a greater
risk factor for suicidal behaviors than depression alone, individuals with
combined anxiety, depression, acute AOD use, and suicidal thoughts should
be assessed for possible hospitalization, including involuntary commitment.
Similarly, people who have uncontrollable agitation or who experience depersonalization
may need to be confined. However, if tension is the main manifestation,
there is less need for protection.
If the patient describes acute anxiety secondary to hallucinogen or
marijuana use, the first line of treatment is "talking the patient down."
If this does not calm down the patient, pharmacologic treatments can be
used in some situations where the anxiety symptoms remain overwhelming
and dangerous. Benzodiazepines may be indicated over the short term. Sedating
antidepressants may be used during the subacute phase.
Phencyclidine-induced states can be extremely variable; they can be
brief and mild or long-lasting and associated with significant danger and
seizures. PCP can induce vertical nystagmus (involuntary motion of the
eyeball), which is otherwise rare. Glutethimide causes agitated intoxication
alternating with severe sleepiness and depression.
Agitated patients who do not have parasites (scabies, lice, and crabs)
but complain of the sensation of insects crawling on or under their skin
have probably used stimulants. Tactile hallucinations are hallucinations
that involve the sense of touch. Formications are a type of tactile
hallucination that involves the sensation of something creeping or crawling
on or under the skin. Formication is seen in patients with alcohol withdrawal
delirium and during the withdrawal phase of stimulant intoxication. Bilateral
(affecting both sides of the body) and symmetrical symptoms (itching, scratching,
and redness) are indicative of formications rather than of parasites. Manifestations
of parasite infestations are not symmetrical but have asymmetrical patterns
on each side of the body.
Subacute Assessment Issues
While danger to self and others is not a hallmark of anxiety disorders,
people in dissociated states may put themselves in great danger and require
involuntary commitment. The relationship between anxiety, depression, and
suicide has been noted. Thus the potential for harm to self and others
should be considered. The possibility of medical disturbance and psychological
and AOD issues must be considered. Consider the example of a patient who
is treated in the emergency room for a panic attack. Once the patient is
transferred to treatment in an outpatient mental health clinic, a plan
should be developed that includes assessing AOD use, functional level (liabilities
and strengths), and physical status, including cardiac and endocrine tests
as indicated. Specifically, patients should be assessed for hyperthyroidism;
this is especially true for women, who are four times as likely as men
to have this disorder. Anxious people should also be evaluated for early
stages of HIV infection and transient ischemic attacks. Neurological status
should be carefully evaluated.
A psychosocial assessment is needed. If AOD use has been ruled out,
it should be determined if an overwhelming stressor has provoked the anxiety
response, such as grief or psychosocial stressors. For example, confusion
about sexual orientation can be a potent source of stress that can lead
to anxiety symptoms. Anxiety can also have cultural influences. For example,
there is a subgroup of addicted people who have lost the majority of their
friends to AIDS. When an individual has a pervasive anxiety disorder, develops
AOD problems, and lives in a dismal social situation, a thorough biopsychosocial
assessment is needed.
Grounding people in the here and now is most important. This should
be accompanied by providing education about addiction to the patient and
family. There are several self-help and support groups for people with
anxiety and phobias. People with phobias are often treated in specialized
treatment programs that utilize desensitization techniques, biofeedback,
and behavioral and cognitive therapies. These specialized treatment strategies
have been shown to be effective by empirical research.
Long-Term Assessment Issues
In long-term treatment, dissociative states may occasionally emerge in
patients, and counselors should have the skills for handling these patients.
In people who appear to be in a glassy-eyed dissociative state, the interviewer
should evaluate AOD use, and if this is ruled out, consider dissociation.
If the patient appears to be in a dissociative state, the clinician should
ground the patient in time and place, and focus on here-and-now issues.
Focusing on external events and processes rather than the patient's internal
processes or history is helpful. These methods will be effective whether
the patient proves to be in a drug-induced state or is manifesting a frank
dissociative disorder. Both AOD and mental health counselors need to evaluate
these patients.
Some people who experience anxiety are in fact experiencing an anxious
depression, but the diagnosis must be reevaluated over a 30-day period.
This is sufficient time for observation except in the case of subacute
withdrawal from benzodiazepines. After 30 days, all traces of AODs will
be gone, most neurochemical disturbances will disappear, and acute withdrawal
symptoms should be over. By this time, a depression can be seen with some
clarity.
Once patients have established and somewhat consolidated abstinence
in their lives, they should be provided with educational and vocational
testing and given support to help plan short-term and long-term goals.
Patients with dual disorders may experience setbacks during overall periods
of improvement. Thus, concrete planning efforts for future goals often
occur over a long period of time. Although generalized anxiety disorder
may severely restrict day-to-day functioning of some patients, most respond
well to treatment.
Acute Treatment Strategies
Some very anxious patients misinterpret their symptoms of chronic anxiety
as symptoms of an acute anxiety episode. Their misinterpretation may prompt
the therapist to make the same misinterpretation. Two of the acute anxiety
conditions most commonly encountered in emergency room settings are panic
attacks and dissociative states -- which may resemble psychosis.
Acute interventions include calming reassurance, reality orientations,
breathing management, and when needed, sedative medications such as benzodiazepines.
These interventions are nearly identical to those used for the two most
common AOD-related anxiety emergencies: withdrawal from sedative-hypnotics
(including alcohol) and intoxication from stimulants (including cocaine).
While the use of benzodiazepines is generally not problematic during acute
withdrawal, their use may be problematic for abstinent recovering people
who experience panic attacks. Indeed, such people may have abused benzodiazepines
before they became abstinent. Acute interventions should include behavioral,
cognitive, and relaxation therapies, often in combination with long-term
serotonergic and depressant medications. Cognitive therapy can be used;
patient manuals and workbooks exist for such treatment.
During an acute panic attack, people often believe that they are having
a heart attack, feel dizzy, and are unable to catch their breath. Enforced
regular breathing through the use of a paper bag helps to regulate breathing
and diminish excess release of carbon dioxide. Such breathing exercises,
education about symptoms, and reassurance will diminish panic symptoms
for many patients.
Subacute Treatment Strategies
For many patients in early recovery from AOD abuse, treatment of anxiety
disorders can be postponed unless there is a certain or verifiable history
that the anxiety preceded the addiction or is incapacitating. If symptoms
are mild and not interfering with function, including participation in
treatment, it is judicious to wait and see if the symptoms resolve as the
addiction treatment progresses. Subacute withdrawal may be difficult to
differentiate from anxiety disorders.
Antecedent traumas, as well as dysfunctional family situations that
have been identified during the assessments, should be addressed in a supportive
and calming manner. However, affect-liberating therapies should probably
be deferred until stability with respect to AOD abuse and acute anxiety
has been established. Issues of importance to the patient and raised by
the patient should not be ignored, but exploration of underlying trauma
should not be encouraged until the patient is stabilized.
Supportive, cognitive, behavioral, and dynamic therapies can all be
used, but in early recovery, patients need significant support and will
have very limited tolerance for anxiety and depression. The emphasis should
be on supporting recovery, attending 12-step meetings, and participating
in other self-help and group therapies. Insight-oriented treatments must
be carefully measured and limited by their potential to increase anxiety
and trigger relapse. When psychotherapy is required, patients should be
referred to recovery-oriented psychotherapists who will integrate psychotherapy
with 12-step program approaches.
Patients may overuse medications or relapse on illicit drugs. Certain
medications that do not produce physical dependence or withdrawal and have
much lower potential for abuse have been found to be effective for treating
anxiety disorders. Many are as effective as the benzodiazepines but without
the abuse liability. The antidepressants fluoxetine (Prozac) and sertraline
(Zoloft) and the antianxiety medication buspirone (BuSpar) are relatively
new medications that can be used to treat symptoms of anxiety disorders,
have good safety profiles, are not euphorigenic, and have few drug interaction
cautions. They can be used in the management of subacute withdrawal states.
When these drugs do not produce the desired results, the tricyclic and
monoamine oxidase inhibitors (MAOIs) antidepressants may be used. (See
Chapter
9 for a discussion of psychiatric medication.)
Medications should be used in combination with nondrug treatment approaches.
Although studies are still under way, acupuncture, aerobic exercise, stress
reduction techniques, and visualization techniques appear to be useful
components of treatment and recovery. These tools can be valuable adjuncts
for the reduction of stress. It appears that acupuncture is more effective
if used regularly for 2 weeks or more. Patients should be taught that efforts
to improve their general health, such as eating more healthful foods and
exercising regularly, can lead to better mental health.
Long-Term Treatment Issues
While medications are useful for anxiety disorders, they are not a substitute
for addiction treatment or other activities related to recovery from other
illnesses. Cognitive and behavioral techniques used in addiction are often
as effective as medications in treatment of anxiety disorders but generally
take longer to achieve an equivalent response. For patients with dual disorders,
psychotherapy has significant advantages over AOD counseling alone. Many
techniques of cognitive and behavioral therapy can be incorporated into
AOD abuse treatment.
The consumption of foods containing stimulants should not be overlooked.
People who consume significant amounts of caffeine and sugar may have a
higher risk for episodes of anxiety and depressive symptoms. Chocolate
should be avoided. Diets that cause significant variations in blood sugar
levels should be avoided. It is important to be sure that eating habits
don't imitate the rushes and crashes of AOD abuse. Diets that cause variations
in blood sugar levels may tend to aggravate or induce both mood and anxiety
states. Patients should avoid large quantities of refined carbohydrates.
Over the long term, special attention should be given to the resolution
of preexisting and long-term trauma issues. Patients with dissociation
and PTSDmay manifest poor social judgment, and special attention should
be given to risky practices. People who continue to experience episodes
of depersonalization or MPD will require special support and counseling,
especially concerning sexually transmitted diseases and risk-reduction
issues. Those who continue to experience these episodes may need special
counseling about risk factors. During these episodes, people may be more
likely to have sex, and may forget about the risk of HIV infection.
Experts in the treatment of these disorders have developed techniques
of working with patients, including the management of behavior during trance
and dissociated states, as well as fugue states in which people
suddenly travel away from home or work, assume a new identity, and are
unable to recall their previous identity. Many of the psychotherapeutic
management issues that relate to patients with dissociative disorders run
parallel to those outlined in the section of Chapter
7 on borderline personality disorder.
Use of 12-Step and Other Self-Help Programs
Participation in the 12-step programs provides valuable therapeutic experiences
for many recovering people who have anxiety disorders. People who have
a social phobia and the fear of public speaking are often extremely resistant
to attending self-help meetings. Yet, such people can make tremendous recovery
gains in terms of anxiety desensitization and AOD recovery.
There are few situations that are as safe, supportive, and predictable
and less demanding than the average 12-step group meeting. For this reason,
groups such as Alcoholics Anonymous provide ideal situations to help patients
desensitize social fears. However, anxious patients must not simply be
thrust unprepared into 12-step group meetings. Rather, AOD staff should
educate and prepare such patients regarding the process and approach of
12-step group meetings or other self-help groups.
A Stepwise Approach to Using Self-Help
It is important for AOD abuse treatment staff to appreciate the difficulty
and distress that are experienced by people who have social phobias and
fears of speaking in public. Staff who assist such patients with 12-step
group participation should become knowledgeable about the signs and symptoms,
course, and treatment of generalized anxiety disorder, panic disorder,
the phobias -- especially social phobia -- and other anxieties related
to public speaking and social situations.
Staff can help socially anxious patients participate in 12-step group
meetings by using a stepwise approach of progressively active exposure
and participation -- based somewhat on the principles of systematic desensitization.
Patients can be encouraged and counseled to participate in progressively
intense levels of group preparation and participation.
One of the least intense levels of preparation involves the use of mock
Alcoholics Anonymous meetings consisting of staff and patients. This process
makes it possible to frequently stop the meeting, discuss various meeting
components, examine group methods, and allow potential participants to
observe and practice. This type of approach can be helpful with most other
patients with dual disorders.
The next level of intensity involves the attendance at a 12-step group
meeting as a nonspeaking observer. However, staff should encourage patients
to understand that being a nonspeaking observer is a transitional phase,
and is not a substitute for active participation. For this reason, it may
be helpful to limit nonspeaking observation by the patient to a specific
number of meetings.
The next level of intensity involves patients attending a limited number
of 12-step meetings during which they identify themselves beyond just giving
their name but do not talk about themselves. The therapist can give assistance
by providing easily rehearsable suggestions for self-introductions such
as, "Hi, my name is Mary. I'm an alcoholic and I am glad to be here, although
I am a little nervous."
Since much of the networking and mutual support associated with the
12-step group meetings occur outside of the meeting, anxious patients should
be encouraged to do more than merely attend and participate in the meetings.
Rather, they should be encouraged to arrive before the meeting begins and
to linger and mingle with others following the meeting. Patients can be
encouraged to volunteer to help set up the room, make the coffee, or clean
up afterwards. In particular, socially phobic patients can be encouraged
to join others for coffee and conversation after the meetings on a more
one-to-one basis, a traditional aspect of 12-step group involvement.
By participating in step-by-step, rehearsed activities, many anxious
and depressed patients seem to break through an internal barrier. As they
do, participation in self-help group meetings becomes an integral aspect
of recovery from AOD and psychiatric problems.
The stepwise approach described for patients with anxiety disorders
can be adapted for patients who are depressed. Anxious patients often avoid
group participation and public speaking, saying to themselves, "If I talk
or if I am noticed, I will freak out." Similarly, depressed patients often
avoid group participation and other recovery activities, perhaps thinking,
"I just don't have the energy to go. No one will care anyway. Why bother?"
The therapist must elicit comments, understand them, and help patients
to reverse these internal barriers to recovery and participation in group
and other social activities. For practical guidance on these issues, the
reader is encouraged to read the information on step work and "thinking-error
work" in the chapter on personality disorders, adapted from Step Study
Counseling With the Dual Disordered Client by K. Evans and J. M. Sullivan.
Treating Anxiety During AOD Abuse Treatment
-
It can be postponed unless anxiety interferes with AOD abuse treatment.
-
Anxiety symptoms may resolve with abstinence and AOD abuse treatment.
-
Affect-liberating therapies should be postponed until the patient is stable.
-
Psychotherapy, when required, should be recovery oriented.
-
Nonpsychoactive medications should be used when medications are needed.
-
Antianxiety treatments such as relaxation techniques can be used with and
without medications.
-
A healthy diet, aerobic exercise, and avoiding caffeine can reduce anxiety.
Chapter 7 -- Personality Disorders
Overview
Definitions and Diagnoses
The word personality describes deeply ingrained patterns of behavior
and the manner in which individuals perceive, relate to, and think about
themselves and their world. Personality traits are conspicuous features
of personality and are not necessarily pathological, although certain styles
of personality traits may cause interpersonal problems. Personality
disorders are rigid, inflexible, and maladaptive behavior patterns
of sufficient severity to cause significant impairment in functioning or
internal distress. Personality disorders are enduring and persistent styles
of behavior and thought, not atypical episodes.
Several alcohol and other drug (AOD)-induced states can mimic personality
disorders. If a personality disorder coexists with AOD use, only the personality
disorder will remain during abstinence. AOD use may trigger or worsen personality
disorders. The course and severity of personality disorders can be worsened
by the presence of other psychiatric problems such as mood, anxiety, and
psychotic disorders.
The personality disorders include paranoid, schizoid, schizotypal, histrionic,
narcissistic, antisocial, borderline, avoidant, dependent, obsessive-compulsive,
passive-aggressive, and self-defeating personality disorder. Many features
of the personality disorders may occur during an episode of another mental
disorder. Individuals may meet criteria for more than one personality disorder.
Four personality disorders have been selected for detailed discussion:
borderline, antisocial, narcissistic, and passive-aggressive. These are
among the greatest challenges to treatment providers. This TIP provides
information about engagement, assessment, crisis stabilization, and longer-term
care, and describes a continuum of care for patients with personality disorders.
Antisocial personality disorder involves a history of chronic
antisocial behavior that begins before the age of 15 and continues into
adulthood. The disorder is manifested by a pattern of irresponsible and
antisocial behavior as indicated by academic failure, poor job performance,
illegal activities, recklessness, and impulsive behavior. Symptoms may
include dysphoria, an inability to tolerate boredom, feeling victimized,
and a diminished capacity for intimacy. Borderline personality disorder
is
characterized by unstable mood and self-image, and unstable, intense, interpersonal
relationships. These people often display extremes of overidealization
and devaluation, marked shifts from baseline to an extreme mood or anxiety
state, and impulsiveness.
Narcissistic personality disorder describes a pervasive pattern
of grandiosity, lack of empathy, and hypersensitivity to evaluation by
others. Passive-aggressive personality disorder involves covertly
hostile but dependent relationships. People with this disorder commonly
lack adaptive or assertive social skills, especially with regard to authority
figures. They often display a passive resistance to demands for adequate
social and occupational performance. They generally fail to connect their
passive-resistant behavior with their feelings of resentfulness and hostility
toward others. Exhibit
7-1 describes the characteristics of passive-aggressive, antisocial,
and borderline personality disorders.
Avoidant personality disorder includes social discomfort, hypersensitivity
to both criticism and rejection, and timidity, with accompanying depression,
anxiety, and anger for failing to develop social relations. Obsessive-compulsive
personality disorder describes a disorder of perfectionism and inflexibility.
Symptoms may include distress associated with indecisiveness and difficulty
in expressing tender feelings, feelings of depression, and anger about
being controlled by others. Hypersensitive to criticism, these people may
be excessively conscientious, moralistic, scrupulous, and judgmental.
Histrionic personality disorder is characterized by a pervasive
pattern of excessive emotionality and attention seeking. Behavior may include
constant seeking of approval or attention, striking self-centeredness,
or sexual seductiveness in inappropriate situations. Paranoid personality
disorder is characterized by a pervasive and unjustified proclivity
to interpret the actions of others as intentionally threatening, demeaning,
and untrustworthy.
Dependent personality disorder is characterized
by a pervasive pattern of dependent and submissive behavior and an intense
preoccupation with possible abandonment. Persons with this disorder often
feel anxious and depressed, and may experience intense discomfort when
alone for more than a brief time.
Schizoid personality disorder involves a pervasive pattern of
indifference to social relationships and a restricted range of emotional
experience and expression. Schizotypal personality disorder entails
deficits in interpersonal relatedness and peculiarities of ideation, appearance,
and behavior and dysphoric states such as anxiety and depression. Self-defeating
personality disorder is characterized by a pattern of self-defeating
behavior in work and personal relationships, often with complaints of exploitation
by others; these persons are often unaware of their contributions to the
outcomes of their behavior.
Personality disorders not otherwise specified (NOS) include disorders
of personality functioning that are not classifiable as specific personality
disorders. Instead, individuals do not meet the full criteria for any one
personality disorder; yet their symptoms cause significant impairment in
social or occupational functioning, or cause subjective distress. Personality
disorders NOS include impulsive, immature, and sadistic personality disorders.
Diagnoses should be clinically based, and not influenced by professional,
personal, cultural, or ethnic biases. For example, in the past some African
Americans were stereotyped as having paranoid personality disorders; women
have been diagnosed too frequently as being histrionic, but they are seldom
diagnosed as antisocial or psychopathic; Native Americans with spiritual
visions have been misdiagnosed as delusional or having borderline or schizotypal
personality disorders.
AOD Use Among People With Personality Disorders
People with a personality disorder often use AODs for purposes that relate
to the personality disorder: to diminish symptoms of the disorder, to enhance
low self-esteem, to decrease feelings of guilt, and to amplify feelings
of diminished individuality.
People with borderline personality disorder often use AODs in chaotic
and unpredictable patterns and in polydrug patterns involving alcohol and
other sedative-hypnotics taken for self-medication. People with personality
disorders often develop problems with benzodiazepines that have been prescribed
for complaints such as anxiety, which may lead to relapse to the primary
drug of choice.
Many people with antisocial personality disorder use AODs in a polydrug
pattern involving alcohol, marijuana, heroin, cocaine, and methamphetamine.
The illegal drug culture corresponds with their view of the world as fast-paced
and dramatic, which supports their need for a heightened self-image. Consequently,
they may be involved in crime and other sensation-seeking, high-risk behavior.
Some may have extreme antisocial symptoms. They tend to prefer stimulants
such as cocaine and the amphetamines. Rapists with severe antisocial personality
disorder may use alcohol to justify conquests. People with less severe
antisocial personality disorder may use heroin and alcohol to diminish
feelings of depression and rage.
People with narcissistic personality disorder are often polydrug users
with a preference for stimulants. Alcohol has disinhibiting effects, and
may help to diminish symptoms of anxiety and depression. Socially awkward
or withdrawn people with narcissistic personality disorder may be heavy
marijuana users. One group of people with narcissistic personality disorder
uses steroids to build up a sense of physical perfection. When not using
AODs, people with narcissistic personality disorder may feel that others
are hypercritical of them or do not sufficiently appreciate their work,
talents, and generosity. During a crisis, these people may be severely
depressed and upset.
Drug preference among people with passive-aggressive and self-defeating
personality disorders often varies according to gender. Women may prefer
alcohol and other sedative-hypnotics to sedate negative feelings such as
anxiety and depression. Although men may use these AODs, they may also
use stimulants to disinhibit aggressive or risk-taking behaviors. People
with passive-aggressive personality disorder often complain of somatic
problems, such as migraines, muscle aches, and ulcers. They may seek over-the-counter
medications as well as cocaine and amphetamines to relieve somatic symptoms.
Key Issues and Concerns
Progress with patients who have personality disorders can be slow. Therapists
should be realistic in their expectations and should know that patients
will try to test them. To respond to such tests, therapists should maintain
a matter-of-fact, businesslike attitude, and remember that people with
personality disorders often display maladaptive behaviors that have helped
them to survive in difficult situations. These behaviors may be called
"survivor behaviors."
It is important to educate patients about their AOD use and psychiatric
disorders. Patients should learn that recovery from AOD use is not synonymous
with treatment for personality disorders. Written and oral contracts can
be a useful part of the treatment plan. They should be simple, clear, direct,
and time-limited. Contracts can help patients create safe environments
for themselves, prevent relapse, or promote appropriate behavior in therapy
sessions and in self-help meetings.
Treatment of people with personality disorders requires attention to
several particular issues, such as violence to self or others, transference
and countertransference, boundaries, treatment resistance, symptom substitution,
and somatic complaints.
Suicidal Behavior
All suicidal behavior, from threats to attempts, must be taken seriously
and assessed immediately to determine the type of immediate intervention
needed. Special attention must be given to previous attempts and their
seriousness, previous intervention strategies, whether the failure of the
attempt was intended or accidental, the relation of previous suicidal behavior
to psychiatric symptoms, and current psychiatric symptoms. All suicidal
behavior should provoke the following questions:
-
How specific is the plan?
-
What method will be used?
-
When will it happen?
-
How available are materials (drugs, weapons)?
Patient Contracting
Management of self-harm can be accomplished by creating written or oral
contracts with patients. In these contracts, a patient may promise to avoid
certain self-harm or high-risk behavior (such as suicide or relapse), or
may promise to engage in a specific healthy behavior (such as calling his
or her 12-step sponsor or a suicide prevention hotline) when self-harm
or a high-risk behavior appears imminent.
Therapists should attend to the patient's need for safety. Safety may
range from the need for safe shelter to escape domestic violence to the
need to reside in a controlled environment in order to remain abstinent.
Transference and Countertransference
Transference and countertransference can present problems in group and
individual therapy. Therapists should be prepared to manage these issues.
Transference refers to positive and negative feelings and perceptions that
the patient projects onto the therapist. Countertransference refers to
distortions in the therapeutic process due to the therapist's unresolved
conflicts. Both transference and countertransference rely on the mechanism
of projection.
Projection is a combination of personal past experiences along with
feelings experienced during the course of therapy. Being aware of transference
issues and commenting on them when appropriate is extremely important when
working with these patients.
Clear Boundaries
Boundaries are clear expectations regarding limitations or requirements
in roles or behavior. Boundaries are ethical and practical ground rules
that help therapists to be therapeutically helpful to patients. The clinician
and patient must establish and maintain clear boundaries. Boundaries must
also be set in group therapy sessions. For example, therapists should not
lend money to patients or involve them in financial deals. Patients should
not establish intimate relationships with others in group therapy.
Changing Roles
People with personality disorders often assume certain roles or ways of
social interaction. They may shift from one role to the next, depending
upon the situation. Some of these roles include: the victim, the persecutor,
and the rescuer.
As these patients assume a specific role (such as the victim), other
people may be prompted to assume a complementary role (such as the rescuer).
Therapists should be aware of the roles that people with personality disorders
may assume. They should resist assuming dysfunctional complementary roles
themselves and become aware when they do assume such roles.
Resistance
Patients with personality disorders often exhibit acting-out behaviors
that were developed as psychological defenses and survival techniques.
The patient may be reenacting a response learned during experiences of
abuse or trauma. Resistances are defenses and coping mechanisms that help
patients survive in situations confronted in therapy which are perceived
as threatening.
Confronting a patient's resistance without helping the patient develop
other strategies for safety will probably escalate the patient's tension.
Therapists should view and use resistance as a therapeutic issue, not as
a challenge to treatment.
Subacute Withdrawal
It is becoming increasingly clear that alcohol and most other drugs of
abuse produce acute and subacute withdrawal syndromes. Depending on the
specific drug, subacute withdrawal may include mood swings, irritability,
impairment in cognitive functioning, short-and long-term memory problems,
and intense craving for AODs. Subacute withdrawal syndromes often trigger
relapse and exacerbate existing psychiatric symptoms
Symptom Substitution
During periods of abstinence from AODs, some people will engage in other
types of compulsive behaviors. Some of these behaviors include eating disorders,
and compulsive spending, gambling, and sex. Relationship problems may also
increase.
Somatic Complaints
Patients with addictions to prescription drugs often seek treatment because
of somatic complaints. Therapists should watch for use of prescription
and over-the-counter drugs and for drug-seeking behaviors.
Therapist Well-Being
Therapists should be mindful of their own well-being, which can be compromised
when working with patients with personality disorders. Clinicians can be
drawn into playing certain roles in the lives of patients with personality
disorders. To prevent this, therapists should care for themselves by seeking
outside supervision. Therapists should join or develop support systems
with others in the field through 12-step program participation, regular
meetings with other therapists, grand rounds, and the like.
The following sections describe specific strategies and techniques that
therapists can use when working with patients who have an AOD use disorder
and a borderline, antisocial, narcissistic, or passive-aggressive personality
disorder.
Each section describes techniques for assessing patients and engaging
them in treatment, stabilizing crises, providing long-term care, and creating
a continuum of care. Each section concludes with a case example in which
the reader is asked to make a treatment decision. Where appropriate, clinical
tools are provided.
Key Issues and Concerns in The Treatment of Personality Disorders
-
Slow progress in therapy
-
Suicidal behavior
-
Patient contracting
-
Transference and countertransference
-
Clear boundaries
-
Changing roles
-
Resistance
-
Subacute withdrawal
-
Symptom substitution
-
Somatic complaints
-
Therapist well-being
Borderline Personality Disorder
Engagement
Safety is an anchor for patients with borderline personality disorder,
for whom abandonment and fear of rejection are often core issues. To engage
and assess these patients, the therapist should acknowledge and join with
the patient's need for safety. The therapist's absence, even for brief
periods, can prompt acting-out behavior.
Acting-out behavior is a maladaptive survivor response that expresses
a need for safety. Therapists should identify each patient's motivation
for recovery, which may be rooted in safety. Further, therapists should
discover what safety means to the patient.
Therapists can learn how patients create their own feelings of safety
by asking them about safe spots, magic getaway places, closet-sitting,
rocking or other repetitive movements, or other techniques the patient
may use to generate a sense of security. To help patients with borderline
personality disorder establish and maintain a sense of safety, therapists
can continually ask patients: "What do you need right now?" "What do you
want right now?"
Therapists may work with patients to develop a patient-generated list
of the conditions that they need in order to feel safe. Therapists may
ask patients: "What would have been helpful (in a specific situation) to
make you feel safe?" Through teaching cognitive skills to promote patients'
sense of safety, therapists can help patients with borderline personality
disorder to assume personal responsibility for their own safety.
Written and verbal contracts can identify specific ways to help patients
stay physically and emotionally safe and to prevent relapse. Written and
verbal contracts for safety should be developed during the assessment process
with simple and clear behavioral responses regarding the management of
unsafe feelings and behaviors. These contracts can be very simple and direct:
-
"If I feel like I want to get drunk, I will call my sponsor."
-
"If I feel like getting loaded, I will go to the next NA meeting."
-
"If I feel like hurting myself, I will call a crisis hotline and go to
my sister's house."
-
"I will report self-harm thoughts and behaviors to the therapist at the
next session."
Assessment
When assessing a patient, the therapist is attempting to understand and
view the patient within a holistic framework. Areas of assessment may include
a history of AOD and mental health treatment, suicidal planning, dissociative
experiences, psychosocial history, history of sexual abuse, and a history
of psychotic thinking. Some patients may also require a neurological examination.
The assessment of patients with borderline personality disorder should
look for a history of self-harm. Behaviors such as AOD use should be described
as unsafe behaviors. However, clinicians should help people with borderline
personality disorder to avoid black-and-white thinking, such as right/wrong
and good/bad, and all-or-nothing styles of thinking. Specifically, the
assessment should include the following:
-
A history of previous treatment, including psychiatric medications administered,
and a description of what worked and what did not work in treatment, as
well as information on why the patient left earlier treatment. Patients
are not always a reliable source of information about themselves, and therapists
should evaluate this information accordingly. The treatment history can
help the therapist avoid unnecessary repetition of treatment strategies,
such as skill-building activities in which the patient is already competent
(for example, relaxation strategies). The history taking is an opportunity
to examine patients' strengths and weaknesses.
-
A list of potential means available to patients to injure themselves in
their own homes, such as a large supply of medication.
-
History and evidence of dissociative experiences, such as trance states,
rocking, flashbacks, nightmares, and repressed memories. Any and all parts
of a memory can be repressed. One model for assessing dissociation and
identifying repressed memories is the BASK model. The BASK model is a quick
way to check what part of the memory is missing, and whether or not it
is Behavior, Affect, Sensation, or Knowledge. Survivors of abuse may detach
themselves from their feelings so that they recall memories of abuse in
a robot-like fashion.
-
Attachment to a special object. Anniversary reactions are also common to
survivors of abuse, whose memories or feelings may be triggered by certain
dates, events, or objects. For no apparent reason, the survivor may become
sick or suicidal when faced with a situation similar to a past reminder
of abuse.
-
History of fugue states and losing time. For example, patients with borderline
personality disorder might start watching a movie and suddenly reorient
later in the middle of another movie, with no clear memory of the elapsed
time.
-
Psychosocial history and history of sexual abuse. It is common for people
to feel as if they were sexually abused without having any actual memories
of the abuse or trauma. Questions should be framed in a manner that facilitates
the acquisition of all relevant information. By asking open-ended questions
while paying attention to the patient's body language, the therapist may
be able to draw useful conclusions.
-
Neurological workup of individuals who have a history of self-mutilating
behaviors that could have resulted in cognitive impairment such as head-slamming.
Some psychologists will conduct neurological screening; in other cases,
a neurologist should be consulted.
-
Psychotic-like thinking and history of suicidal behavior, especially under
intense stress. Psychotic-like thinking may be evident during episodes
of trauma and stress. For example, a patient may state, "The walls are
bleeding."
Crisis Stabilization
Safety issues are at the core of crisis stabilization. To ensure the patient's
safety or to detox a patient, a brief psychiatric hospitalization may be
necessary. Issues to be addressed during crisis stabilization might include
an unwillingness or inability to contract for safety. A written release
of medical information is important to coordinate care with physicians
and addiction counselors.
At this stage, therapists should avoid psychodynamic confrontations
with patients and should not engage patients in further therapy for abuse
or trauma. The treatment focus should be on addressing the patient's need
for safety, especially important with patients who have borderline personality
disorder. More complicated and emotionally charged material should be deferred
until the patient has better skills to manage emotional pain.
It may be helpful to describe out-of-control crisis behavior as a survivor
response. Therapists and patients should avoid rigid black-and-white thinking.
Describing events or issues as being more helpful or less helpful may circumvent
the inflexibility of seeing life's challenges and problems only as black
and white, while ignoring the numerous grey areas of experience.
During crisis stabilization, the continued use of written and verbal
contracts is critical. These contracts should be rooted in the here-and-now,
and should offer patients practical ways to manage crisis behavior. The
contracts must focus on safety. Contracts written on 3-by-5-inch cards
that they can carry and read when necessary are very helpful for patients
with borderline personality disorder. Contracts should be simple and concrete
and should emphasize problem-solving skills.
Therapists should work on relapse management strategies that are clear
and concrete, such as: "Before I use cocaine, I will call my sponsor."
At the same time, therapists should encourage patients to be honest about
relapse. Therapists should assume a posture of concerned support about
relapse and view it as an opportunity to learn from past mistakes and strengthen
relapse prevention skills and the therapeutic relationship.
The family -- as defined by each patient -- should take part in this
process. It may be useful to encourage contracts with family members. These
contracts can dissuade family members from assuming dysfunctional roles
such as the victim, the persecutor, and the rescuer. The family should
learn how to set boundaries with the patient, and should learn not to play
certain roles, especially the role of rescuer.
Longer-Term Care
Individual Counseling
In individual therapy, issues stemming both from borderline personality
disorder and from AOD use may emerge. Issues related to unsafe behavior
or AOD use will continue to be important. Longer-term care is a stage in
which teaching the patient skills, such as assertiveness and boundary setting,
can be useful.
Patients may need to be educated about survivor issues without exploring
more psychodynamically based issues. Patients should be oriented to a survivor
framework, but therapists must build slowly before engaging patients in
retrieving painful memories.
The abuse survivor should demonstrate the necessary skills to benefit
from psychotherapy. Patients should tell the therapist when they are not
ready to discuss certain issues. Once patients are ready to do so, the
integration of psychodynamic material and trauma therapy may begin. There
is no pressing need for the retrieval of early memories of trauma. Rather,
the focus of therapy may be on behavior rather than memory.
Therapists might try to frame acting-out behaviors as survivor behaviors.
Complications at this stage can include a variety of compulsive and impulsive
behaviors, such as eating disorders (obesity, anorexia, bulimia), compulsive
spending and money mismanagement, relationship problems, inappropriate
sexual behaviors, and unprotected sex (in regard to STDs and pregnancy).
Other maladaptive behaviors include sexual impulsiveness, which can cause
confusion about sexual identity dramatized in experimental sexual relationships,
adding to the crisis and drama on which people with borderline personality
disorder often thrive.
Therapists may want to consider limiting access to educational material
about adult children of alcoholics (ACOAs) for patients with borderline
personality disorder. Reading some ACOA material and self-help books and
participating in self-help support groups may be detrimental to some patients'
recovery. For some patients, self-labeling can become counter-productive
-- and in worst-case scenarios, it can lead to self-fulfilling prophesies.
For example, books suggesting that some people self-mutilate in order
to relieve pain may teach patients with borderline personality disorder
to self-mutilate. Some books offering "inner-child work" lead the patient
through age-regressive exercises that can cause an overwhelming flood of
feelings the abused patient may not yet be ready to manage.
Therapists should remember that progress in treating patients with borderline
personality disorder and AOD problems can be slow. There may be many setbacks.
Rather than looking for enormous changes in personality or behavior, therapists
should look for small, measurable signs of improvement.
In addition, therapists may want to consider the following in treating
patients with borderline personality disorder:
-
Using mini-contracts for each session to encourage the patient to stay
focused.
-
Immediately asking patients about any crises that have occurred, reviewing
the entire week, not just a particular day.
-
Stating the purpose of each session.
-
Running through a checklist can be helpful. A list might include: homework,
failing tests, arguments with others, interactions with the criminal justice
system, problems in school or work life, family relationships and friends,
relapses, thoughts of self-harm, nightmares, flashbacks, painful situations,
and bad memories. Questions should be specific.
-
Encouraging patients to keep mood and dream journals (especially during
survivor work) between sessions for brief comments on mood.
-
Conducting survivor work only after daily living skills are successfully
demonstrated.
-
Keeping and dating all correspondence and notes from telephone conversations.
Having previous conversations documented can help to remind the patient
of earlier agreements and conversations.
Group Therapy
There are special issues concerning work with people with borderline personality
disorder in group therapy. Therapists should consider the following:
-
Making contracts for all members to stay in the room.
-
Making contracts for group rules that promote safe behavior and not hurting
oneself or others.
-
Working with transference and countertransference issues.
-
Discussing thoughts and feelings about other group members as they arise.
-
Setting time limits at the start of each session.
-
Making mini-contracts for those who have issues to work on in each session.
-
Having group members sign contracts for abstinence and reporting self-harm
and AOD use to the group.
-
Making contracts for confidentiality.
-
Disallowing participants to form intimate or exclusive relationships. Supportive
activities, such as calling one another during crises or attending 12-step
meetings together, are acceptable and should be encouraged.
-
Evaluating safety issues in screening people with borderline personality
disorder for group therapy. Patients should be safe from predatory, manipulative
behavior of others, and should not engage in such behaviors themselves.
-
Promoting same-sex groups.
Twelve-Step Participation
Although 12-step involvement is important for patients with borderline
personality disorder, some may not be immediately able to attend 12-step
meetings. Some patients may find it more helpful to participate in pre-12-step
practice sessions. These patients should be helped to organize their thoughts,
to practice saying "pass," and to create safety in a 12-step meeting. Counselors
may want to use the step work handout as a treatment tool for working with
people with borderline personality disorder (see Exhibit
7-2 and Chapter
6 on use of 12-step meetings).
Patients should be encouraged to join same-sex 12-step groups when possible.
People with borderline personality disorder may find it helpful to use
same-sex sponsors as guides to recovery. When possible, therapists should
educate the sponsor about survivor behaviors. The sponsor may even attend
a therapy session to learn why the patient is taking medications. Antidepressants
or lithium may be an important part of the patient's recovery. Explaining
how medications are helpful may enable sponsors to help improve medication
compliance.
Some sponsors may have problems setting boundaries. Such sponsors should
not be paired with borderline patients. If they must be paired, however,
they need to understand how important boundaries are in helping borderline
patients feel safe. Understanding this may keep them from taking on borderline
patients, who may be more than they can handle. Material in the step program
should be limited to the here-and-now. Patients should not engage in dealing
with sexual abuse issues until they are ready.
Longer-term care should include specialized 12-step work. In using step
one ("We admitted we were powerless over alcohol -- that our lives had
become unmanageable.") with patients who have borderline personality disorder,
therapists should encourage patients to recognize that powerlessness does
not mean helplessness. Instead, patients should focus on gaining personal
control over AOD use. Faith and hope concepts used in 12-step work may
also be difficult for this group to comprehend or integrate.
Continuum of Care
An aftercare plan for patients with dual disorders is essential. This plan
should integrate rather than fragment strategies for treating the patient.
It should include methods to coordinate care with other treatment providers.
Relapse prevention is critical and should be managed through careful planning
throughout treatment. Relapse should be defined as engagement in any unsafe
behavior such as AOD use, self-harm, and noncompliance with medications.
Relapse prevention should focus on preventing AOD use and recurrence of
psychiatric symptoms.
Patients should be encouraged to participate in 12-step groups and other
self-help and support groups such as Adults Molested As Children (AMAC),
Incest Survivors Anonymous (ISA), and Survivors of Incest Anonymous (SIA).
Acute hospitalization may be necessary during suicidal crises. Again,
the emphasis of treatment should remain on safety. Outpatient therapy should
continue. AOD treatment should be obtained when appropriate. Therapists
should be wary of triangulation in coordinating with other professionals.
Case Example
Rachel was 32 years old when she was taken by ambulance to the local hospital's
emergency room. Rachel had taken 80 Tylenol capsules and an unknown amount
of Ativan in a suicide attempt. Once stable medically, Rachel was evaluated
by the hospital's social worker to determine her clinical needs.
The social worker asked Rachel about her family of origin. Rachel gave
a cold stare and said, "I don't talk about that." Asked if she had ever
been sexually abused, Rachel replied, "I don't remember." Rachel acknowledged
previous suicide attempts as well as a history of cutting her arm with
a razor blade during stressful episodes. Rachel reported that the cutting
"helps the pain."
Rachel denied having "a problem" with AODs but admitted taking "medication"
and "drinking socially." A review of Rachel's medications revealed the
use of Ativan "when I need it." Rachel used Ativan three or four times
a week. She reported using alcohol "on weekends with friends" but was vague
about the amount. Rachel did acknowledge that before her suicide attempts,
she drank alone in her apartment. This last suicide attempt was a response
to her breakup with her boyfriend. Rachel's insurance company is pushing
for immediate discharge.
Question -- Should Rachel be discharged? Where should she be sent? Exhibit
7-3 shows a recovery model for treatment of borderline personality
disorder.
Antisocial Personality Disorder
Clinicians should be careful to avoid mislabeling patients. Although some
women may have antisocial personality disorder, they receive this diagnosis
less often than men. Instead, they may be misdiagnosed as having borderline
personality disorder. Among the male prison population, 20 percent may
have antisocial personality disorder. However, once they are abstinent,
many AOD-using offenders may not meet the criteria for antisocial personality
disorder.
Engagement
In engaging the patient with antisocial personality disorder, it is useful
to join with the patient's world view, which may include a need for control
and a sense of entitlement. In this context, entitlement refers to people
who believe their needs are more important than the needs of others. Entitlement
may include rationalization of negative behavior (such as robbery or lying).
People with antisocial personality disorder may evidence little empathy
for their victims. If incarcerated, they may believe they should be released
immediately. In an AOD treatment program, they may describe themselves
as being unique and requiring special treatment.
The primary motivation of the patient with antisocial personality disorder
is to be right and to be successful. It is useful to work with this motivation,
not against it. Although this motivation may not reflect socially acceptable
reasons for changing behavior, it does offer a point from which to begin
treatment. Wanting to be clean and sober, to keep a job, to avoid jail,
and to become the chair of an AA meeting are reasonable goals, despite
a self-serving appearance. Therapists may help patients by working with
patients' world view, rather than by trying to change their value system
to match those of the therapist or of society.
Patients should understand their role in the process. In engaging patients,
therapists may want to use contracts to establish rules for conduct during
treatment. The contract should explicitly state all expectations and rules
of conduct and should be honored by all parties. Such an approach can be
useful with people with antisocial personality disorder, who often view
relationships as unfair contracts in which one person attempts to take
advantage of the other. Therapists may find that once a level of interpersonal
respect has been established, working with antisocial patients can lead
to important gains for the patient.
Assessment
In addition to an objective psychosocial and criminal history, the following
steps may be useful in assessing the antisocial patient:
-
Taking a thorough family history.
-
Finding out whether or not the patient set fires as a child, abused animals,
or was a bed-wetter.
-
Taking a thorough sexual history that includes questions about animals
and objects.
-
Taking a history of the patient's ability to bond with others. Therapists
can ask: "Who was your first best friend?" "When was the last time you
saw him or her?" "Do you know how he or she is?" "Is there any authority
figure who has ever been helpful to you?"
-
Asking questions to find out about possible parasitic relationships and
taking a history of exploitation of self and others. In this context, parasitic
refers to a relationship in which one person uses and manipulates another
until the first has gotten everything he or she wants, then abandons the
relationship.
-
Taking a history of head injuries, fighting, and being hit. It may be useful
to perform neuropsychological testing.
-
Testing urine for recent AOD use.
-
HIV testing.
The assessment should consider criminal thinking patterns, such as rationalization
and justification for maladaptive behaviors. There is a special need to
establish collateral contacts and to assess for criminal history and the
relationship of AOD use to behavior.
Useful assessment instruments include the Minnesota Multiphasic Personality
Inventory (MMPI), the Millon Clinical Multiaxial Inventory (MCMI), the
PCL-R (Hare Psychopathy Checklist-Revised), and the CAGE questionnaire.
Crisis Stabilization
People with antisocial personality disorder may enter treatment profoundly
depressed, feeling that all systems have failed them. Often, their scams
and lofty ideas have failed and they feel exposed, feel like losers, and
have no ego strength. They are at risk for suicide, especially during intoxication
or acute withdrawal. They may require psychiatric hospitalization and detoxification.
They may become acutely paranoid. Containment in the form of a brief
hospitalization may be indicated for patients experiencing acute paranoid
reactions to avoid acting out against others. For less acute paranoid reactions,
therapists should try to avoid cornering patients, disengage from any power
struggle, offer lower stimulus levels, and create options, especially if
those are supplied by the antisocial patient. During this phase, clarification
without harsh confrontation is recommended.
When patients with antisocial personality disorder have crises, therapists
should become cautious and careful. During crises, these patients may engage
in dangerous physical behavior in order to avoid unpleasant situations
or activities, and therapists should avoid angry confrontations.
Longer-Term Care
Individual Counseling
It is helpful to view the process of working with antisocial patients as
a process of adaptation of thinking rather than the restructuring of a
patient into a person whose morals and values match those of the therapist
or society. Therapists may benefit from modifying their own expectations
of treatment outcomes, and realize that they may not help some patients
to develop empathic and loving personalities. It is enough to guide patients
to lead lives that follow society's rules.
Individual therapy offers the therapist an opportunity to point out
patients' errors in thinking without causing them to feel humiliated in
the presence of the therapy group. Other issues for individual therapy
may include continued relapse management and identity of empathy. Three
key words summarize a strategy for working with people with antisocial
personality disorder: corral, confront, and consequences.
Corral.
Corralling with regard to patients with antisocial personality disorder
means coordinating treatment with other professionals, establishing a system
of communications with other professionals and with the patient, contracting
patients to be responsible for their AOD use in the recovery program, monitoring
information about the patient, and working toward specific treatment goals.
Patients may benefit by signing agreements to comply with the treatment
plan and by receiving written clarification of what is being done and why.
Interventions and interactions should be linked to original treatment goals.
One approach to treatment that adds to the notion of "corralling" is
to "expand the system." Spouses, family members, friends, and treatment
professionals may be invited to participate in counseling sessions as a
way to provide collateral data. This is sometimes called "network therapy."
Confront.
In confronting antisocial patients, therapists can be direct without being
abusive. They can be clear in pointing out antisocial thinking patterns.
They can remark on contradictions between what patients say and what patients
do. Random AOD testing is essential for monitoring patients. Honest reporting
of AOD use should be an active part of treatment.
Consequences.
Patients should bear the consequences of their behavior. For instance,
violation of probation or rules should be recorded. Patients who are offenders
should be encouraged to report behavior that violates probations, thus
taking responsibility for their own actions. Positive consequences that
demonstrate to patients the benefits of appropriate behavior should also
be designed and incorporated into the treatment plan. Financial incentives
and opportunities for power or recognition can be a key element of treatment.
Case management may involve coordinating care with a variety of other
professionals and individuals, including those in the criminal justice
system, AOD counselors, and family members. Therapists need to make it
clear to patients that the therapist must talk to other providers and to
family members. Thus, it is helpful for patients to sign releases of information
for all people involved in their treatment.
The question of terminating therapy can be a puzzling one for therapists
treating antisocial patients. The patient may frequently express a desire
to end treatment. This desire should be closely examined to determine whether
it is a manifestation of patient resistance or whether it is a valid request.
There is some question about whether it is appropriate to terminate therapy
with patients who have antisocial personality disorder who may need ongoing
treatment. Reasons for termination may include noncompliance with treatment,
continued drug use without improvement, any aggressive behavior, parasitic
relationship with other patients, or any unsafe behavior.
Patients with antisocial personality disorder compulsively try to break
rules. If a treatment plan is not devised to work with a person who wants
to redefine rules, termination should be considered and transfer to more
appropriate care should be arranged.
Continued thinking-error work, as described in Exhibit
7-4, may help patients to identify various types of rationalizations
that they may use regarding their behaviors.
Group Therapy
Group therapy is a useful setting in which people with antisocial personality
disorder can learn to identify errors not only in their own thinking, but
in the thinking of others. The group can help identify relapse thinking.
For example, when an individual begins to glamorize stories of AOD use
or criminal and acting-out behaviors, the group can help to limit that
grandiosity. Therapists may also ask people with antisocial personality
disorder to discuss feelings associated with the behavior being glamorized.
Role play exercises can be useful tools in group therapy. However, therapists
should be careful to prevent patients with antisocial personality disorder
from using newly learned skills to exploit or control other group members.
In group therapy, patients with antisocial personality disorder can be
encouraged tomodel prosocial behaviors and learn by practicing them. Role
play exercises can help these patients to focus on their shortcomings rather
than on the faults of others.
AOD therapists should avoid creating groups that consist entirely of
patients with antisocial personality disorder. Such groups are best conducted
in very controlled settings in which therapists have control over the environment.
Patients with antisocial personality disorder may be asked to sign contracts
that establish healthy and nonparasitic relationships with other group
members. This means not becoming romantically involved with other members,
not borrowing money from them, and not developing exploitive relationships.
Therapists themselves should try not to become obsessed with being manipulated
or tricked by group members. Such power struggles are not helpful.
Counseling Tips for Patients With Antisocial Personality Disorder
| Corral: |
-
Coordinate treatment.
-
Communicate with other providers.
-
Make contracts with patients.
|
| Confront: |
-
Be direct, not abusive.
-
Identify antisocial thinking.
-
Conduct random AOD testing.
|
| Consequences: |
-
Make patients responsible for their behavior.
-
Record violations of rules.
-
Allow patients to experience consequences of their behavior.
-
Designate positive consequences of good behavior.
|
Continuum of Care
A key to treating people with antisocial personality disorder is to be
flexible within an array of containment interventions. Therapists should
have the ability to quickly move a patient from a less controlled environment
to a more controlled environment. Patients benefit from sanctions that
match the degree of severity of behavior. Sanctions should not be "punishments"
but responses to the need for containment and more intensive treatment.
Antisocial patients need a range of treatment and other services: from
residential to outpatient treatment, from vocational education to participation
in long-term relapse prevention support groups, and from 12-step programs
to jail.
When patients with antisocial personality disorder shed aspects of the
disorder, they may become more dependent. Therapists often try to limit
such dependence. However, with regard to antisocial patients, such a transition
should be allowed rather than confronted. It often represents a healthy
change. Feelings of dependency are easily frustrated at this stage, and
disappointment may result in relapse.
Case Example
Mark was 27 years old when he was arrested for driving while intoxicated.
Mark presented himself to the court counselor for evaluation of possible
need for AOD treatment. Mark was on time for the appointment and was slightly
irritated at having to wait 20 minutes due to the counselor's schedule.
Mark was wearing a suit (which had seen better days) and was trying to
present himself in a positive light.
Mark denied any "problems with alcohol" and reported having "smoked
some pot as a kid." He denied any history of suicidal thinking or behavior
except for a short period following his arrest. He acknowledged that he
did have a "bit of a temper" and that he took pride in the ability to "kick
ass and take names" when the situation required. Mark denied any childhood
trauma and described his mother as a "saint." He described his father as
"a real jerk" and refused to give any other information.
In describing the situation that preceded his arrest, Mark tended to
see himself as the victim, using statements such as "The bartender should
not have let me drink so much," "I wasn't driving that bad," and "The cop
had it out for me." Mark tended to minimize his own responsibility throughout
the interview. Mark had been married once but only briefly. His only comment
about the marriage was, "She talked me into it but I got even with her."
Mark has no children and currently lives alone in a studio apartment. Mark
has attended two meetings of Alcoholics Anonymous "a couple of years ago
before I learned how to control my drinking."
Question -- What might the court counselor recommend to the judge as
an appropriate treatment plan for Mark?
Exhibit 7-5
shows
a treatment tool for use with patients who have antisocial personality
disorder.
Narcissistic Personality Disorder
Engagement
In trying to engage and assess patients, therapists should remember that
patients with narcissistic personality disorder will have certain traits
that should be addressed therapeutically. Therapists should try to join
with patients' hypersensitivity and need for control by saying such things
as "I'm impressed with what a bright and sensitive person you are. If we
work as a team, I think we can help you get out of this spot."
Patients with narcissistic personality disorder often have a need to
be the center of attention and to control events. They crave affection
and admiration from others. They are perfectionists (about themselves).
They may try to create dramatic crises to obtain attention to return the
focus to themselves. As with patients with antisocial personality disorder,
entitlement issues are very important. Patients with narcissistic personality
disorder feel as if everyone and everything owes them -- without any contribution
on their part.
It is helpful for therapists to work with these personality traits in
therapy. Working with narcissistic motivations for recovery, such as an
improved appearance or a desire to continue in a job or to make romantic
and sexual conquests, may help the patient to change inappropriate behaviors.
Therapists may benefit from working with, rather than against, ego inflation.
Therapists who try to squelch the narcissistic ego may be met with rage.
Therapists should position themselves as trying to help the narcissistic
patient reach his or her goals.
Therapists may work with patients to identify thinking errors that interfere
with the patient's ability to work. These errors may include beliefs such
as "Everybody loves me." Therapists may need to work with patient's victim-stance
thinking. An example of such thinking is "Everybody is out to get me."
The antisocial thinking-error work described in the previous section (see
Exhibit 7-4) can be a very effective tool for working with the narcissist.
To manage narcissistic rage and depression, therapists may contract
for patient safety as well as for the safety of others. The therapist may
offer the patient a combination of empathy and reality testing. For example,
when patients say, "Everything is messed up," or "Everybody is causing
me trouble," therapists may empathize with patients, while also indicating
the reality of the situation and the need for behavior change.
Assessment
Some examples of items to cover during the assessment include:
-
A psychosocial history, including early childhood beliefs with regard to
looks, behaviors, and thoughts
-
A history of AOD use
-
A sexual history to identify the ability to be empathic with partners
-
Early Memory Procedures test (EMP)
-
CAGE questionnaire
-
Millon Clinical Multiaxial Inventory (MCMI-II)
-
California Personality Inventory (CPI).
Crisis Stabilization
Therapists may need to assess patients' defenses, and to put those defenses
to therapeutic use. For example, when a patient blames the police for "setting
me up," the therapist can mention that the best way to avoid being set
up again is to not drink and drive.
Patients with narcissistic personality disorder have a central concern
with being perfect. For these individuals, the disease concept approach
can assist in recovery by removing blame from the patient and conceptualizing
the illness as a biochemical disorder. This can help to lessen the feelings
of failure which can be a barrier to treatment.
People with narcissistic personality disorder may become depressed when
they feel deeply wounded, when their systems have failed them, and when
they sense that their world is falling apart. When wounded, they are at
the highest risk for acting out against themselves and others. When in
a narcissistic rage, patients may become homicidal, feeling a need to seek
revenge. This rage comes from the intensity of the narcissist's wound.
The counselor needs to work carefully with this rage and to avoid getting
into power struggles.
When these patients are in suicidal crises, patients should sign contracts
for safety. Safety may include brief psychiatric hospitalizations that
are goal oriented and designed for stabilization.
When working with HIV-positive patients with narcissistic personality
disorder, therapists may establish contracts with them to engage in safer-sex
practices. Often sexual prowess is part of the narcissistic ego-inflation.
Their need to see themselves as great lovers, coupled with self-centeredness,
puts them at high risk for sexually transmitted diseases.
Longer-Term Care
Individual Counseling
There will be an ongoing need to manage the rage and depression of patients
with narcissistic personality disorder and their need for attention, control,
and admiration. Continued attention to self-centeredness and the need to
work the 12 steps is essential. Step work designed for people with antisocial
personality disorder (as previously described in Exhibit
7-5) can be helpful for patients with narcissistic personality disorder.
Similarly, the individual and group approaches to the treatment of patients
with antisocial personality disorder can be used for patients who have
narcissistic personality disorder. Indeed, it may be helpful to view the
patient with narcissistic personality disorder as a hypersensitive patient
with an antisocial personality disorder.
Group Therapy
People with narcissistic personality disorder may benefit from group therapy.
In group therapy, therapists may need to set time limits in a firm but
pleasant manner, pointing out the need for all patients to have group time.
At the start of each session, therapists should make a contract with patients
with narcissistic personality disorder to encourage prosocial behaviors
and to avoid attempts to dominate, control, or compete for attention with
other group members. Some behaviors to contract for might include:
-
To limit the time that they can speak during group sessions
-
To not interrupt others while they speak
-
To respect other group members' time and feelings
-
To give responses to other group members
-
To receive responses and feedback from others.
It is important not to smash the narcissistic ego or to attack the narcissistic
patient within the group. It is more useful to comfort and confront the
narcissist simultaneously: "I understand that the part of you that is sensitive
is wounded to hear that the group does not believe everything you are saying."
Continue to work with the narcissist's defenses, not against them.
Continuum of Care
For patients with narcissistic personality disorder, the least restrictive
treatment environment is preferable. It permits patients to feel that they
are in control. These patients should be moved quickly from inpatient to
outpatient levels of care. If they do not like the treatment, they will
stop participating. Thus, it is critical not to overpathologize the patient's
disorder with constant criticism. However, acute hospitalization for psychiatric
emergencies (such as homicidal or suicidal plans) may be necessary.
Narcissistic patients generally enjoy the attention they receive through
involvement in outpatient treatment; retention in the program is easily
accomplished. Long-term outpatient involvement is critical to maintain
narcissistic patients' prosocial behavior and sobriety. Therapists who
strive to build narcissistic patients' strengths and who pay close attention
to them in therapy will find them active participants in the recovery process.
In addition to their personality disorder and AOD use disorder, some patients
may engage in compulsive sexual or spending behaviors that should be addressed
therapeutically.
Tip for Narcissistic Patients
A helpful exercise for patients with narcissistic personality disorder
is to ask them not to say anything during a specific number of 12-step
or self-help groups, but to simply listen. Once this has been done, narcissistic
patients should discuss their feelings with the therapist in response to
the exercise.
Case Example
Bill is a 45-year-old male who was referred by his employer to the company's
employee assistance program (EAP). The employer was concerned about Bill's
temper, his difficulty accepting criticism, and his difficulty in getting
along with other staff. At the EAP appointment, Bill's appearance was that
of an extremely well-groomed man who paid exceptional attention to his
dress and attire. His manners were impeccable, although he was critical
of the receptionist at the EAP's office for not offering him coffee when
he came in. Bill was friendly but cool toward the EAP counselor, tending
to gloss over the importance of his boss's concerns.
When the EAP counselor asked him for more specifics about his problems
with his coworkers, Bill became extremely defensive and hammered away in
a raging attack on his coworkers and their jealousy of his success. Bill
felt that his boss was a well-intentioned but incompetent person who frequently
made mistakes. Bill also felt that his boss didn't appreciate the caliber
of his work or the time he put into his work. Bill took pride in his perfectionism,
attention to detail, and firm and inflexible beliefs.
Bill was not married, although he reported that he had come close a
few times only to discover that these women had "fooled him" in one way
or another. Bill reported to have only one male friend and indicated that
he much preferred the company of women to men. Bill denied having any "problem
with drugs" but did indicate that he uses marijuana and cocaine recreationally.
Bill reported using alcohol most weekends and occasionally drinking to
the point where he "forgot" what happened.
Question -- What should the EAP counselor suggest as a treatment plan
to address employer concerns over Bill's behavior?
Passive-Aggressive Personality Disorder
Engagement
As in working with all patients with personality disorders, therapists
should attempt to join with the world-view of patients with passive-aggressive
personality disorder, rather than work against it. Therapists may try to
work with patients' need for safety and with their ambivalence toward recovery.
Therapists should work with patients' indirect displays of anger and assertiveness.
Passive-aggressive patients try to avoid commitment and responsibility.
All interventions should be focused on the patient's needs, wants, and
desires, a strategy that promotes treatment compliance.
Assessment
Areas to address in the assessment include the following:
-
Survival skills and self-care assessment
-
Monitoring of use of over-the-counter drugs, such as NyQuil, Dexatrim,
Benadryl, niacin, laxatives, and tryptophan (somatic illnesses are often
medicated with these chemicals)
-
Information on all other professionals and medical providers being seen
for treatment
-
Psychosocial and AOD history, and mental status
-
Coexisting anxiety disorders
-
Medication evaluations for antidepressants or other nonaddictive substances
-
Identification of the patient's typical passive-aggressive maneuvers or
"scripts."
Useful assessment instruments include the MMPI, CAGE, or MAST, to assist
clinical review and/or to evaluate substance abuse.
Crisis Stabilization
Often, several issues must be managed during crises experienced by patients
with passive-aggressive personality disorder, such as responses to abusive
relationships, obtaining safe housing, and receiving emergency psychiatric
admissions for suicidal crises. These patients may need to be detoxified
from benzodiazepines and other sedative-hypnotics. To manage various crises,
therapists may need to insist that patients provide release of information
authorizations for all providers of care. This can help the therapist to
coordinate services. Verifying all prescribed medications can prevent medical
emergencies and improve patient responsibilities.
Longer-Term Care
Patients who have AOD use disorders that involve prescription drugs will
find it helpful to inform their prescribing physicians of their involvement
in treatment and recovery efforts. This helps to stop the supply of psychoactive
medications, to learn assertive behavior, and to teach personal responsibility
for recovery.
Patients with passive-aggressive personality disorder require skill
building in several areas including: assertiveness, boundary setting, anger
management, and identifying and expressing their feelings directly. They
will also need to work through sexual intimacy problems. This might be
done in a same-sex group, individual therapy, or marital or couple therapy.
Treatment planning should include goals and objectives that are reasonable
and measurable. For example, a goal may be set to increase the length of
time during which a patient is abstinent between relapse episodes. An excellent
focus for the skill-building part of therapy is developing the ability
to express anger through assertiveness rather than through indirect acting
out.
Passive-aggressive patients may engage in compulsive behaviors including
eating disorders and compulsive shopping and spending; money management
problems, as well as AOD relapse, may also occur. Throughout treatment,
therapists should continue to monitor the patient's use of alcohol, prescribed
and over-the-counter medications, and other drugs.
Individual Counseling
In individual therapy, therapists may help patients to express their emotions
directly. Therapists can encourage patients to process comments made when
the patient appears to be passive or disinterested in the process. Therapists
can prompt patients to express their needs, wants, and desires directly
without waiting until a later session. Therapists can use written and verbal
contracting as an ongoing therapeutic method. Therapists should not apologize
for setting and enforcing limits and reinforcing boundaries between the
passive-aggressive patient and the program staff.
Group Therapy
Patients with passive-aggressive personality disorder should be encouraged
to join same-sex support groups. This helps them identify strongly with
same-sex peers and prevents relationships built on a mutual need to avoid
recovery. Group therapy sessions provide patients an opportunity to develop
ways to manage hostility.
When hostility manifests itself during group sessions, therapists may
manage it by commenting on the hostile behavior, asking other group members
to comment, and asking the patient to respond. The therapist may then quickly
assess the patient by asking: What do you need? Who can you ask for it?
When can you ask for it? The patient can then rehearse appropriate behavior
in group.
Parents can be taught not to assume these dysfunctional roles. Patients
who are also parents may need to be taught parenting skills to help them
avoid creating destructive relationships with their children. Passive-aggressive
parents need direct methods for dealing with their children's behavior
so that children do not develop personality and emotional problems themselves.
Children raised by parents who are overcontrolling, unpredictable, and
hostile can develop antisocial or dissociative defenses and styles.
Once patients with passive-aggressive personality disorder have managed
to work through primary issues, therapists may want to use opposite-sex
models who can demonstrate appropriate types of behavior. Learning how
to set limits on opposite-sex facilitators helps with generalization of
newly learned skills.
Twelve-Step Work
Control is an essential feature of the passive-aggressive personality.
Therapeutic work that centers on step one of the 12 steps can be helpful.
Therapists should remember to emphasize that patients can gain certain
types of control by giving up other kinds of control. Step work discussed
in the section on borderline personality disorder (Exhibit
7-2) can be helpful.
Patients may benefit from participation in 12-step programs for their
AOD problems and for relationship dependencies and conflicts. Patients
should be educated about avoiding romantic involvement with other group
participants, and especially escaping a bad relationship by becoming involved
in a new relationship.
Continuum of Care
Inpatient hospitalization may be necessary for detoxification of patients
who have AOD use disorders that involve sedative-hypnotics such as the
benzodiazepines. Ongoing therapy for substance use and psychiatric issues
can be done on an outpatient basis with a combination of individual same-sex
group therapies and integration into 12-step or self-help recovery groups.
Brief inpatient psychiatric stays may also be necessary to deal with
psychiatric emergencies such as overwhelming depression, anxiety, or suicidal
ideation or behavior.
Patients may need assistance to locate shelters and safe housing when
domestic violence is a problem or threat. A primary care physician is essential
so that medical management can be provided and coordinated with psychosocial
treatment. A complication to recovery for many passive-aggressive patients
may be compulsive eating or spending problems. Ongoing assessment and treatment
of these issues as part of the overall treatment plan are encouraged.
Case Example
Jane was 37 when she sought marriage counseling with Dr. Myers. She attended
the initial appointment with her husband. Both Jane and her husband were
vague and nonspecific about what they needed from couple counseling. Jane
was quiet until the last 10 minutes of the appointment when she started
crying, stating that "nothing was going to help." Jane's husband, confused
but accommodating, tried unsuccessfully to comfort Jane who withdrew to
a chair in the corner of the office, refusing to talk. Dr. Myers contracted
with Jane to meet with her individually for three sessions to assist in
developing a better understanding of her unhappiness and frustration in
the marriage. Both Jane and her husband agreed.
Jane attended the first session on time and was "ready to get to the
bottom of this problem." Jane openly discussed her own "dysfunctional family,"
discussing parents who were both alcoholic and physically abusive. Jane
discussed her difficulties dealing with feelings of depression and fear.
Jane further reported how frustrated and upset she got whenever her husband
criticized her or when he was angry at her.
Jane reported having thoughts of suicide, although there was no plan
or history of any attempts. Jane found it helpful to have a "glass of wine"
when anxious and reported to have a prescription medication that she can
take for "her nerves" when she gets overwhelmed.
Further discussion revealed Jane to be getting a prescription for alprazolam
(Xanax) from her family doctor. She was vague about how much alprazolam
she used but said she took it "several times a week." Jane complained about
recent weight gain. She felt if she could get her weight under control,
"everything else would be fine." Jane reported to be drinking only juices
and coffee and using over-the-counter diet pills when she got too hungry.
She was somewhat defensive about her drinking and use of medications and
preferred to discuss issues related to her husband. At the end of the session,
she commented, "I hope this helps my marriage and my husband's drinking"
and she left. Jane missed the second appointment, calling 3 days later
stating she had "forgotten about the appointment." Jane attended the third
appointment but was 25 minutes late.
Question -- What should Dr. Myers' treatment plan consist of and what
should she do next?
Tips for Use With Passive-Aggressive Patients
To show patients the effect of letting hostilities and needs build up
internally, the therapist can blow up a balloon until it nearly bursts,
letting it fly around the room. This demonstrates visually what it is like
to let overwhelming feelings build up. The therapist should be willing
to sit in silence, forcing the patients to respond. Watch for patients
enabling other group members' codependency. Relationship issues are a cornerstone
of the passive-aggressive patient's problems.
Coordination of Care
Work With Other Parties
It is easy for therapists to assume dysfunctional roles with patients who
have personality disorders. Also, because of the chaos that may accompany
treatment, important patient information may be missed. Maintaining ongoing
and up-to-date contacts is essential for all patients with personality
disorders. The following are tips to remember in coordination of care of
patients with personality disorders.
Primary case manager.
Frequently, patients with personality disorders have many different people
and systems in their lives. The identification of one key person as a gatekeeper
for information can greatly improve coordination of care and reduce interagency
conflicts.
Legal issues.
Providers should obtain releases of information to monitor any new involvement
in the criminal justice system or to be aware of the disposition of old
charges. Issues of divorce and child custody may need to be monitored in
the sessions, with the goal of having the patient spend an appropriate
amount of session time on these topics.
Managed care.
Typically, managed care does not provide benefits for patients with personality
disorders. Many patients with personality disorders also meet criteria
for psychiatric disorders such as depression or anxiety. Brief stays in
hospitals and limited insurance coverage need to be realistically evaluated
so treatment goals match benefits and assets available for care.
Funding issues.
Reimbursement for the treatment of patients with dual disorders may not
include patients who have personality disorders. Often, a coexisting diagnosis
of depression or anxiety is appropriate. For billing or funding purposes,
listing the AOD problem as the primary illness may be an option.
Staffing and cross-training.
All staff benefit from training in AOD treatment in general, and in working
with AOD-using patients with personality disorders in particular. Integrated
treatment for coexisting disorders is most effective.
Medical issues.
Patients participating in inpatient AOD treatment should have a complete
physical examination. Outpatients should have a current (within past 30
days) physical examination on file. Physical examinations are particularly
important for patients who have coexisting medical problems or who are
HIV positive. HIV testing should be encouraged.
Integration into 12-step self-help groups.
It is important to encourage 12-step participation as a means of ensuring
long-term recovery. Therapists and patients should discuss patients' objections
to participation in these self-help group meetings. Patients should be
encouraged to find 12-step groups with which they are comfortable.
Chapter 8 -- Psychotic Disorders
Dual-Focus Perspective
This chapter is an overview of current assessment and treatment principles
for patients with alcohol and other drug (AOD) use disorders and psychosis.
Along with an increased awareness of the treatment needs of patients with
these dual disorders, an increased emphasis on service systems has evolved.
These and other forces have prompted the need to reassess traditional models
and service approaches to develop assessment and treatment strategies that
meet the specific needs of patients with AOD use disorders and psychosis.
All too often, AOD use disorders are undetected in patients with psychotic
disorders, and traditional treatment approaches are often inadequate. For
example, attempts have been made to treat psychotic and AOD use disorders
in a sequential manner, treating one disorder first and then the other.
While a single-focus approach is helpful for differential diagnosis, and
is effective in treating some patients, it is frequently unsuccessful for
patients with AOD problems who have severe and recurrent psychotic episodes.
This chapter provides an overview of a dual-focus approach to the assessment
and treatment of patients with these dual disorders. A single-focus approach
emphasizes the importance of developing a diagnosis and subsequent treatment
plan -- such as is done when treating patients who have a single disorder.
In a dual-focus approach, the emphasis is not on making a diagnosis, but
rather on 1) the severity of presenting symptoms, 2) crisis intervention
and crisis management, 3) stabilization, and 4) diagnostic efforts within
the context of multiple-contact, longitudinal treatment. By concentrating
on symptoms, crisis management, and stabilization, clinicians can simultaneously
focus on patients' treatment needs that are caused by both the psychotic
and AOD use disorders, rather than focusing on one disorder or the other.
Dual-Focus Approach for Assessing and Treating Patients with Dual
Disorders
-
Initial focus on severity of presenting symptoms, not on diagnosis of one
disorder or another
-
Acute crisis intervention and crisis management
-
Acute, subacute, and long-term stabilization of patient
-
Ongoing diagnostic efforts
-
Multiple-contact longitudinal treatment.
Definitions and Diagnoses
The term psychosis describes a disintegration of the thinking process,
involving the inability to distinguish external reality from internal fantasy.
The characteristic deficit in psychosis is the inability to differentiate
between information that originates from the external world and information
that originates from the inner world of the mind (such as distortions of
normal thinking processes) or the brain (such as abnormal sensations and
hallucinations).
Psychosis is a common feature of schizophrenia. Psychotic symptoms are
often a feature of organic mental disorders, mood disorders, schizophreniform
disorder, schizoaffective disorder, delusional (paranoid) disorder, brief
reactive psychosis, induced psychotic disorder, and atypical psychosis.
Schizophrenia is best understood as a group of disorders with
similar clinical profiles, invariably including thought disturbances in
a clear sensorium and often with characteristic symptoms such as hallucinations,
delusions, bizarre behavior, and deterioration in the general level of
functioning.
Severe disturbances occur with relation to language and communication,
content of thought, perceptions, affect, sense of self, volition, relationship
to the external world, and motor behavior. Symptoms may include bizarre
delusions, prominent hallucinations, incoherence, flat affect, avolition,
and anhedonia. Functioning is impaired in interpersonal, academic, or occupational
relations and self-care.
Schizophrenia can be divided into subtypes: 1) in the paranoid type,
delusions or hallucinations predominate; 2) in the disorganized type, speech
and behavior problems predominate; 3) in the catatonic type, catalepsy
or stupor, extreme agitation, extreme negativism or mutism, peculiarities
of voluntary movement or stereotyped movements predominate; 4) in the undifferentiated
type, no single clinical presentation predominates; and 5) in the residual
type, prominent psychotic symptoms no longer predominate. The diagnosis
of schizophrenia requires a minimum of 6 months' duration of symptoms,
with active psychotic symptoms for 1 week (unless successfully treated).
Clinicians generally divide the symptoms of schizophrenia into two types:
positive and negative symptoms. Acute course schizophrenia is characterized
by positive symptoms, such as hallucinations, delusions, excitement, and
disorganized speech; motor manifestations such as agitated behavior or
catatonia; relatively minor thought disturbances; and a positive response
to neuroleptic medication.
Chronic course schizophrenia is characterized by negative symptoms,
such as anhedonia, apathy, flat affect, social isolation, and socially
deviant behavior; conspicuous thought disturbances; evidence of cerebral
atrophy; and generally poor response to neuroleptics. In general, acute
substance-induced psychotic symptoms tend to be positive symptoms. .
Schizophreniform disorder is a condition exhibiting the same
symptoms of schizophrenia but marked by a sudden onset with resolution
in 2 weeks to 6 months. Some patients exhibit a single psychotic episode
only; others may have repeated episodes separated by varying durations
of time.
Schizoaffective disorder is a condition that includes persistent
delusions, auditory hallucinations, or formal thought disorder consistent
with the acute phase of schizophrenia, but the condition is also frequently
accompanied by prominent manic or depressive symptoms. Schizoaffective
disorder is further divided into bipolar (history of mania) and unipolar
(depression only) types. .
Delusional disorders are characterized by prominent well-organized
delusions and by the relative absence of hallucinations; disorganized thought
and behavior; and abnormal affect. The delusional disorders are divided
into six types: persecutory, grandiose, erotomanic, jealous, somatic, and
unspecified.
Brief reactive psychosis describes a condition in which an individual
develops psychotic symptoms after being confronted by overwhelming stress.
The onset of symptoms is abrupt, without the gradual symptom development
often seen in schizophrenia or schizophreniform disorder, and the duration
is brief (no longer than 1 month). .
Induced psychotic disorder describes a disorder characterized
by the uncritical acceptance by one person of the delusional beliefs of
another. In other words, a dominant partner has a delusional psychosis
that is believed and accepted by a passive partner.
Substance-Induced Disorders
AOD-induced psychotic disorders are conditions characterized by
prominent delusions or hallucinations that develop during or following
psychoactive drug use and cause significant distress or impairment in social
or occupational functioning. This disorder does not include hallucinations
caused by hallucinogens in the context of intact reality testing.
Although there can be great variability in individual susceptibility
to AOD-induced psychotic symptoms, it is important for the clinician to
determine if the presenting symptoms could plausibly be induced by the
type and amount of drug apparently consumed. For example, vivid auditory,
visual, and tactile hallucinations are plausible side effects of a 5-day,
high-dose cocaine binge. However, should these symptoms emerge during a
brief episode of mild alcohol intoxication, it is likely that the symptoms
represent an underlying psychotic process that has been exacerbated by
the use of alcohol.
Stimulant-Induced Symptoms
Psychotic symptoms induced by stimulant intoxication are unusual
when stimulants are used in low doses and for brief periods. Acute stimulant
intoxication in the context of a chronic, high-dose pattern can cause symptoms
of psychosis, especially if coupled with a lack of sleep and food and environmental
stressors. Stimulant-induced psychotic symptoms can mimic a variety of
psychotic symptoms and disorders including delirium, delusions (often persecutory
and paranoid), prominent hallucinations, incoherence, and loosening of
associations. Stimulant delirium often includes formication, a tactile
hallucination of bugs crawling on or under the skin.
Depressant-Induced Symptoms
Particularly when unmedicated, sedative-hypnotic withdrawal can
include symptoms of psychosis. Acute withdrawal from alcohol, barbiturates,
and the benzodiazepines can produce a withdrawal delirium, especially if
use was heavy and tolerance was high or if the patient has a concomitant
physical illness. Hallucinations and delusions are common features of sedative-hypnotic
withdrawal delirium.
Psychedelic- and Hallucinogen-Induced Symptoms
Many psychedelic drugs, such as the amphetamine-related psychedelics (for
example, MDMA and MDA), are not hallucinogenic at the lower doses associated
with situational psychedelic drug use. However, in a chronic, high-dose
pattern of use (which is rare), psychotic symptoms are possible, by virtue
of the drugs' stimulant properties. Other psychedelic drugs, such as LSD,
have strong hallucinogenic properties.
Hallucinogen intoxication can cause hallucinogenic hallucinosis,
characterized by perceptual distortions, maladaptive behavioral changes,
and impaired judgment. Hallucinogen intoxication may also prompt hallucinogenic
delusional disorder and a hallucinogenic mood disorder. However, hallucinogen-induced
perceptual distortions such as hallucinations or visions are not considered
evidence of psychosis when the drug user retains reality testing and is
aware that the distortions are drug induced. Acute marijuana intoxication
can
produce a delusional disorder that may include persecutory delusions, depersonalization,
and emotional lability. Similarly, acute PCP intoxication
can lead
to delirium, delusions, or a PCP-induced mood disorder.
Prevalence
Various studies have noted that the lifetime prevalence rate for schizophrenia
is roughly 1 percent among the general population (Africa
and Schwartz, 1992). In the Epidemiologic Catchment Area (ECA) studies,
the prevalence rate for schizophrenia and schizophreniform disorders combined
were as follows: 1) 1-month prevalence rate: 0.7 percent; 2) 6-month prevalence
rate: 0.9 percent; and 3) lifetime prevalence rate: 1.5 percent (Regier
et al., 1988).
The ECA studies reported that the lifetime prevalence rate of schizophrenia
was 1.5 percent, and the 6-month prevalence rate was 0. 8 percent. The
lifetime and 6-month prevalence rates of schizophreniform disorder were
both 0.1 percent (Regier
et al., 1990).
Clinical observation of high rates of AOD use disorders among patients
with schizophrenia were supported by the ECA studies. Among individuals
identified as having a lifetime diagnosis of schizophrenia or schizophreniform
disorder, 47 percent have met criteria for some form of an AOD use disorder.
Indeed, the odds of having an AOD use disorder are 4.6 times greater for
people with schizophrenia than the odds are for the rest of the population:
the odds for alcohol use disorders are over three times higher, and the
odds for other drug use disorders are six times higher (Regier
et al., 1990).
One study noted that among patients with AOD use disorders, 7.4 percent
had a lifetime diagnosis of schizophrenia; the 1-month prevalence rate
was 4.0 percent (Ross
et al., 1988), although other studies of persons in AOD abuse treatment
found the prevalence of schizophrenia to be about the same as in the general
population -- about 1 percent (Rounsaville
et al., 1991). While patients with AOD use disorders may experience
acute episodic psychotic symptoms, few meet the diagnostic criteria for
schizophrenia if AOD-induced symptoms are excluded.
Among severely mentally ill outpatient treatment populations, AOD use
disorders are common; often more than 50 percent have AOD use disorders,
depending upon the treatment setting. Among patients being treated for
psychiatric problems in acute settings such as inpatient hospitals, combined
psychiatric and AOD use disorders are also common.
Among patients with combined psychotic and AOD use disorders, bizarre
behavior and communication generally prompt a mental health referral. Thus,
people with psychotic disorders usually receive services through the mental
health system and are rarely treated in the typical addiction treatment
program.
Lifetime Prevalence Rates
-
Among the general population, 1 percent have a schizophrenic disorder.
-
Among schizophrenic patients, 47 percent have an AOD use disorder.
Case Examples
The following three case examples can help to demonstrate the need for
a dual-focus approach to treating patients with combined psychotic and
AOD use disorders, or patients with psychotic symptoms and AOD use disorders.
Martha
Married for over 15 years, Martha was responsible for most of the duties
related to raising four children and maintaining the home. In the past,
she had been treated for an episode of postpartum psychosis. Until recently,
she had not required any psychiatric medications or mental health services.
Her husband, a successful businessman, was the family's only source
of financial support and was emotionally distant. While Martha believed
that her husband was frequently out of town on business trips, he was actually
nearby having an affair with a woman whom Martha had known for many years.
One day, he abruptly informed Martha of the affair and moved out of the
house.
During the next 3 days, Martha was intensely depressed and agitated.
Her normally infrequent and low-dose alcohol use escalated as she attempted
to diminish her agitation and insomnia. During this time, she ate and slept
very little. She began to feel extremely guilty for even the smallest problem
experienced by her four children. She felt burdened by what she called
her "transgressions, faults, and sins." She expressed fears about being
doomed to "eternal damnation." Loudly and inconsolably, she declared that
she "had lost her soul" and would have to repent for the rest of her life.
While being taken to a nearby clinic for evaluation, she passionately described
a conspiracy by members of the Catholic Church to steal her soul.
Thomas
In his inner-city neighborhood, Thomas is well known by the local medical
clinic, AOD treatment program, and community mental health program. During
the day, he spends much of his time walking around the neighborhood, frequently
talking to himself or arguing with an unseen individual. He spends most
of his evenings in the park in a wooded area away from other people, except
in the winter when he sleeps in community-run shelters.
Thomas has a prominent scar in the center of his forehead. When asked
about it, he describes in great detail his "third eye," and the fact that
he can see into the future through the eye. When asked about his stated
reluctance to live in an apartment, he describes an aversion to "electromagnetic
fields" that drain his "life force" and make it difficult for him to "think
about good things." For extended periods lasting several months, Thomas
appears disheveled and agitated, and can be seen drinking heavily or using
whatever drugs are available.
However, he also experiences prolonged periods during which he does
not drink or use other drugs, appears well groomed, and exhibits less severe
psychotic behavior. In general, Thomas is pleasant and well liked, although
he is known to become hostile and potentially violent during periods when
he uses AODs.
Laura
During a rock concert, Laura was brought by her boyfriend Morris to the
paramedics at a first aid station in a large auditorium. Morris described
Laura's gradual deterioration over a 1-hour period. At first, Laura displayed
abrupt shifts in affect, giddy and laughing one moment and agitated and
impulsive the next. Morris said that she began "talking crazy" and not
making much sense. He also mentioned that Laura had brief bursts of absolute
terror lasting a few seconds or minutes, during which he had to stop her
from running away. Morris believed that she was responding to hallucinations.
He said that Laura stopped speaking and appeared to have lost the ability
to do so. Later, she had a hard time walking and tried to crawl away from
Morris. By the time that the paramedics were able to examine her, Laura
was rigid, immobile, mute, and unable to communicate with others. Later,
Morris admitted that they had used some PCP.
Case Example Discussion
As can be seen, Martha, Thomas, and Laura have very different long-term
needs. Martha's brief reactive psychosis and depression may never recur,
and the relationship between her alcohol use and psychiatric symptoms should
be explored. Thomas's chronic psychosis and frequent AOD abuse episodes
are intricately woven together and require combined treatment. Until Laura's
boyfriend provided information about Laura's acute drug use, the reason
for her psychotic episode was unclear.
These case examples are valuable to demonstrate how the absence of a
dual-focus approach can lead to treatment failure. While Martha's psychotic
episode was related to overwhelming stress, her alcohol use might be underemphasized
in a traditional mental health setting. Doing so may obscure the possibility
that her drinking severely deepened her depression, increased daytime agitation,
and exacerbated the psychotic episode.
While Thomas has an ongoing psychosis and AOD abuse problems, focusing
on only one set of these problems means that he bounces back and forth
between the mental health and addiction treatment programs, depending upon
his current symptoms. His involvement with the local medical clinic for
treatment of physical injuries that are sustained during episodes of impaired
thinking often complicates his already uncoordinated treatment.
While Laura's drug-induced psychosis may fade as the drug is eliminated
from her body, the episode can be used as a point of entry into AOD abuse
treatment. Also, her immediate needs will be the same irrespective of the
cause of her psychotic episode.
As these case examples illustrate, patients who experience psychosis
and AOD use problems are often highly symptomatic and may have multiple
psychosocial and behavioral problems. It is common for patients with dual
disorders to have undergone different approaches to treatment by different
providers without long-term success. Furthermore, clarifying the diagnosis
and "underlying disorder" is extremely complicated in the early phases
of assessment. The first step in treatment of a person with a dual disorder
is an assessment that addresses biological, psychological, and social issues.
Acute Assessment
A common difficulty that clinicians experience is determining whether psychotic
symptoms represent a primary psychiatric disorder or are secondary to AOD
use. However, in the early phase of assessment, the goal is to stabilize
the crisis rather than to establish a final diagnosis. The final diagnosis
is often best determined during a multiple-contact, longitudinal assessment
process. All assessments include direct client interviews, collateral data,
client observations, and a review of available documented history.
Assessment of High-Risk Conditions
The initial step of every assessment is to determine whether the individual
has an imminent life-threatening condition. There are three domains of
high risk that require assessment: biological (or medical), psychological,
and social. At any given time, one aspect of this biopsychosocial approach
may be more urgent than the others.
Medical Risks
With regard to medical or biological issues, the goal of assessment is
to ensure that patients do not have life-threatening disorders such as
AOD-induced toxic states or withdrawal, delirium tremens, or delirium.
Also, patients may be exhibiting symptoms that represent an exacerbation
of their underlying chronic mental illness. The symptoms may be due to
an aggravation of medical problems such as neurological disorders (for
example, brain hemorrhage, seizure disorder), infections (central nervous
system infection, pneumonia, AIDS-related complications), and endocrine
disorders (diabetes, hyperthyroidism). The presence of cognitive impairment
(such as acute confusion, disorientation, or memory impairment), unusual
hallucinations (such as visual, olfactory, or tactile), or signs of physical
illness (such as fever, marked weight loss, or slurred speech) show a high
risk for an acute medical illness. Patients who exhibit this degree of
risk need to be immediately referred for a comprehensive medical assessment.
Psychological Risks
With regard to psychological issues, the primary goal must be an assessment
of danger to self or others and other manifestations of violent or impulsive
behavior. Patients with a dual disorder involving psychosis have a higher
risk for self-destructive and violent behaviors. Patients should be assessed
for plans, intents, and means of carrying out dangerous behaviors. Patients
who are imminently suicidal, homicidal, or dangerous need to be in a secure
setting for further assessment and treatment. In addition, some patients
may have cognitive impairment related to their dual disorder and be unable
to adequately care for basic needs.
Social Risks
With regard to social issues, the primary goal is to ensure that patients
have access to minimal life supports and have their basic needs met. Patients
with a dual disorder involving psychosis are particularly vulnerable to
homelessness, housing instability, victimization, poor nutrition, and inadequate
financial resources. Patients who lack basic supports may require aggressive
crisis intervention, such as the provision of food and assistance with
locating a safe shelter. Lack of these social supports can be life threatening
and can worsen medical and psychiatric emergencies.
Biopsychosocial Assessment of High-Risk Conditions
-
Biological risks: Assess for life-threatening medical problems
-
Psychological risks: Assess for violent and impulsive behaviors
-
Social risks: Assess basic needs and life supports.
High-Risk Probing Questions
To provide a thorough assessment of patients who are experiencing psychotic
symptoms, it is important to directly question patients about the three
domains of medical, psychological, and social safety.
Medical Safety
In the absence of overwhelming medical and psychiatric crises, the clinician
should ask patients a series of questions that relate to medical assessment.
One example is: "Have you been diagnosed or hospitalized for any major
medical disorders?" Similar questions should address the recent onset of
significant medical symptoms, episodes of head trauma or loss of consciousness,
prescribed and over-the-counter medications, recent changes in medications,
the use of AODs, and nutritional and sleep needs.
In addition, the assessment of medical symptoms should include a thorough
cognitive examination of patients' orientation, memory, concentration,
language, and comprehension.
Psychological Safety
Psychological safety issues relate to self-destructive and violent behaviors
or an inability to care for oneself. The clinician should ask direct questions
about plans, means, and intent for violence. Plans include specificity
of lethal methods, such as time and place. Means include implements such
as medications, ropes, and guns. Intent refers to the desire or explicit
goal to end either one's own or another's life.
In particular, patients should be asked about command hallucinations
and delusions that direct the person to hurt him- or herself or another.
Impaired judgment or cognition that may result in an increased likelihood
of impulsive, destructive behaviors.
It is also important to ask patients about their past, and particularly
recent, history of violent behaviors, since a history of suicidal and homicidal
behaviors is the best predictor of current risk for such behaviors.
Assessing Psychological Safety
-
Suicide plans, means, and intent
-
Delusions and command hallucinations
-
Impulsivity or impaired judgment or cognition
-
History of suicidal or homicidal behaviors.
Social Safety
Patients should be asked direct questions about past and current access
to basic needs such as food, shelter, money, medication, or clothing. Patients
should be assessed for past and recent episodes of victimization and of
exchanging sex for money, drugs, and shelter.
Comprehensive Assessment
It is essential to rule out imminently life-threatening medical or AOD-induced
emergencies which may be causing or contributing to the psychotic symptoms.
Probing Questions for Psychiatric And AOD Abuse Assessment
Once medical and AOD-induced emergencies have been addressed or ruled out,
the focus of probing assessment questions should relate to the severity
of presenting behaviors and symptoms rather than to whether symptoms are
primary or secondary to AOD use. The focus should be on assessing the severity
of the immediate symptoms. With the exception of life-threatening emergencies,
the clarification of "primary versus secondary" is an important issue in
working with patients who have a dual disorder involving psychosis, but
such clarification requires multiple-contact, longitudinal diagnostic differentiation.
Examples of key probing questions for delusions include the following:
-
"Do you sometimes feel as if people are talking about you?"
-
"Do you sometimes feel as if people are purposefully trying to injure or
offend you?"
-
"Have you ever felt as if you were receiving special messages through the
television, radio, or some other source?"
-
"Do you sometimes feel that you have special powers that other people do
not have?"
-
"Have you ever felt that something or someone outside of yourself was controlling
your behavior, thoughts, or feelings against your will?"Examples of key
probing questions for auditory hallucinations include:
-
"Do you sometimes hear things that other people cannot hear?"
-
"During these episodes, what exactly do you hear?"
-
"If you heard voices, what were the voices saying?"
-
"If you heard voices, did the voices tell you what to do, or criticize
your thoughts or behaviors?"
-
"How often do you have these experiences?"
Examples of key probing questions for AOD use disorders include:
-
"Do you often drink or use other drugs more than you plan to?"
-
"Have you made attempts to cut down or stop using alcohol and other drugs?"
-
"How much time during the week do you spend obtaining, using, or recovering
from the effects of alcohol and other drugs?"
-
"Since you began using, have you stopped spending time with family and
friends and begun spending more time using alcohol and other drugs or spending
more time with people who do?"
It is important to recognize that direct interview questions will be of
limited value for some patients in detecting substance use. Patients may
underestimate, overestimate, or not recognize the severity or existence
of their AOD use disorder.
Standardized Screening and Assessment Measures
There are several standardized instruments for AOD abuse screening and
assessment. While valuable for assessing patients with AOD use disorders,
these instruments have not been extensively tested among patients with
concomitant psychotic and AOD use disorders. However, even brief instruments
such as the CAGE questionnaire, the Michigan Alcohol Screening Test (MAST),
and case manager rating scales will detect most AOD use disorders in this
group.
Such instruments may be unreliable when used with patients who are acutely
psychotic or whose residual impairments interfere with their capacity to
respond to the interview questions. Since these tools involve self-report
interviews, denial mechanisms may also reduce accuracy. Also, instruments
that rely heavily on detecting signs of dependency syndromes (such as the
Alcohol Dependency Scale) may fail to detect significant numbers of people
with dual disorders. This is because even limited AOD use may be extremely
problematic for patients with a psychotic disorder.
Especially for patients with psychotic symptoms, clinicians should inquire
about the use, frequency, and quantity of all drugs of abuse, not merely
alcohol. Also, clinicians can adapt the CAGE questionnaire (see
Chapter 3) in such a way that the possible relation-ships between AOD
use and psychotic symptoms can be elicited. For example, patients can be
asked if they have cut down (or increased) their AOD use in relation
to hearing "voices" or because of paranoia. They can be asked if they become
more or less annoyed, angry, or irritable when using AODs. Clinicians
can ask patients if they feel guilty about using AODs when taking
medication, or if their guilt causes them to occasionally stop taking their
medication.
Patients can be asked if AODs have been used to diminish the side effects
of medications prescribed for psychiatric problems. Also, they should be
asked if AOD use or withdrawal has ever been associated with a hospitalization
or a suicide attempt. Patients should be asked if the frequency, quantity,
and episode duration of their AOD use has changed and what consequences
are associated with these changes.
Standardized assessment measures include the MAST, which has been demonstrated
to have value for assessing this group. The Addiction Severity Index (ASI)
is an instrument that guides the interviewer through a series of questions
about drug use and consequences, as does the American Psychiatric Association's
Structured Clinical Interview for DSM-III-R (SCID).
Alternatives to direct interview scales with demonstrated efficacy include
case manager rating scales that are based on longitudinal observations
of the patient, and aggregate multiple sources of information, including
medical records, families, the criminal justice system, employers, landlords,
and related sources. The patient's informed consent must be obtained before
these contacts are made.
Clinician's Observations
An important aspect of the assessment is the clinician's observations.
The clinician should make careful note of the patient's overall behavior,
appearance, hygiene, speech, and gait. Of particular interest are any acute
changes in these behaviors, as well as the emergence of disorganized or
bizarre thinking and behavior. A long-term therapeutic relationship with
the patient increases the opportunity to make clinical observations that
assist in making the differential diagnosis. Within this context, clinicians
can better understand the relationships between the AOD use and the psychiatric
symptoms.
Collateral Resources
As previously mentioned, data obtained from direct interviews and self-reports,
as well as observational data, are limited. One important way of augmenting
these approaches is to obtain information from collateral sources by directly
interviewing family members and significant others about the psychiatric
and AOD-related behavior of patients. The family interview can also be
a useful means to obtain further information regarding family history of
psychiatric and AOD use disorders.
Other collateral information can include available documentation such
as medical and criminal justice records, as well as information gathered
from other sources such as landlords, housing settings, social services,
and employers. Case managers may be in a unique position to compile aggregate
reports from these various sources, since they are able to follow these
patients over an extended period of time in a variety of settings.
Laboratory Tests
Laboratory tests for drug detection can be valuable both in documenting
AOD use and in assessing AOD use in relation to psychotic symptoms. Objective
urine and blood toxicology screens and alcohol Breathalyzer tests can be
useful. Data from urine screens may be particularly useful for patients
who deny regular use of AODs and who may benefit from objective feedback
about the presence or absence of AOD use. Toxicology screens that document
an absence of drug use can provide positive feedback for abstinent patients
who are actively working to maintain sobriety.
Liver function tests have limited assessment value, particularly for
patients ingesting large amounts of alcohol. However, the absence of abnormal
liver findings should not be used as an indication of nonproblematic alcohol
use.
Social Issues
While psychiatric, medical, or AOD-induced disorders may be more visible
to the clinician than social problems, the latter can contribute significantly
to the emergence and maintenance of these disorders. Indeed, the psychotic
patient with dual disorders is more likely than not to have significant
impairment in the social area. Thus, identifying the problem areas of a
specific patient's social life becomes a core component of the service
or treatment plan.
Actively helping patients to secure basic needs is a powerful way to
engage them in the treatment process. Patients with dual disorders frequently
face problems with living conditions, employment, homelessness, housing
instability, loss of social support systems, and nutrition. The frustration
and emotional turmoil that accompany problems in these areas can be intense.
Indeed, many cases of treatment failure that are perceived as resistance
to treatment and denial actually represent the failure of the treatment
provider to recognize the impact of a patient's deteriorated social situation
and to help the patient gain access to services.
In addition to social needs, clinicians should be aware of and sensitive
to the impact of race, culture, ethnicity, nationality, gender issues,
sexual orientation, and sexual history upon the lives of their patients.
Primary Health Care
A current or recent comprehensive medical evaluation is an essential aspect
of the overall assessment. Nonmedical clinical personnel should become
familiar with patients' medical histories and specifically inquire about
the possible relationship between existing medical conditions and presenting
symptoms.
Meeting the medical needs of patients with psychiatric and AOD use disorders
is a critical aspect of treatment. For patients with psychotic disorders,
attention to medical needs is even more important, since they generally
have a high prevalence of medical problems, including chronic medical problems
that are frequently untreated or undertreated.
During long-term treatment, it is important to evaluate the relationships
between patients' medical problems and their psychotic and AOD use disorders.
For example, medical problems may: 1) coexist with psychotic and AOD use
disorders, 2) prompt or exacerbate psychotic and AOD use disorders, or
3) be the direct or indirect result of psychotic and AOD use disorders.
It is especially important for these patients to have easy access to
treatment for medical conditions that are strongly associated with AOD
use, such as tuberculosis, hepatitis, and HIV/AIDS. In addition, they should
have easy access to treatment for basic medical needs, such as diabetes
and hypertension, as well as cardiovascular, respiratory, and neurological
disorders. Attention should be provided for the pregnant woman with regard
to prenatal care and ongoing monitoring of pregnancy. The pregnant woman
may be especially at risk for relapse when her regular antipsychotic medication
regimen is contraindicated.
In addition to medical treatment, patients with dual disorders that
involve psychosis need basic education about fundamental health care, hygiene,
and AIDS prevention. A program that serves patients with dual disorders
should include basic medical education components on site as a routine
part of treatment, rather than referrals to another agency.
For patients who are prescribed medications, it is important to assess
the types of medications, whether or not the medications are being taken,
and the types of side effects they may cause. Patients should be asked
specifically about the frequency, dosage, and duration of any prescription
medication.
Medication noncompliance is the rule, not the exception, for people
with dual disorders. Psychiatric medication noncompliance is particularly
associated with dual disorders that involve psychosis, causing significant
impact on presenting symptoms and level of function. Because of this common
association between AOD use and noncompliance and the limitation of self-reports,
it is useful to complement this assessment with an assessment of serum
drug levels of psychiatric medications.
In addition to considering AOD use as a primary factor that affects
the use of psychiatric medications, it is also important to consider the
potential role of psychiatric medications in subsequent AOD use. For example,
side effects such as akathisia (severe restlessness) or sedation may be
caused by antipsychotic medications, and patients may take AODs in an attempt
to medicate these unwanted side effects.
Frequently, psychoactive substances become replacements for adequate
and nutritious food. Nutritional impairment is associated with impaired
cognition. A lack of regular meals and poor nutrition are common occurrences
among patients with dual disorders; thus, access to regular meals should
be assessed.
Also, acute dental problems as well as ongoing dental care should be
assessed. Because this group frequently experiences financial difficulties,
access to dental care is often limited or nonexistent. Attention should
be given to the social and emotional consequences of poor dental health,
such as poor self-esteem and diminished social interaction.
Treatment Issues
The most important initial step in treatment is to identify high-risk conditions
that require immediate treatment, while recognizing that there will likely
be important issues that require long-term management.
Acute Management
Within the area of acute management, it is useful to differentiate between
acute management of crises and the resolution of subacute problems that
may be severe but not life threatening.
High-Risk Conditions
The initial critical consideration for high-risk conditions is to determine
if patients require emergency medical treatment, psychiatric treatment,
or both. The critical decision is whether patients require hospitalization,
and if so, what type of treatment is required (for example, primary health
care, detoxifi-cation, or psychiatric care). This aspect of treatment necessarily
involves medical assessment and intervention.
With regard to biological or medical issues, the priority is addressing
and stabilizing the acute crisis in a hospital-based setting. Once the
acute crisis has been stabilized, mental health and AOD use consultation
may be necessary to address the concomitant psychiatric and AOD disorders.
With regard to high-risk psychological conditions (that is, danger to
self or others and other violent and impulsive behavior), the initial focus
is on stabilizing the acute psychological crisisÒproviding that
acute medical causes have been ruled out. Stabilization may require acute
involuntary psychiatric hospitalization. Thus, coordination with emergency
mental health services and the local police department is necessary to
ensure the immediate safety of the patient and others.
With regard to high-risk social conditions (homelessness, housing instability,
victimization, and unmet basic needs), the priority is on implementing
aggressive social crisis intervention. Meeting patients' basic needs is
critical in the management of the treatment of dual disorders that include
psychosis. The high-risk social conditions may be related to the medical
or psychiatric crisis, and therefore will require followup upon hospital
discharge.
Regardless of the priority of crisis intervention, the overall biopsychosocial
needs of patients must be addressed in a holistic manner, considering both
the psychosis and the AOD use disorder. The approach must be integrated
and comprehensive despite the higher visibility of one of the disorders.
Subacute Conditions
Following the resolution of the acute crisis, subacute conditions must
be addressed before long-term management can occur. (Subacute conditions
can also occur as a precursor to acute relapse of psychiatric symptomatology
or AOD use.) Examples of specific subacute management issues include resuming
or adjusting psychotropic medication, patients' comfort with the medication,
medication compliance, addressing acute psychiatric symptoms, establishing
early AOD use treatment intervention, and establishing or sustaining patients'
connection with support systems and services for obtaining housing and
meeting basic needs.
The subacute phase allows for an opportunity to reassess the diagnosis
and overall treatment needs. The ultimate goal should be to establish a
long-term treatment plan, to avert imminent decompensation or relapse,
and to address long-term needs.
Long-Term Management
The overall goal of long-term management should involve: 1) providing coordinated
and integrated services for both the psychiatric and AOD use disorders,
and 2) doing so with a long-term focus that addresses biopsychosocial issues.
Patients with severe or persistent psychiatric and AOD use disorders,
such as Thomas, require dually focused, integrated treatment. Patients
like Martha, who have mild or brief symptoms of mental illness, may benefit
from parallel treatment or self-help. Patients with AOD-induced psychiatric
symptoms similar to Laura's should receive long-term management and treatment
by AOD abuse treatment providers. Irrespective of the treatment setting,
the goal is to help patients with dual disorders gain control over their
psychiatric and AOD use disorders.
Gaining such control is a long-term process. For this group, the initial
expectation during the engagement period should not be immediate compliance
with psychiatric treatment or immediate abstinence. Indeed, mandating these
treatment prerequisites may interfere with access to services or lead to
the patient's rejection of the treatment services. Abstinence from AOD
use is the long-term goal for patients with dual disorders that involve
psychosis, but should not be a prerequisite for offering or continuing
treatment services.
Therapeutic Engagement
The first step in the long-term treatment of patients with dual disorders
that involve psychosis is to engage them in the treatment process. The
basis of therapeutic engagement is building a relationship with patients.
Engagement is a long-term process, not a single event that occurs only
during the initial stages of treatment. The engagement process may need
to be revisited throughout the course of treating these two unremitting
disorders.
Frequently, patients with dual disorders do not acknowledge or appreciate
that AOD use or a psychiatric disorder is a problem in their lives. Hence,
establishing a relationship with these patients may first require knowing
what they want and need. They may not want AOD treatment or psychiatric
services. Rather, they may best be engaged by offering them assistance
to meet their basic needs such as housing or entitlements or by providing
basic medical and legal services.
A variety of approaches can be used to facilitate the engagement process.
These include assertive outreach by case managers and clinicians, offering
to facilitate the acquisition of basic services and entitlements and help
with legal services. Similarly, engagement may be facilitated through involvement
with alternative social and recreational activities, programs, clubs, and
drop-in centers.
Engagement techniques can include the therapist's involvement with the
family and other significant parties. Indeed, at times, clinicians may
be able to maintain contact with patients only through the family.
Patients often want help finding and keeping a job. Thus, engagement
includes vocational rehabilitation.
For patients who have particularly severe psychiatric or AOD use disorders
and do not respond to these initial attempts at engagement in the treatment
process, the use of therapeutic coercive approaches may be necessary. Patients
with severe dual disorders may have gross cognitive impairment due to AOD
use and may be severely disorganized due to psychiatric illness. They may
be impulsive, exhibit extremely poor judgment, or be chronically dangerous
to themselves or others.
Without therapeutic coercive interventions, some of these patients may
be at substantial risk of catastrophic outcomes, including death, injury,
violent behavior, or long-term incarceration. Examples of therapeutic coercive
approaches include the appointment of a representative payee, guardian,
or conservator and the use of parole or probation. Legal advocacy by a
case manager for court-mandated treatment services may be essential for
engaging and maintaining treatment services. Other mechanisms include commitment
to outpatient treatment services, conditional discharge, and commitment
to appropriate inpatient dual disorder treatment.
Therapeutic coercive efforts should be temporary and reserved for patients
who have failed with other interventions. The long-term goal for these
patients is to regain control over their lives. As mentioned above, service
providers have traditionally expected patients to be motivated before initiating
treatment. They have often misinterpreted the lack of engagement as denial
or resistance to treatment.
It is essential for treatment professionals to understand that the provider
is responsible for motivating or providing incentives for the patient to
engage and remain in treatment.
Concurrent and Integrated Dually Focused Treatment
Service providers in traditional treatment programs have often maintained
that patients with dual disorders should be treated sequentially, that
is, by treating the AOD use disorder before treating the psychiatric disorder,
or vice versa. Rather, there should be an ongoing dual focus on both disorders,
especially for patients with psychosis or AOD use disorders.
Particularly for the severely disorganized patient or for the patient
with persistently disabling conditions, integrated treatment is essential.
Ideally, the services should be integrated within the same agency and program.
When mental health and addiction treatment services are not integrated,
fragmentation of services and discontinuous service are significant risks.
In situations where services cannot be integrated, it is crucial for one
provider to accept full responsibility for the patient and to aggressively
coordinate service with other programs and services. For treatment to be
effective, and to ensure continuity of care, a long-term relationship and
treatment approach should be developed.
For patients with milder psychiatric symptoms, parallel treatment approaches
such as concurrent psychiatric and AOD treatment may be helpful, although
such approaches have the disadvantage of placing the burden of integrating
different treatment options on patients. This burden should be minimized
by a case manager or clinician who can provide appropriate clinical liaison
between different agencies.
Engaging the Chronically Psychotic Patient
| Noncoercive Engagement Techniques |
Coercive Engagement Techniques |
-
Assistance obtaining food, shelter, and clothing
-
Assistance obtaining entitlements and social services
-
Drop-in centers as entry to treatment
-
Recreational activities
-
Low-stress, nonconfrontational approaches
-
Outreach to patient's community.
|
-
Involuntary commitment
-
Mandated medications
-
Representative payee strategie
|
Long-Term Perspective
For patients with dual disorders involving psychosis, a long-term approach
is imperative. Research has shown that individuals become abstinent and
gain control over psychiatric symptoms through a process that frequently
takes years, not days or months. Front-loaded, intensive, expensive, and
highly stimulating short-term treatment modalities are likely to fail with
this group of patients.
Both psychotic and AOD use disorders tend to be chronic disorders with
multiple relapses and remissions, supporting the need for long-term treatment.
Also, an accurate diagnosis and an assessment of the role of AODs in the
patient's psychosis necessitate a multiple-contact, longitudinal assessment
and treatment perspective.
Treatment Teams
Especially for programs that treat patients with psychotic and AOD use
disorders, it is essential that the program philosophy be based on a multidisciplinary
team approach. Ideally, team members should be cross-trained, and there
should be representatives from the medical, mental health, and addiction
systems. Staff members should learn to use gentle or indirect confrontation
techniques with these patients.
Assertive Case Management
Team members should endorse an assertive case management approach, wherein
the case manager is not limited to the treatment site, but is expected
to provide services to patients in their own environments. The case manager
must not attempt to solely broker treatment services or exclusively provide
office-based treatment. A supportive and psychotherapeutic approach to
individual, group, and family work should be employed.
For these patients, flexible hours are necessary. Because crises frequently
occur during evening and weekend hours, services should be provided during
these hours. In addition, alternative social activities and peer group
activities often take place in the evening and on weekends.
Also, individual and group programs for patients with dual disorders
that involve psychosis should be based on a behavioral and psychoeducational
perspective, not a psychodynamic approach. Educational information should
be frequently repeated and presented in concrete terms using a multimedia
format. Programs should be modified to include frequent breaks and shorter
sessions than normal.
Special care should be taken with regard to patient education and group
discussion about Higher Power issues. Staff members should be trained to
teach patients and lead group discussions about spirituality and the concept
of a Higher Power. Staff members should understand the difference between
spirituality and religion, and especially the differences between spirituality,
religion, and delusional systems that have a religious or spiritual content.
Personalized Service Planning
It is essential that the treatment plan for each patient be personalized,
and based on the specific needs and stated goals of the patient, rather
than on the clinician's goals. The patient should participate in the ongoing
review and evaluation of the treatment plan.
Associated Psychosocial Needs
Even intensive, carefully designed AOD abuse treatment is likely to fail
if the extensive psychosocial problems associated with dual disorders are
not concurrently addressed. Common psychosocial concerns of this group
include housing, finances and entitlements, legal services, job assistance,
and access to adequate food, clothing, and medication.
Housing
A particularly common complication of dual disorder patients with psychosis
is housing instability and homelessness. Among the possible housing services
that may be particularly useful are shelters, supervised housing settings,
congregated living settings, treatment milieu settings, and therapeutic
communities. Ideally, residential options and placements should be long
term, with the goal of promoting independent, stable, and safe housing.
Despite the long-term goal of sobriety, the housing needs of patients
with chronic psychosis and AOD use disorders may be met temporarily by
housing that is not explicitly drug free. Shelters or other forms of temporary
housing that are not explicitly drug free but provide basic safety from
weather and violence are better than no housing at all.
Various housing settings are necessary, including housing for current
AOD-using individuals ("wet" or "damp" housing setting) and settings for
individuals who are abstinent. Although there is a need for this broad
range of housing, many communities do not currently have it. Within this
range of agency-supported housing, there should be explicit policies regarding
AOD use, understood by both the patient and the clinician.
It is also critical for treatment programs to have easy access to housing
for patients with special needs, such as women and children, pregnant women,
and battered women. Specific housing should be developed for patients with
specialized, ongoing medical and psychological needs associated with complications
of serious medical conditions such as AIDS.
Vocational Services
Vocational services are also essential for the long-term stabilization
and recovery of the dual disorder patient. Both AOD and mental health services
have traditionally referred clients to generic vocational rehabilitation
services. These services must be integrated and modified for the specialized
needs of the individual with psychosis and AOD use disorders. Temporary
hire placements and job coaching options are important elements to incorporate
into rehabilitation services for this group.
Sober Support Groups
An essential part of treatment for patients with dual disorders is the
development of alternative peer group settings that do not include drug
use. Developing these non-AOD-using social networks can be enhanced by
programs that provide social club activities, recreational activities,
and drop-in centers on site, as well as linkages to other community-based
social programs. At the same time, patients should be encouraged to establish
and maintain relationships, including family relationships, that are supportive
of treatment goals.
Family
Treatment of the dual disorder patient can be substantially supported and
enhanced by direct involvement of the patient's family. Services can include
family psychoeducational groups that specifically focus on education about
AOD use disorders and psychosis. This also includes multifamily treatment
groups that may include the individual with the dual disorder.
Families may also be helpful in identifying early signs of psychiatric
or AOD use relapse symptoms. They can work with the treatment team in initiating
acute relapse prevention and intervention. Confidentiality issues need
to be addressed at the beginning of treatment, with the goal of identifying
a significant support person who has the patient's permission to be involved
in the long-term treatment process.
Relapse Prevention
An essential component of relapse prevention and relapse management is
close monitoring of patients for signs of AOD relapse and a return of psychotic
symptoms. Relapse prevention also includes closely monitoring the development
of patients' AOD refusal skills and their recognition of early signs of
psychiatric problems and AOD use. The goals of relapse prevention are:
1) identification of patients' relapse signs, 2) identification of the
causes of relapse, and 3) development of specific intervention strategies
to interrupt the relapse process.
Close monitoring involves the long-term observation of patients for
early signs of impending psychiatric relapse. Such signs may include the
emergence of paranoid symptoms and symptoms related to AOD use such as
hostile or disorganized behavior. For example, a sign of paranoid symptoms
may be the patient's sudden and constant use of sunglasses. Additional
important clues may involve changes in daily routine, changes in social
setting, loss of daily structure, irritation with friends, and rejection
of help. Family members who reside with the dual disorder patient are often
the first to detect early signs of psychotic or AOD use relapse.
Additional signs of possible psychotic or AOD relapse include eviction
from housing, job loss, or involvement with the criminal justice system.
It is important that the clinician understand that routine daily stressors
may have an intense impact on the dually diagnosed patient and may prompt
relapse.
Objective laboratory tests may also be particularly useful in detecting
early risk of AOD relapse. This includes the use of random urine toxicology
screens, the alcohol Breathalyzer test, and blood tests to detect street
drugs. As medication noncompliance is strongly associated with both AOD
use and psychotic relapse, blood medication levels (including antipsychotic
and lithium levels) may be particularly useful. Finally, intramuscular
forms of antipsychotic medications may be particularly useful for verifying
and assuring long-term compliance with antipsychotic medications.
In addition to close monitoring by health care professionals, family
members, and significant others, an important component of relapse prevention
is assisting the dual disorder patient to develop skills to anticipate
the early warning signs of psychiatric and AOD use disorders. These skills
can be acquired through direct individual psychoeducation and participation
in role play exercises and psychoeducation groups. These patients should
be trained to use AOD refusal skills and to recognize situations that place
them at risk for AOD use.
Similarly, these patients may benefit significantly from behavioral
therapy; development of relaxation, meditation, and biofeedback skills;
exercise; use of visualization techniques; and use of relapse prevention
workbooks. Pharmacologic strategies may include the use of disulfiram or
naltrexone for certain patients.
Group Treatment
Group process is a core element of AOD abuse and mental health treatment.
However, for patients with psychosis, group treatment should be modified
and provided in coordination with a comprehensive service plan. The different
types of groups specifically designed for the dual disorder patient include
persuasion groups, active treatment groups, dual disorder-oriented 12-step
groups (Double Trouble groups), pre-12-step groups, and groups that focus
on medication and anger management.
Groups that are specifically designed for dual disorder patients are
essential during the early phases of treatment. Patients who have accepted
the goal of abstinence, have maintained psychiatric stability, and have
essential social skills may benefit from carefully selected traditional
12-step programs that are sensitive to the needs of the severely mentally
ill. However, during the early phases of treatment, an unfacilitated referral
to traditional 12-step programs will likely result in treatment failure.
(See the discussion on the use of the 12-step programs in Chapter
6.) A wide variety of group settings may be useful for the person with
a dual disorder. However, the core approach should include psychoeducational,
supportive, behaviorally oriented, and skill-building activities.
Medication
With patients who have dual disorders that involve psychosis, a common
provider mistake that often leads to psychiatric or AOD use relapse involves
a lack of attention to medication issues. Most important, treatment programs
must provide aggressive treatment of medication side effects. Ignoring
the side effects of prescribed medication often results in patients using
AODs to diminish the unwanted medication side effects.
Equally important, patients should be educated and thoroughly informed
about: 1) the specific medication being prescribed, 2) the expected results,
3) the medication's time course, 4) possible medication side effects, and
5) the expected results of combined medication and AOD use. Whenever possible,
family members and significant others should be educated about the medication.
Medication should not simply be prescribed or provided to the psychotic
patient with dual disorders. Rather, it is critical to discuss with patients
1) their understanding of the purpose for the medication, 2) their beliefs
about the meaning of medication, and 3) their understanding of the meaning
of compliance. It is important to ask patients what they expect from the
medication and what they have been told about the medication. Overall,
it is important to understand the use of medication from the patient's
perspective. Indeed, informed consent relative to a patient's use of medication
requires that the patient have a thorough understanding of the medication
as described above.
It is also important to help patients prepare for peer reaction to the
use of medication when they participate in certain 12-step programs. Patients
should be taught to educate other people who may have biases against prescription
medications or who may be misinformed about antipsychotic medications.
Patients receiving medication should participate in professionally led
medication education groups and medication-specific peer support groups.
These groups will help patients deal with the emotional and social aspects
of medication, promote medication compliance, and help clinicians and patients
identify and address early noncompliance and side-effect problems.
Overall, there must be a specific and aggressive treatment strategy
that helps make medication use simple and comfortable. The scheduling and
administration of medication should be simple and convenient for patients.
The ideal schedule for oral medications is once per day. The use of injectable
medications may be the most comfortable and effective option for some patients
with dual disorders.
Anything that helps patients feel more comfortable about taking medication
should be considered. In addition, an important treatment goal is a medication
regimen that is self-monitoring.
When patients experience difficulty acquiring medication, the treatment
program should directly help patients acquire them, not make referrals
and recommendations.
Staff and Administrative Training
Traditional training in mental health and AOD abuse treatment, and in medicine
in general, has been inadequate relative to the unique needs of the dual
disorder patient. Thus, program staff require ongoing education about current
understanding and treatment of dual disorders. It is imperative that the
service principles of each discipline be presented and modified for application
to people with dual disorders. Training also must be integrated, not sequential
or parallel.
Perhaps the most important goal of clinical staff development and training
is the cross-training of addiction and mental health personnel. Addiction
specialists need training in psychiatric and mental health issues, while
mental health and psychiatric specialists need training in AOD and addiction
issues. In addition to cross-training, both addiction and mental health
clinical staff require clinical and theoretical training in dual disorders.
Clinical staff training content must include information about the assessment
and treatment of high-risk and subacute problems and about long-term treatment
issues. There must be a focus on the interaction between AOD use and psychiatric
symptoms. In addition, attention must be given to high-risk behaviors such
as violence to self or others, suicide, impulsive behavior, and high-risk
sexual behavior.
Clinical staff training must also address less obvious clinical issues
such as cultural competency and sensitivity to the roles of culture, ethnicity,
nationality, religion, and spirituality.
While 1- or 2-day workshops may be useful for disseminating clinical
information, ongoing and routine education is critical. To emphasize the
multidisciplinary team approach, staff education should be done in a group
setting with interaction among group participants and trainers.
The need for clinical supervision among clinical staff is crucial. Supervision
must be an ongoing, routine process, not driven by clinical crises. Nonetheless,
because treatment of dual disorders involves frequent crises, the clinical
supervisor must be readily available to team members and able to provide
rapid coaching and support.
An important aspect of clinical supervision and clinical staff development
is education in the theoretical basis of treatment. Irrespective of disciplines,
all clinical staff must thoroughly understand and support the philosophical
basis, values, and goals of the treatment program in which they work. Further,
an important task of the clinical supervisor is to integrate the formal
theory and principles within the specific treatment setting.
Clinical staff education and development must include the formation
of procedures and supports to prevent staff burnout and demoralization.
Components of staff burnout prevention include mechanisms for multidisciplinary
group support, a focus on long-term rather than short-term gains for patients,
anticipation and expectation of relapse as part of psychotic and AOD use
disorders, and an understanding of relapse as a treatment opportunity rather
than a treatment failure.
Program administrators, whether they are in contact with patients or
not, require clinical education in dual disorder issues to provide an appropriate
environment for the treatment of patients with dual disorders and to better
understand the needs of staff and patients. Thus, program administrators
require education in the latest conceptual and technological developments
in the fields of psychiatry and AOD treatment as well as in dual disorders.
It is important for program administrators to regularly review, articulate,
and discuss the program's philosophy, goals, and objectives with all program
staff. Enhanced and open communication between administration and staff
in both individual and group settings is also critical. For example, administrators
should regularly communicate with staff regarding administrative constraints
such as financial limitations, legal mandates, and political influences.
Administrators should thoroughly understand the appropriate role of
clinical supervision: that this supervision is designed for skill enhancement
and staff support. Clinical supervision skills are critical for providing
effective services to high-risk populations such as patients with psychotic
and AOD use disorders.
There should be open discussion of administrative styles, since these
significantly affect staff morale and performance. Similarly, administrators
should be aware of the influence of their personal characteristics upon
staff and patients. For example, administrators should become aware of
the influence that their culture, ethnicity, gender, sexual orientation,
and background has on others.
Chapter 9 -- Pharmacologic Management
Pharmacologic Risk Factors
Addiction is not a fixed and rigid event. Like psychiatric disorders, addiction
is a dynamic process, with fluctuations in severity, rate of progression,
and symptom manifestation and with differences in the speed of onset. Both
disorders are greatly influenced by several factors, including genetic
susceptibility, environment, and pharmacologic influences. Certain people
have a high risk for these disorders (genetic risk); some situations can
evoke or help to sustain these disorders (environmental risk); and some
drugs are more likely than others to cause psychiatric or AOD use disorder
problems (pharmacologic risk).
Pharmacologic effects can be therapeutic or detrimental. Medication
often produces both effects. Therapeutic pharmacologic effects include
the indicated purposes and desired outcomes of taking prescribed medications,
such as a decrease in the frequency and severity of episodes of depression
produced by antidepressants.
Detrimental pharmacologic effects include unwanted side effects, such
as dry mouth or constipation resulting from antidepressant use. Side effects
perceived as noxious by patients may decrease their compliance with taking
the medications as directed.
Some detrimental pharmacologic effects relate to abuse and addiction
potential. For example, some medications may be stimulating, sedating,
or euphorigenic and may promote physical dependence and tolerance. These
effects can promote the use of medication for longer periods and at higher
doses than prescribed.
Thus, prescribing medication involves striking a balance between therapeutic
and detrimental phar-macologic effects. For instance, therapeutic antianxiety
effects of the benzodiazepines are balanced against detrimental pharmacologic
effects of sedation and physical dependency. Similarly, the desired therapeutic
effect of abstinence from alcohol is balanced by the possibility of damage
to the liver from prescribed disulfiram (Antabuse).
Side effects of prescription medications vary greatly and include detrimental
pharmacologic effects that may promote abuse or addiction. With regard
to patients with dual disorders, special attention should be given to detrimental
effects, in terms of 1) medication compliance, 2) abuse and addiction potential,
3) AOD use disorder relapse, and 4) psychiatric disorder relapse (Ries,
1993a).
Psychoactive Potential
Not all psychiatric medications are psychoactive. The term psychoactive
describes
the ability of certain medications, drugs, and other substances to cause
acute psychomotor effects and a relatively rapid change in mood or thought.
Changes in mood include stimulation, sedation, and euphoria. Thought changes
can include a disordering of thought such as delusions, hallucinations,
and illusions. Behavioral changes can include an acceleration or retardation
of motor activity. All drugs of abuse are by definition psychoactive.
In contrast, certain nonpsychoactive medications such as lithium (Eskalith)
can, over time, normalize the abnormal mood and behavior of patients with
bipolar disorder. Because these effects take several days or weeks to occur,
and do not involve acute mood alteration, it is not accurate to describe
these drugs as psychoactive, euphorigenic, or mood altering. Rather, they
might be described as mood regulators.
Similarly, some drugs, such
as antipsychotic medications, cause normalization of thinking processes
but do not cause acute mood alteration or euphoria.
However, some antidepressant and antipsychotic medications have pharmacologic
side effects such as mild sedation or mild stimulation. Indeed, the side
effects of these medications can be used clinically. Physicians can use
a mildly sedating antidepressant medication for patients with depression
and insomnia, or a mildly stimulating antipsychotic medication for patients
with psychosis and hypersomnia or lethargy (Davis
and Goldman, 1992). While the side effects of these drugs include a
mild effect on mood, they are not euphorigenic. Nevertheless, case reports
of misuse of nonpsychoactive medications have been noted, and use should
be monitored carefully in patients with dual disorders.
While psychoactive drugs are generally considered to have high risk
for abuse and addiction, mood- regulating drugs are not. A few other medications
exert a mild psychoactive effect without having addiction potential. For
example, the older antihistamines such as doxylamine (Unisom) exert mild
sedative effects, but not euphoric effects.
Reinforcement Potential
Some drugs promote reinforcement, or the increased likelihood of
repeated use. Reinforcement can occur by either the removal of negative
symptoms or conditions or the amplification of positive symptoms or states.
For example, self-medication that delays or prevents an unpleasant event
(such as withdrawal) from occurring becomes reinforcing. Thus, using a
benzodiazepine to avoid alcohol withdrawal can increase the likelihood
of continued use.
Positive reinforcement involves strengthening
the possibility that a certain behavior will be repeated through reward
and satisfaction, as with drug-induced euphoria or drug-induced feelings
of well-being. A classic example is the pleasure derived from moderate
to high doses of opiates or stimulants. Drugs that are immediately reinforcing
are more likely to lead to psychiatric or AOD use problems.
Tolerance and Withdrawal Potential
Long-term or chronic use of certain medications can cause tolerance to
the subjective and therapeutic effects and prompt dosage increases to recreate
the desired effects. In addition, many drugs cause a well-defined withdrawal
phenomenon after the cessation of chronic use. Patients' attempts to avoid
withdrawal syndromes often lead them to additional drug use. Thus, drugs
that promote tolerance and withdrawal generally have higher risks for abuse
and addiction.
A Stepwise Treatment Model
As can be seen, there are pharmacologic as well as hereditary and environmental
factors that influence the development of AOD use problems. All of these
factors should be considered prior to prescribing medication, especially
when the patient is at high risk for developing an AOD use disorder. High-risk
patients include people with both psychiatric and AOD use disorders, as
well as patients with a psychiatric disorder and a family history of AOD
use disorders.
One aspect of this issue relates to the pharmacologic profile of certain
medications that are used in the treatment of specific psychiatric disorders.
For instance, many medications used to treat symptoms of depression and
psychosis are not psychoactive or euphorigenic. However, many of the medications
used to treat symptoms of anxiety, such as the benzodiazepines, are psychoactive,
reinforcing, have potential for tolerance and withdrawal, and have an abuse
potential, especially among people who are at high risk for AOD use disorders.
Other antianxiety medications, such as buspirone (BuSpar), are not psychoactive
or reinforcing and have low abuse potential, even among people at high
risk.
Thus, decisions about whether and when to prescribe medication to a
high-risk patient should include a risk-benefit analysis that considers
the risk of medication abuse, the risk of undertreating a psychiatric problem,
the type and severity of the psychiatric problem, the relationship between
the psychiatric disorder and the AOD use disorder for the individual patient,
and the therapeutic benefits of resolving the psychiatric and AOD problems.
For example, the early and aggressive medication of high-risk patients
who have severe presentations of psychotic depression, mania, and schizophrenia
is often necessary to prevent further psychiatric deterioration and possible
death. For these patients, rapid and aggressive medication can shorten
the length of the psychiatric episodes. In contrast, prescribing benzodiazepines
to high-risk patients with similarly severe anxiety involves a substantial
risk of promoting or exacerbating an AOD use disorder. For these high-risk
patients, the use of psychoactive medication should not be the first line
of treatment.
Rather, for some high-risk patients, treatment efforts should involve
a stepwise treatment model that begins with conservative approaches and
progressively becomes more aggressive if the treatment goals are not met
(Landry
et al., 1991a). For example, the stepwise treatment model for treating
high-risk patients with anxiety disorders may involve three progressive
levels of treatment: 1) nonpharmacologic approaches when possible; 2) nonpsychoactive
medication when nonpharmacologic approaches are insufficient; and 3) psychoactive
medications when other treatment approaches provide limited or no relief
(Landry
et al., 1991).
Pharmacologic Risk Factors
A medication may have:
-
Psychoactive potential (causes acute psychomotor effects)
-
Reinforcement potential (decreases negative symptoms and increases positive
symptoms)
-
Tolerance and withdrawal potential (a higher does is needed to gain the
effect or to avoid ill effects).
A Stepwise Management Approach For Mild and Moderate Mental Disorders
*
-
Step One:
-
Try nonpharmacologic approaches
-
Step Two:
-
Add nonpsychoactive medications if Step One is unsuccessful
-
Step Three:
-
Add psychoactive medications if Steps One and Two are unsuccessful.
* For severe conditions, such as psychotic depression, mania, and schizophrenic
disorders, rapid and aggressive use of medications is needed to prevent
danger to self or others and further psychiatric deterioration.
Nonpharmacologic Approaches
Depending upon the psychiatric disorders and personal variables, numerous
nonpharmacologic approaches can help patients manage all or some aspects
of their psychiatric disorders (Weiss
and Billings, 1988). Examples include psychotherapy, cognitive therapy,
behavioral therapy, relaxation skills, meditation, biofeedback, acupuncture,
hypnotherapy, self-help groups, support groups, exercise, and education.
Nonpsychoactive Pharmacotherapy
Some medications are not psychoactive and do not cause acute psychomotor
effects or euphoria. Some medications do not cause psychoactive or psychomotor
effects at therapeutic doses but may exert limited psychoactive effects
at high doses (often not euphoria, but sometimes dysphoria).
For practical purposes, all of these medications can be described as
nonpsychoactive, since the psychoactive effect is not prominent. Medications
used in psychiatry that are not euphorigenic or significantly psychoactive
include but are not limited to the azapirones (for example, buspirone),
the amino acids, beta-blockers, antidepressants, monoamine oxidase inhibitors,
antipsychotics, lithium, antihistamines, anticonvulsants, and anticholinergic
medications.
Psychoactive Pharmacotherapy
Some medications can cause significant and acute alterations in psychomotor,
emotional, and mental activity at therapeutic doses. At higher doses, and
for some patients, some of these medications can also cause euphoric reactions.
Medications that are potentially psychoactive include opioids, stimulants,
benzodiazepines, barbiturates, and other sedative-hypnotics.
Stepwise Treatment Principles
One of the emphases of stepwise treatment is to encourage nondrug treatment
strategies for each emerging symptom before medications are prescribed.
Nondrug treatment strategies alone are inappropriate for acute and severe
symptoms of schizophrenia and mood disorders, but nondrug strategies do
have their place in the treatment of virtually any psychiatric problem,
and may provide partial or total relief of some symptoms related to severe
psychiatric disorders. For example, relaxation therapy can minimize or
eliminate somatic symptoms of anxiety that may accompany an agitated depression.
A second emphasis of stepwise treatment is to encourage the use of medications
that have a low abuse potential. This conservative approach must be balanced
against other therapeutic and safety considerations in acute and severe
conditions, such as psychosis or mania. On the other hand, a conservative
approach is not the same as undermedication of psychiatric problems. Undermedication
often leads to psychiatric deterioration and may promote AOD relapse. There
should be a balance between effective treatment and safety.
A third emphasis of stepwise treatment is to encourage the idea that
different treatment approaches should be viewed as complementary, not competitive.
For example, if psychotherapy or group therapy does not provide complete
relief from a situational depression (such as prolonged grief), then antidepressants
should be considered as an adjunct to the psychotherapy, but not as a substitute
for psychotherapy.
In practice, treatment providers often use a combination of drug and
nondrug strategies. This practice includes medication to treat the acute
manifestations of the disorder while the individual learns long-term management
strategies. For example, an individual may be prescribed nonpsychoactive
buspirone to reduce anxiety symptoms while learning stress reduction techniques
and attending group therapy.
These guidelines are broad, general, and more applicable to chronic
than to acute psychiatric problems. Also, these guidelines have limited
application to very severe psychiatric problems.
Specific Medications and Recovery
Antihistamines
Several antihistamines are approved for sale as over-the-counter hypnotics,
including diphenhydramine (Nytol, Benadryl), doxylamine (Unisom), and pyrilamine
(Quiet World). The efficacy of these drugs is not uniform, and tolerance
to the anxiolytic and hypnotic effects is rapid, limiting their utility
for episodic use. Antihistamines are frequently prescribed for mild anxiety
and insomnia, particularly for patients in general hospitals, patients
with physical illness (Salzman,
1989), and elderly patients.
Antihistamines and Recovery
In general, the early antihistamines exert very mild anxiolytic and hypnotic
effects, but lack euphoric properties and do not promote physical dependence
(Meltzer,
1990). While lacking significant abuse potential themselves, antihistamines
may cause problems for some patients by reinforcing the idea of self-medication
of insomnia and anxiety. Taken in high doses, antihistamines may cause
acute delirium, alter mood (often causing dysphoria), or cause morning-after
depression. Under close medical supervision, the conservative use of antihistamines
can be valuable in treating brief episodes of insomnia during an otherwise
drug-free recovery process. Patients in recovery should be discouraged
from purchasing and using over-the-counter antihistamines.
Antidepressants
The antidepressants include several types of medication, such as tricyclics,
monoamine oxidase inhibitors (MAOIs), and other, newer, antidepressants
such as trazodone (Desyrel), bupropion (Wellbutrin), sertraline (Zoloft),
and fluoxetine (Prozac). Antidepressants are effective for the treatment
of depression, and several are valuable for the treatment of anxiety disorders,
including generalized anxiety disorder, phobias, and panic disorder.
Antidepressants and Recovery
The antidepressants are not euphorigenic, and do not cause acute mood alterations.
Rather, they are mood regulators and diminish the severity and frequency
of depressive episodes; they also have anti-panic capabilities unrelated
to sedation.
While the general effects of most of the older tricyclic antidepressants
are similar, they differ considerably with regard to side effects. For
example, some antidepressants such as doxepin (Sinequan) exert a mild sedating
effect, while others such as protriptyline (Vivactil) exert a mild stimulating
effect. These side effects can be clinically useful. For example, clinicians
might give antidepressants with slight sedating effects to depressed patients
with insomnia or give those with mild stimulating effects to depressed
patients who experience low energy and hypersomnia (Davis
and Goldman, 1992).
Other side effects of tricyclic antidepressants are common. Anticholinergic
effects such as dry mouth, blurred vision, constipation, urinary hesitancy,
and toxic-confusional states are common anticholinergic effects. Adrenergic
activation symptoms may include tremor, excitement, palpitation, orthostatic
hypotension, and weight gain. These noxious side effects are frequently
the cause of requests to switch from one medication type to another. Also,
side effects often prompt discontinuation of medication, which may provoke
reemergence of the psychopathology. Tricyclics unfortunately are quite
toxic when combined with AODs. Therefore use of tricyclic antidepressants
in early recovery should be carefully monitored.
More expensive, but much less toxic when used with AODs, are the newer
serotonin reuptake inhibitors including fluoxetine, paroxitine (Paxil),
and sertraline. These agents also have anticompulsive effects, and their
side effects tend to be slight to moderate stimulation rather than sedation.
They are much safer to use in early recovery.
Overall, the use of antidepressants is consistent with a psychoactive-drug-free
philosophy, does not compromise recovery from addiction, and enhances recovery
from depressive and panic disorders. However, patient information must
include clear explanations of the reasons for prescribing, the expected
results, and the risks of adverse effects, including overdose. The risk-benefit
analysis must include the risk of lethal overdose with tricyclic antidepressants,
especially for depressed patients (Reid,
1989).
Beta-Blockers
The beta-blockers such as propranolol (Inderal) are well-recognized medications
for the treatment of hypertension, cardiac arrhythmias, and angina pectoris.
They also have clinical efficacy as an adjunct in the treatment of anxiety
(Lader,
1988). The b-blockers may reduce or eliminate the adrenergic discharge
associated with panic attacks, thus blocking the somatic components of
some anxiety states, especially when somatic symptoms predominate (Trevor
and Way, 1989). b-blockers diminish the tremor and restlessness related
to lithium or antipsychotics in some patients.
Beta-Blockers and Recovery
The Beta-blockers are not psychoactive, euphorigenic, or mood altering.
Since tolerance to the anti-panic effects of b-blockers develops rapidly,
they cannot be used for extended periods of time for this purpose. Rather,
they are often used prophylactically for anticipated panic-producing situations,
or for episodes of anxiety that may last a few days. The b-blockers are
also used to decrease acute and subacute anxiety symptoms during detoxification
from sedative-hypnotics such as the benzodiazepines. Overall, the use of
b-blockers is consistent with a psychoactive-drug-free philosophy, does
not compromise recovery from addiction, and can be an important adjunct
to anxiety management.
Benzodiazepines
While all of the benzodiazepines have anxiolytic characteristics, they
differ in their effectiveness in treating generalized anxiety disorder,
mixed anxiety and depression, panic attacks, phobic-avoidance behaviors,
and insomnia. In general, the benzodiazepines promote sedation, central
nervous system depression, and muscle relaxation, and thus are effective
for anxiety reduction and, at higher doses, for short-term management of
insomnia.
The Benzodiazepines and Recovery
The benzodiazepines are psychoactive, mood altering, and reinforcing. Chronic
use and subsequent cessation can cause withdrawal symptoms. Studies have
shown that the benzodiazepines are not uniformly euphorigenic. Also, patients
with a family and personal history of AOD abuse and addiction are more
likely to experience euphoria with the benzodiazepines (Ciraulo
et al., 1988, 1989).
Benzodiazepines are the most commonly used agents to moderate alcohol
withdrawal and prevent dangerous withdrawal conditions such as delirium
tremens and seizures. They are also widely used during detoxification from
sedative-hypnotics. The benzodiazepines are frequently prescribed for use
alone and in combination with antipsychotics during the treatment of acute
psychotic symptoms caused by mania, schizophrenia, and drugs of abuse such
as cocaine. Such treatment should be limited to the acute episode for most
patients with dual disorders, so that one problem (psychosis) is not replaced
by another problem (physical dependence or addiction). The benzodiazepines
are not usually recommended for long-term use in patients with dual disorders
unless all nonpsychoactive approaches have failed. That is, if all other
less potentially adverse medications have proven inadequate and the benzodiazepines
are indicated, then careful dispensing, regulation of dose, and scrupulous
monitoring are required.
Overall, the use of benzodiazepines after the medical management of
withdrawal is not consistent with a psychoactive-drug-free philosophy and
may compromise recovery from addiction (Zweben
and Smith, 1989). However, they can be used in the management of acute
and severe withdrawal, panic, and psychosis with special guidelines in
nonroutine situations.
Buspirone
Buspirone is the most well known of a new group of drugs (the azapirones)
that selectively diminish multiple symptoms of anxiety without the acute
mood alteration, sedation, or associated somatic side effects seen in the
sedative-hypnotic anxiolytics. Buspirone is useful for generalized anxiety
disorder, chronic anxiety symptoms, anxiety with depressive features, and
anxiety among elderly patients. Buspirone is generally equivalent to the
benzodiazepines with regard to anxiety management (Petracca
et al., 1990; Strand
et al., 1990). However, it takes several weeks for the maximal therapeutic
effect of buspirone to occur.
Buspirone and Recovery
Buspirone is not psychoactive, mood altering, or euphorigenic (Balster,
1990). In particular, buspirone does not cause the mood alteration,
central nervous system depression, sedation, and muscle relaxation associated
with the benzodiazepines. However, many people with experience taking benzodiazepines
may associate these mood alterations with relief of anxiety. As a result,
patients who have experience with the benzodiazepines may misinterpret
the absence of these side effects as evidence that the medication is ineffective.
Educating patients about the distinction between anxiety reduction and
sedation and about treatment expectations can avoid these misinterpretations.
Overall, the use of buspirone is consistent with a psychoactive-drug-free
philosophy, does not compromise recovery from addiction, and enhances recovery
from anxiety disorders.
Clonidine
Used in the form of a patch (Catapres Transdermal Therapeutic System patches)
or tablets (Catapres), clonidine is well recognized as a treatment for
symptoms of hypertension, including hypertensive symptoms that occur during
withdrawal from depressant drugs, especially the opioids. In addition,
clonidine appears to have anxiolytic and anti-panic properties comparable
to the antidepressant imipramine. Patients may become less anxious but
remain symptomatic. Some patients who have anxiety-depression or panic-anxiety
experience significant antianxiety effects from clonidine. The anti-panic
effect is the result of clonidine's ability to decrease locus ceruleus
firing and thus decrease adrenergic discharge. Thus, clonidine may be useful
for short-term use in the treatment of refractory anxiety with panic (Domisse
and Hayes, 1987; Uhde
et al., 1989).
Clonidine and Recovery
Clonidine is not psychoactive, euphorigenic, or mood altering. Clonidine
may have significant antianxiety effects when administered to patients
with anxiety-depression and panic-anxiety. However, tolerance to the anti-panic
effects of clonidine can develop within several weeks. Thus, clonidine
may be most useful for short-term use in the treatment of refractory panic
disorder.
Overall, the use of clonidine is consistent with a psychoactive-drug-free
philosophy, does not compromise recovery from addiction, and may be an
adjunct in the treatment of anxiety symptoms.
Neuroleptic (Antipsychotic) Medications
The neuroleptic medications are most effective in suppressing the positive
symptoms of psychosis such as hallucinations, delusions, and incoherence.
In addition, they may help reduce disturbances of arousal, affect, psychomotor
activity, thought content, and social adjustment (Africa
and Schwartz, 1992). These psychotic symptoms may accompany schizophrenia,
brief reactive psychosis, schizophreniform disorder, mania, depression,
and organic mental disorders induced by AODs and medical conditions (Ries,
1993a).
Although neuroleptic medications are equally effective in suppressing
psychotic symptoms, individuals may respond to one medication better than
another. The chief differences among the neuroleptics relate to dosage,
onset of effects, and (especially) side effects. Some side effects may
be clinically useful, such as nighttime sedation with chlorpromazine or
avoidance of appetite stimulation with molindone (Moban) (Africa
and Schwartz, 1992).
In general, low-potency neuroleptics, for example, chlorpromazine, thioridazine
(Mellaril), and clozapine (Clozaril), have significant sedative and hypotensive
properties. Tolerance to these properties may develop within a few weeks.
Also, low-potency neuroleptics are inherently anticholinergic, so that
the use of additional anticholinergic drugs to prevent extrapyramidal symptoms
may be unnecessary. The high-potency neuroleptics such as fluphenazine
(Prolixin) and haloperidol (Haldol) cause more extrapyramidal side effects
than the low-potency medications.
Neuroleptic Drug-Induced Extrapyramidal Symptoms
The extrapyramidal system is a network of nerve pathways that links nerves
in the surface of the cerebrum (the deep mass of the brain), the basal
ganglia deep within the brain, and parts of the brain stem. The extrapyramidal
system influences and modifies electrical impulses that are sent from the
brain to the skeletal muscles.
When this system is damaged or disturbed, execution of voluntary movements
and muscle tone can be disrupted, and involuntary movements, such as tremors,
jerks, or writhing movements, can appear. These disturbances are called
extrapyramidal syndromes, which can be caused by all of the neuroleptic
medications except clozapine.
Medicating Extrapyramidal Symptoms
Extrapyramidal symptoms are unwanted, noxious, and uncomfortable. Compliance
with neuroleptic medications is worsened because of the onset of these
drug-induced symptoms. A class of medications called anticholinergic agents
can eliminate the muscle spasms in the neck, oral, facial, cheek, and tongue
regions. Several other types of medications may also be helpful, including
amantadine and beta-blockers.
Anticholinergic agents can also reduce the extrapyramidal movement disorder
called akathisia, which consists of purposeless movements, usually of the
lower extremities, often accompanied by the experience of severe, uncomfortable
restlessness. These medications include benztropine (Cogentin), biperiden
(Akineton), diphenhydramine (Benadryl), trihexyphenidyl (Antitrem), and
procyclidine (Kemadrin). Patient response should be monitored because some
anticholinergic medications may be mildly psychoactive for some AOD patients.
Neuroleptic Medications and Recovery
Neuroleptic drugs are not euphorigenic and do not cause acute mood or psychomotor
alterations. However, side effects are common. Most of the neuroleptics
cause sedation as a side effect, although adaptation to the sedative (but
not the antipsychotic) effects develops within days or weeks. The anticholinergic
side effects of neuroleptic medications can include dry mouth, constipation,
and blurred vision. The neuroleptics can also cause extrapyramidal symptoms.
The adverse side effects of neuroleptic medications are a frequent cause
of medication compliance problems. These adverse effects can also prompt
patients to use AODs to self-medicate noxious symptoms.
Because patients with psychotic symptoms often experience significant
biopsychosocial problems, the neuroleptics allow them to engage in problem-solving
and recovery-oriented interpersonal activities. Overall, the use of neuroleptics
is consistent with a psychoactive-drug-free philosophy, does not compromise
recovery from addiction, and enhances recovery from psychotic disorders.
Lithium
Lithium is the standard and first-line treatment for manic episodes, even
though 10-14 days may be required before full effect is achieved. The initial
symptoms managed by lithium include increased psychomotor activity, pressured
speech, and insomnia. Later, lithium diminishes the symptoms of expansive
mood, grandiosity, and intrusiveness. Lithium also treats signs related
to disorganization of the form of thought such as flight of ideas and loosening
of association.
Lithium and Recovery
Lithium does not cause acute mood alteration, and is not psychoactive or
mood altering. Rather, lithium is a mood regulator, and diminishes symptoms
of acute mania. The common adverse effects of lithium include thirst, urinary
frequency, tremor, and gastrointestinal distress. Lithium allows patients
who may have seriously disabling symptoms to engage in problem-solving
and recovery-oriented interpersonal activities. Overall, the use of lithium
is consistent with a psychoactive-drug-free philosophy, does not compromise
recovery from addiction, and enhances recovery from bipolar disorders.
Anticonvulsants
Anticonvulsants have a role in the management of bipolar disorders, mania,
schizoaffective disorder, and alcohol and benzodiazepine withdrawal. In
addition, these medications may be prescribed for "flashbacks" related
to drug use or post-traumatic stress disorder. These medications, such
as carbamazepine (Tegretol) and valproic acid, are not psychoactive. The
typically minor side effects of sedation and nausea may emerge as treatment
is initiated. Rarely, carbamazepine causes a decrease in white blood cell
count. Both medications are monitored according to blood levels. For the
treatment of bipolar disorder, the anticonvulsants are most often used
when lithium has failed. However, they are occasionally used by highly
skilled physicians as first-line treatment. These medications are consistent
with a psychoactive-drug-free philosophy, and may enhance the abilities
of those who need them to participate in the recovery process.
Drug Interaction Cautions
There are certain risks associated with AOD use and withdrawal among patients
who are also being administered medications to treat psychiatric disorders.
Because of these risks, serious consideration should be given to inpatient
treatment for withdrawal.
-
Alcohol and barbiturates can cause increased tolerance by increasing the
amount of liver enzymes responsible for their metabolism. These same liver
enzymes are also responsible for metabolizing many antidepressant, anticonvulsant,
and antipsychotic medications. Thus, serum levels of medications will be
decreased, possibly to subtherapeutic levels. Without assessing for possible
AOD use, some physicians may mistakenly increase medication doses.
-
Alcohol interferes with the thermoregulatory center of the brain, as do
antipsychotic drugs. Patients taking both medications may be unable to
adjust their body temperature in response to extremes in the external environment.
-
The interaction of stimulants in a person taking monoamine oxidase inhibitor
antidepressants can lead to a life-threatening hypertensive crisis.
-
Alcohol and cocaine enhance the respiratory depression effects of opioids
and some neuroleptics such as the phenothiazines. This effect can increase
vulnerability to overdose death.
-
Marijuana has anticholinergic effects. In combination with the anticholinergic
medications such as Cogentin, marijuana use can lead to an anticholinergic
(atropine) psychosis.
-
Patients who are vulnerable to hallucinations, such as schizophrenic patients,
are at high risk for having hallucinations during the withdrawal from alcohol
and other sedative-hypnotics.
-
Antipsychotics and antidepressants lower the seizure threshold and enhance
seizure potential during withdrawal from sedative-hypnotics and alcohol.
-
Alcohol intoxication and withdrawal disturbs the fluid electrolyte balance
in the body, which can lead to lithium toxicity.
Appendix A -- Bibliography
-
Africa, B., and Schwartz, S.R.
-
Schizophrenic disorders. In: Goldman, H.H., ed. Review of General Psychiatry,
Third Edition. Norwalk, Connecticut: Appleton & Lange, 1992. pp. 226-241.
-
American Psychiatric Association.
-
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised.
Washington, D.C.: American Psychiatric Association, 1987.
-
American Psychiatric Association.
-
DSM-IV Draft Criteria, 3/1/93. Washington, D.C.: American Psychiatric Association,
1993.
-
Anthenelli, R.M., and Schuckit, M.A.
-
Affective and anxiety disorders and alcohol and drug dependence: diagnosis
and treatment. Journal of Addictive Diseases 12(3)73-87, 1993.
View this and related citations using
or
-
Baker, F.
-
Coordination of alcohol, drug abuse, and mental health services. Technical
Assistance Publication Series Number 4. Washington, D.C.: Office for Treatment
Improvement, Alcohol, Drug Abuse, and Mental Health Administration, 1991.
View this and related citations using
or 
-
Balster, R.L.
-
Abuse potential of buspirone and related drugs. Journal of Clinical Psychopharmacology
10(3, Suppl.):31S-37S, 1990.
View this and related citations using
or 
-
Beck, A.T., and Ward, J.
-
Beck Depression Inventory. In: Beck A.T., ed., Depression: Causes and Treatment.
Philadelphia: University of Pennsylvania Press, 1972.
-
Bernadt, M.W., and Murray, R.M.
-
Psychiatric disorder, drinking and alcoholism: what are the links? British
Journal of Psychiatry 148:393-400, 1986.
View this and related citations using
or 
-
Blume, S.B.
-
Dual diagnosis: Psychoactive substance dependence and the personality disorders.
Journal of Psychoactive Drugs 21(2):139-144, 1989.
View this and related citations using
or
-
Brown, R.L.
-
Identification and office management of alcohol and drug disorders. In:
Fleming, M.F., and Barry, K.L., eds. Addictive Disorders. St. Louis: Mosby
Yearbook, 1992.
-
Brown, V.B., Ridgely, M.S., Pepper, B., Levine, I.R., and Ryglewicz, H.
-
The dual crisis: Mental illness and substance abuse, present and future
directions. American Psychologist 44(3):565-569, 1989.
View this and related citations using
or 
-
Bryant, K.J., Rounsaville, B., Spitzer, R.L., and Williams, J.B.
-
Reliability of dual diagnosis, substance dependence and psychiatric disorders.
Journal of Nervous and Mental Disease 180(4):251-257, 1992.
View this and related citations using
or 
-
Burns, D.D.
-
The Feeling Good Handbook. New York: Penguin Books, 1989.
View this and related citations using
or 
-
Carmen, E., and Brady, S.M.
-
AIDS risk and prevention for the chronic mentally ill. Hospital and Community
Psychiatry 41(6):652-657, 1990.
View this and related citations using
or 
-
Castaneda, R., Galanter, M., and Franco, H.
-
Self-medication among addicts with primary psychiatric disorders. Comprehensive
Psychiatry 30(1):80-83, 1989.
View this and related citations using
or 
-
Castaneda, R., Galanter, M., Lifshutz, H., and Franco, H.
-
Effects of drugs of abuse on psychiatric symptoms among hospitalized schizophrenics.
American Journal of Drug and Alcohol Abuse 17(3):313-320, 1991.
View this and related citations using
or 
-
Caton, C.L., Gralnick, A., Bender, S., and Simon, R.
-
Young chronic patients and substance abuse. Hospital and Community Psychiatry
40(10):1037-1040, 1989.
View this and related citations using
or 
-
Ciraulo, D.A., Barnhill, J.G., Ciraulo, A.M., Greenblatt, D.J., and Shader,
R.I.
-
Parental alcoholism as a risk factor in benzodiazepine abuse: A pilot study.
American Journal of Psychiatry 146:1333-1335, 1989.
View this and related citations using
or 
-
Ciraulo, D. A., Barnhill, J.G., Greenblatt, D.J., Shader, R.I., Ciraulo,
A.M., Tarmey, M.F., Molloy, M.A., and Foti, M.E.
-
Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic
men. Journal of Clinical Psychiatry 49:333-337, 1988.
View this and related citations using
or 
-
Clark, H.W., and Zweben, J.E.
-
Legal vulnerabilities in the treatment of chemically dependent dual diagnosis
patients. Journal of Psychoactive Drugs 21(2):251-257, 1989.
View this and related citations using
or 
-
Davis, G.C., and Goldman, B.
-
Somatic therapies. In: Goldman, H.H., ed. Review of General Psychiatry,
Third Edition. Norwalk, Connecticut: Appleton & Lange, 1992. pp. 370-390.
-
Dixon, L., Haas, G., Weiden, P., Sweeney, J., and Frances, A.
-
Acute effects of drug abuse in schizophrenic patients: clinical observations
and patients' self-reports. Schizophrenia Bulletin 16(1):69-79, 1990.
View this and related citations using
or 
-
Domisse, C.S., and Hayes, P.E.
-
Current concepts in clinical therapeutics: anxiety disorders, Part 2. Clinical
Pharmacy 6:196-215, 1987.
View this and related citations using
or 
-
Drake, R.E., Osher, F.C., and Wallach, M.A.
-
Homelessness and dual diagnosis. American Psychologist 46(11):1149-1158,
1991.
View this and related citations using
or 
-
Evans, K., and Sullivan, J.M.
-
Dual Diagnosis: Counseling the Mentally Ill Substance Abuser. New York:
Guilford Press, 1990.
-
Evans, K., and Sullivan, J.M.
-
Step Study Counseling With the Dual Disordered Client. Center City, Minnesota:
Hazelden Educational Materials, 1990.
View this and related citations using
or 
-
Fischer, P.J., and Breakey, W.R.
-
The epidemiology of alcohol, drug, and mental disorders among homeless
persons. American Psychologist 46(11):1115-1126, 1991.
View this and related citations using
or 
-
Gold, M.S.
-
The Good News About Depression. New York: Villard Books, 1987.
View this and related citations using
or 
-
Gold, M.S.
-
The Good News About Drugs and Alcohol. New York: Villard Books, 1990.
View this and related citations using
or 
-
Gold, M.S.
-
The Good News About Panic, Anxiety, and Phobias. New York: Villard Books,
1989.
View this and related citations using
or 
-
Goldman, M.S.
-
Neuropsychological recovery in alcoholics: endogenous and exogenous processes.
Alcoholism: Clinical and Experimental Research 10(2):136-144, 1986.
View this and related citations using
or 
-
Gordon, S.M., Kennedy, B.P., and McPeake, J.D.
-
Neuropsychologically impaired alcoholics: assessment, treatment considerations,
and rehabilitation. Journal of Substance Abuse Treatment 5:99-104, 1988.
View this and related citations using
or 
-
Gorelick, D.A.
-
Serotonin uptake blockers and the treatment of alcoholism. In: Galanter,
M., ed. Recent Developments in Alcoholism. New York: Plenum Press, 1989.
pp. 267-281.
-
El-Guebaly, N.
-
Substance abuse and mental disorders: the dual diagnoses concept. Canadian
Journal of Psychiatry 35:261-267, 1990.
View this and related citations using
or 
-
Hasin, D.S., Endicott, J., and Keller, M.B.
-
Alcohol problems in psychiatric patients: 5-year course. Comprehensive
Psychiatry 32(4):303-316, 1991.
View this and related citations using
or 
-
Hedlund, J.L., and Vieweg, M.S.
-
The Michigan Alcoholism Screening Test (MAST). Journal of Operational Psychiatry
15:55-64, 1984.
View this and related citations using
or 
-
Hendrickson, E.L.
-
Treating the dually diagnosed (mental disorder/substance use) client. Tie
Lines 4(4):1-6, 1988.
View this and related citations using
or 
-
Jensen, K.L.
-
Family issues in treating the "dually diagnosed" client. Tie Lines 7:6-8,
1990.
View this and related citations using
or 
-
Kofoed, L., Kania, J., Walsh, T., and Atkinson, R.M.
-
Outpatient treatment of patients with substance abuse and coexisting psychiatric
disorders. American Journal of Psychiatry 143(7):867-872, 1986.
View this and related citations using
or 
-
Kofoed, L., and Keys, A.
-
Using group therapy to persuade dual-diagnosis patients to seek substance
abuse treatment. Hospital and Community Psychiatry 39(11):1209-1211, 1988.
View this and related citations using
or 
-
Kranzler, H.R., and Liebowitz, N.R.
-
Anxiety and depression in substance abuse: clinical implications. Medical
Clinics of North America 72(4):867-885, 1988.
View this and related citations using
or 
-
Lader, M.
-
Beta-Adrenoceptor antagonists in neuropsychiatry: an update. Journal of
Clinical Psychiatry 49:213-223, 1988.
View this and related citations using
or 
-
Landry, M.J., Smith, D.E., McDuff, D.R., and Baughman, O.L., 3rd.
-
Anxiety and substance use disorders: the treatment of high-risk patients.
Journal of the American Board of Family Practice 4:447-456, 1991.
-
Landry, M.J., Smith, D.E., and Steinberg, J.R.
-
Anxiety, depression, and substance use disorders: diagnosis, treatment,
and prescribing practices. Journal of Psychoactive Drugs 23(4):397-416,
1991a.
View this and related citations using
or 
-
Lehman, A.F., Myers, C.P., and Corty, E.
-
Assessment and classification of patients with psychiatric and substance
abuse syndromes. Hospital and Community Psychiatry 40(10):1019-1030, 1989.
View this and related citations using
or 
-
Mayfield, D., McLeod, G., and Hall, P.
-
The CAGE questionnaire: validation of a new alcoholism screening instrument.
American Journal of Psychiatry 131(10):1121-1123, 1974.
View this and related citations using
or 
-
McLellan, A.T.
-
Predicting response to alcohol and drug abuse treatments: the role of psychiatric
severity. Archives of General Psychiatry 40:620-625, 1983.
View this and related citations using
or 
-
McLellan, A.T., Luborsky, L., Woody, G.E., and O'Brien, C.P.
-
An improved diagnostic evaluation instrument for substance abuse patients:
the Addiction Severity Index 168:26-33, 1980.
View this and related citations using
or 
-
Meek, P.S., Clark, H.W., and Solana, V.L.
-
Neurocognitive impairment: the unrecognized component of dual diagnosis
in substance abuse treatment. Journal of Psychoactive Drugs 21(2):153-160,
1989.
View this and related citations using
or 
-
Meltzer, E.O.
-
Performance effects of antihistamines. Journal of Allergy and Clinical
Immunology 86(4, Part 2):613-619, 1990.
View this and related citations using
or 
-
Meyer, R.E.
-
How to understand the relationship between psychopathology and addictive
disorders: another example of the chicken and the egg. In: Meyer, R.E.,
ed. Psychopathology and Addictive Disorders. New York: Guilford Press,
1986.
-
Meyer, R.E. Prospects for a rational pharmacotherapy of alcoholism.
-
Journal of Clinical Psychiatry 50(11):403-412, 1989.
-
MICA Advisory Committee, State of New Jersey. Glossary of terms common
in MICA treatment.
-
Trenton, New Jersey: State of New Jersey, 1992.
-
Miller, N.S., and Ries, R.K.
-
Drug and alcohol dependence and psychiatric populations: the need for diagnosis,
intervention, and training. Comprehensive Psychiatry 32(3):268-276, 1991.
View this and related citations using
or 
-
Minkoff, K.
-
An integrated treatment model for dual diagnosis of psychosis and addiction.
Hospital and Community Psychiatry 40(10):1031-1036, 1989.
View this and related citations using
or 
-
Minkoff, K., and Drake, R.E., eds.
-
Dual Diagnosis of Major Mental Illness and Substance Disorder. San Francisco:
Jossey-Bass, Inc., 1991.
-
Mooney, A.J., Eisenberg, A, and Eisenberg, H.
-
The Recovery Book. New York: Workman Publishers, 1992.
View this and related citations using
or 
-
Morris, S.K., and Schinke, S.P.
-
Treatment needs and services for mothers with a dual diagnosis: substance
abuse and mental illness. In: Chaneles, S., and Pallone, N.J., eds. Clinical
Treatment of the Criminal Offender in Outpatient Mental Health Settings:
New and Emerging Perspectives. New York: Haworth Press, 1990. pp. 65-84.
-
Nace, E.P., Davis, C.W., and Gaspari, J.P.
-
Axis II comorbidity in substance abusers. American Journal of Psychiatry
148(1):118-120, 1991.
View this and related citations using
or 
-
Nace, E.P., Saxon, J.J., and Shore, N.
-
Borderline personality disorder and alcoholism treatment: a one-year follow-up
study. Journal of Studies on Alcohol 47(3):196-200, 1986.
View this and related citations using
or 
-
Osher, F.C., and Kofoed, L.L.
-
Treatment of patients with psychiatric and psychoactive substance use disorders.
Hospital and Community Psychiatry 40(10):1025-1030, 1989.
View this and related citations using
or 
-
Padgett, D., Struening, E.L., and Andrews, H.
-
Factors affecting the use of medical, mental health, alcohol, and drug
treatment services by homeless adults. Medical Care 28(9):805-821, 1990.
View this and related citations using
or 
-
Penick, E.C., Powell, B.J., Liskow, B.I., Jackson, J.O., and Nickel, E.J.
-
The stability of coexisting psychiatric syndromes in alcoholic men after
one year. Journal of Studies on Alcohol 49:395-405, 1988.
View this and related citations using
or 
-
Pepper, B., and Ryglewicz, H.
-
The young adult chronic patient and substance abuse. Tie Lines 1(2):1-5,
1984.
View this and related citations using
or 
-
Pepper, B., and Ryglewicz, H.
-
Dual-disorder treatment. Maine Dual Disorders Monographs, Volume 3. Maine
Department of Mental Health and Mental Retardation, 1989.
View this and related citations using
or 
-
Petracca, A., Nisita, C., McNair, D., Melis, G., Guerani, G., and Cassano,
G.B.
-
Treatment of generalized anxiety disorder: preliminary clinical experience
with buspirone. Journal of Clinical Psychiatry 51(9, Suppl.):31-39, 1990.
View this and related citations using
or 
-
Quinnet, P.
-
When Self-Help Fails. New York: Crossroads, 1991.
View this and related citations using
or 
-
Regier, D.A., Boyd, J.H., Burke, J.D., Rae, D. S., Myers, J.K., Kramer,
M., Robins, L.N., George, L.K., Karno, M., and Locke, B.Z.
-
One-month prevalence of mental disorders in the United States: based on
five Epidemiologic Catchment Area sites. Archives of General Psychiatry
45:977-986, 1988.
View this and related citations using
or 
-
Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd,
L.L., and Goodwin, F.K.
-
Comorbidity of mental disorders with alcohol and other drug abuse: results
from the Epidemiologic Catchment Area (ECA) study. Journal of the American
Medical Association 264(19):2511-2518, 1990.
View this and related citations using
or 
-
Regier, D.A., Narrow, W.E., and Rae, D.S.
-
The epidemiology of anxiety disorders: the Epidemiologic Catchment Area
(ECA) experience. Journal of Psychiatric Research 24(Suppl. 2):3-14, 1990a.
View this and related citations using
or 
-
Reid, W.H.
-
The Treatment of Psychiatric Disorders. New York: Brunner/Mazel, 1989.
View this and related citations using
or 
-
Reus, V.I.
-
Mood disorders. In: Goldman, H.H., ed. Review of General Psychiatry, Third
Edition. Norwalk, Connecticut: Appleton & Lange, 1992. pp. 226-241.
-
Rickels, K., Weisman, K., Norstad, N., Singer, M., Stoltz, D., Brown, A.,
and Danton, J.
-
Buspirone and diazepam in anxiety: a controlled study. Journal of Clinical
Psychiatry 43(12, Sec. 20):81-86, 1982.
View this and related citations using
or 
-
Ries, R.
-
Clinical treatment matching models for dually diagnosed patients. Psychiatric
Clinics of North America 16(1):167-175, 1993.
View this and related citations using
or 
-
Ries, R.K.
-
The dually diagnosed patient with psychotic symptoms. Journal of Addictive
Diseases 12(3):103-122, 1993a.
View this and related citations using
or 
-
Ries, R.K., and Ellingson, T.
-
A pilot assessment at one month of 17 dual diagnosis patients. Hospital
and Community Psychiatry 41(11):1230-1233, 1990.
View this and related citations using
or 
-
Robins, E., Helzer, J.E., and Przybeck, T.R.
-
Alcohol disorders in the community: a report from the Epidemiologic Catchment
Area study. In: Rose, R., and Barret J., eds. Alcoholism: Origins and Outcome.
New York: Raven Press, 1988. pp. 15-28.
-
Rosenheck, R., Massari, L., Astrachan, B., and Suchinsky, R.
-
Mentally ill chemical abusers discharged from VA inpatient treatment: 1976-1988.
Psychiatric Quarterly 61(4):237-249, 1990.
View this and related citations using
or 
-
Ross, H.E., Glaser, F.B., and Germanson, T.
-
The prevalence of psychiatric disorders in patients with alcohol and other
drug problems. Archives of General Psychiatry 45:1023-1031, 1988.
View this and related citations using
or 
-
Rounsaville, B.J., Anton, S.F., Carroll, K., Budde, D., Prusoff, B.A.,
and Gawin, F.
-
Psychiatric diagnoses of treatment-seeking cocaine abusers. Archives of
General Psychiatry 48:43-51, 1991.
View this and related citations using
or 
-
Ryglewicz, H.
-
Psychoeducation: A wave of the present. Tie Lines 6(2):1-5, 1989.
View this and related citations using
or 
-
Salloum, I.M., Moss, H.B., and Daley, D.C.
-
Substance abuse and schizophrenia: impediments to optimal care. American
Journal of Alcohol Abuse 17(3):321-336, 1991.
View this and related citations using
or 
-
Salzman, C.
-
Treatment with antianxiety agents. In: Treatments of Psychiatric Disorders.
Washington, D.C.: American Psychiatric Association, 1989. pp. 2036-2052.
-
Schorske, B., and Bedard, K.
-
One State's role in building a continuum of care for severe mental illness
and chemical dependency. Community Support Network News 6(2):10, 1989.
View this and related citations using
or 
-
Schuckit, M.A.
-
Genetic and clinical implications of alcoholism and affective disorder.
American Journal of Psychiatry 143(2): 140-147, 1986.
View this and related citations using
or 
-
Spitzer, R.L., Williams, J.B.W., Gibbon, M., and First, M. B.
-
Structured Clinical Interview for DSM-III-R. Washington, D.C.: American
Psychiatric Press, 1990.
-
Strand, M., Hetta, J., Rosen, A., Sorensen, S., Malmstrom, R., Fabian,
C., Marits, K., Vetterskog, K., Liljestrand, A.-G., and Hegen, C.
-
A double-blind, controlled trial in primary care patients with generalized
anxiety: a comparison between buspirone and oxazepam. Journal of Clinical
Psychiatry 51(9, Suppl.):40-45, 1990.
View this and related citations using
or 
-
Stoffelmayr, B.E., Benishek, L.A., Humphreys, K., Lee, J.A., and Mavis,
B.E.
-
Substance abuse prognosis with an additional psychiatric diagnosis: understanding
the relationship. Journal of Psychoactive Drugs 21(2):145-152, 1989.
View this and related citations using
or 
-
Teague, G., Mercer-McFadden, C., and Drake, R.E.
-
Dual diagnosis and continuity of care: New Hampshire's integrated initiatives
for dual diagnosis patients. Tie Lines 6(1):1-3, 1989.
View this and related citations using
or 
-
Thacker, W., and Tremaine, L.
-
Systems issues in serving the mentally ill substance abuser: Virginia's
experience. Hospital and Community Psychiatry 40(10):1046-1049, 1989.
View this and related citations using
or 
-
Torrey, E.F.
-
Surviving Schizophrenia: A Family Manual. New York: Harper & Row, 1983.
View this and related citations using
or 
-
Trevor, A.J., and Way, W.L.
-
Drugs used for anxiety states and sleep problems. In: Goldman, H.H., ed.
Review of General Psychiatry, Second Edition. Norwalk, Connecticut: Appleton
& Lange, 1989.
-
Turner, W.M., and Tsuang, M.T.
-
Impact of substance abuse on the course and outcome of schizophrenia. Schizophrenia
Bulletin 16(1):87-95, 1990.
View this and related citations using
or 
-
Uhde, T.W., Stein, M.B., Vittone, B.J., Siever, L.J., Boulenger, J.P.,
Klein, E., and Mellman, T. A.
-
Behavioral and physiologic effects of short-term and long-term administration
of clonidine in panic disorders. Archives of General Psychiatry 46(2):170-177,
1989.
View this and related citations using
or 
-
Wallen, M., and Weiner, H.
-
The dually diagnosed patient in an inpatient chemical dependency treatment
program. Alcoholism Treatment Quarterly 5(1/2):197-218, 1988.
View this and related citations using
or 
-
Weiss, D.S., and Billings, J.H.
-
Behavioral medicine techniques. In: Goldman, H.H., ed. Review of General
Psychiatry, Second Edition. Norwalk, Connecticut: Appleton & Lange,
1989. pp. 574-579.
-
Weiss, R.D., M.L.
-
Griffin, and Mirin, S.M. Drug abuse as self-medication for depression:
an empirical study. American Journal of Drug and Alcohol Abuse 18:121-129,
1992.
View this and related citations using
or 
-
Weissman, M.M.
-
The epidemiology of anxiety disorders: rates, risks and familial patterns.
Journal of Psychiatric Research 22(Suppl. 1):99-114, 1988.
View this and related citations using
or 
-
Winter, A.S.
-
When Self-Help Isn't Enough. Washington, D.C.: Psychiatric Institutes of
America Press, 1990.
-
Wolfe, H.L., and Sorensen, J.L.
-
Dual diagnosis patients in the urban psychiatric emergency room. Journal
of Psychoactive Drugs 21(2):169-175, 1989.
View this and related citations using
or 
-
Yeary, J.R., and Heck, C.L.
-
Dual diagnosis: eating disorders and psychoactive substance dependence.
Journal of Psychoactive Drugs 21(2): 239-249, 1989.
View this and related citations using
or 
-
Zweben, J.E.
-
Issues in the treatment of the dual-diagnosis patient. In: Wallace, B.,
ed. The Chemically Dependent: Phases of Treatment and Recovery. New York:
Brunner/Mazel, 1992.
-
Zweben, J.E.
-
Counseling issues in methadone maintenance treatment. Journal of Psychoactive
Drugs 23(2):177-190, 1991.
View this and related citations using
or 
-
Zweben, J.E., and Smith, D.E.
-
Considerations in using psychotropic medication with dual diagnosis patients
in recovery. Journal of Psychoactive Drugs 21(2): 221-226, 1989.
View this and related citations using
or 
Appendix B -- Treatment of Patients With Dual Disorders:
Sample Cost Data
To provide readers with illustrative data on the costs of running programs
for patients with dual disorders, the consensus panel Chair obtained data
on actual costs during fiscal year 1991-1992 from three programs in urban
areas. One program, on the West Coast, provided day and evening intensive
outpatient services. The second, in the Northeast, provided intensive outpatient
services during the day. In the third program, in the Northwest, daytime
intensive outpatient services, partial hospitalization, and intensive case
management were provided.
Included in the tables below are descriptive data for each program,
including institutional status (for example, private for-profit or public),
payer mix (for example, Medicaid or self-pay patients), number of clients
served (at 100 percent capacity), salary ranges of various levels of staff,
and other expenses (for example, facility costs). Total expenses and total
revenues for each program are listed at the end.
TREATMENT OF PATIENTS WITH DUAL DISORDERS SAMPLE COST DATA
|
Program 1 |
Program 2 |
Program 3 |
| PROGRAM TYPE |
| Evening Intensive Outpatient |
X |
| Day Intensive Outpatient |
X |
X |
X |
| Partial Hospitalization |
|
|
X |
| Other |
|
|
Day treatment and intensive case management |
| REGION |
West Coast |
Northeast |
Northwest |
| LOCALE |
Urban |
Urban |
Urban |
| INSTITUTIONAL STATUS |
| Private for-profit |
X |
|
|
| Private nonprofit |
| Public |
|
X |
X |
| Other |
| PAYER MIX (BY PERCENT) |
| Insurance/Managed Care |
X |
| Medicaid |
|
66% |
30% |
| Medicare |
X |
|
25% |
| Self-pay |
X |
4% |
| HMO contract |
X |
| State grant/purchase of care |
|
30% |
45% |
|
Program 1 |
Program 2 |
Program 3 |
| NUMBER OF PATIENTS SERVED (AT 100 PERCENT CAPACITY) |
| Daily |
50+ |
45 |
100 |
| Weekly |
320 |
225 |
300 |
| SALARY RANGES |
| Administrators/managers |
$60,000 to 70,000 |
$38,000 to 50,000 |
$35,000 to 60,000 |
| Physicians |
$70/Hour to 100/Hour |
$85,00 |
$70,000 to 90,000 |
| Social workers |
$30,000 to 50,00 |
$30,000 |
$26,000 to 35,000 |
| Psychologists |
$50,000 to 60,000 |
n/a |
$50,000 to 70,000 |
| Support staff |
$18,000 to 27,000 |
$20,000 to 29,000 |
$22,000 to 28,000 |
| Other |
Addiction counselors, $23,000 to 35,000 |
Nurses, counselors and recreational therapists, $25,000
to 38,000 |
Addiction mental health specialists, $23,000 to 33,000 |
|
|
|
Nurses $32,000 to 48,000 |
|
Program 1 |
Program 2 |
Program 3 |
| OTHER EXPENSES (BY PERCENT) |
| Administrative overhead |
7.1% |
24% |
20% |
| Personnel (including fringe benefits) |
80.5% |
60% |
70% |
| Facility costs |
12.4% |
16% |
10% |
|
TOTAL EXPENSES FY 1991-1992 |
TOTAL REVENUES FY 1991-1992 |
| Program 1 |
$482,000 |
$489,000 |
| Program 2 |
$811,052 |
$561,052 |
| Program 3 |
$2,200,000 |
$1,980,000 |
Appendix C -- Federal Resource Panel
-
John J. Ambre, M.D., Ph.D.
-
American Medical Association
-
Robert Anderson
-
Director
-
Criminal Justice Service
-
National Association of State Alcohol and Drug Abuse Directors
-
Richard J. Bast
-
Public Health Advisor
-
Quality Assurance and Evaluation Branch
-
Division of State Programs
-
Center for Substance Abuse Treatment
-
Sandra M. Clunies, M.S., N.C.A.D.C.
-
President, Maryland Addiction Counselor Certification Board
-
Dorynne Czechowicz, M.D.
-
Associate Director
-
Medical and Professional Affairs
-
Division of Clinical Research
-
National Institute on Drug Abuse
-
Walter L. Faggett, M.D.
-
National Medical Association
-
Rita Goodman, M.S., R.N.C.
-
Nurse Consultant
-
Division of Primary Care Services
-
Health Resources and Services Administration
-
John Gregrich
-
Policy Analyst
-
Office for National Drug Control Policy
-
Executive Office for the President
-
Claudia Hart
-
American Psychiatric Association
-
Ruth H. Carlsen Kahn, D.N.Sc.
-
Special Projects Section
-
Division of Medicine
-
Bureau of Health Professions
-
Health Resources and Services Administration
-
Saul M. Levin, M.D.
-
Director
-
Office of Health Care Linkage
-
Center for Substance Abuse Treatment
-
Cherry Lowman, Ph.D.
-
Health Scientist Administrator
-
Treatment Research Branch
-
Division of Clinical and Prevention Research
-
National Institute on Alcohol Abuse and Alcoholism
-
Anna Marsh, Ph.D.
-
Associate Director for Evaluation
-
Office of Applied Studies
-
Center for Substance Abuse Treatment
-
Fred C. Osher, M.D.
-
Deputy Director
-
Office of Programs for the Homeless Mentally Ill
-
National Institute of Mental Health
-
Deborah Parham, Ph.D., R.N.
-
Chief
-
Special Initiatives
-
Policy and Evaluation Branch
-
Bureau of Primary Health Care
-
Health Resources and Services Administration
-
Kay Pearson, R.Ph., M.P.H.
-
Senior Health Policy Analyst
-
Agency for Health Care Policy and Research
-
Public Health Service
-
Bert Pepper, M.D.
-
The Information Exchange
-
New City, New York
-
Richard K. Ries, M.D. (Chair)
-
Director of Inpatient Psychiatry and Dual Disorder Programs
-
Harborview Medical Center
-
Seattle, Washington
-
Harry Schnibbe
-
Executive Director
-
National Association of State Mental Health Program Directors
-
Sarah Stanley, M.S., R.N., C.N.A, C.S.
-
American Nurses Association
-
Patricia M. Weisser
-
National Association of Psychiatric Survivors
Appendix D -- Field Reviewers
-
Arthur I. Alterman, Ph.D.
-
Scientific Director
-
Center for Studies of Addiction
-
University of Pennsylvania School of Medicine
-
Philadelphia, Pennsylvania
-
Robert Anderson
-
Director, Criminal Justice
-
National Association of State Alcohol and Drug Abuse Directors
-
Gloria J. Baciewicz, M.D.
-
Director
-
Alcoholism and Drug Dependency Program
-
University of Rochester Medical Center
-
Rochester, New York
-
Stephen J. Bartels, M.D.
-
Medical Director
-
West Central Services, Inc.
-
Research Associate
-
N.H. Dartmouth Psychiatric Research Center
-
Lebanon, New Hampshire
-
Richard J. Bast
-
Public Health Advisor
-
Center for Substance Abuse Treatment
-
Joseph J. Bevilaqua, Ph.D.
-
Director
-
South Carolina Department of Mental Health
-
Dolores M. Burant, M.D.
-
Program Director and Medical Director
-
University Outpatient Recovery Services
-
Madison, Wisconsin
-
Ricardo Castaneda, M.D.
-
Director
-
Inpatient Psychiatry at Bellevue Hospital
-
New York Medical Center
-
Nancy C. Carter
-
Director
-
Special Division for Alcohol and Drug Abuse Services
-
South Carolina Department of Mental Health
-
Maureen Connelly, Ph.D.
-
Professor
-
Department of Sociology and Social Work
-
Frostburg State University
-
Frostburg, Maryland
-
Marcelino Cruces, L.I.C.S.W.
-
Administrative Coordinator
-
Andromeda Transcultural Mental Health Center
-
Substance Abuse Treatment Division
-
Washington, D.C.
-
Dorynne Czechowicz, M.D.
-
Associate Director for Medical and Professional Affairs
-
Division of Clinical Research
-
National Institute on Drug Abuse
-
Robert E. Drake, M.D., Ph.D.
-
Professor/Director
-
N.H.-Dartmouth Psychiatric Research Center
-
Dartmouth Medical School
-
Lebanon, New Hampshire
-
Mary Katherine Evans, C.A.D.C., N.C.A.C. II
-
Treatment Coordinator
-
Evans and Sullivan
-
Beaverton, Oregon
-
Walter L. Faggett, M.D.
-
Pediatrics/Health Care Consultant
-
Capitol Area Health Services
-
National Medical Association
-
Denis Ferguson, M.A., C.S.A.D.C.
-
Program Manager
-
Substance Abuse Services
-
DuPage County Health Department
-
Wheaton, Illinois
-
James Fine, M.D.
-
Director
-
Addictive Disease Hospital at Kings County Hospital Center
-
Clinical Associate Professor
-
Department of Psychiatry
-
State University of New York
-
Health Service Center at Brooklyn
-
Brooklyn, New York
-
Agnes Furey, L.P.N., C.A.P.
-
Primary Care Coordinator
-
Florida Drug and Alcohol Abuse Program
-
Department of Health and Rehabilitation Services
-
Tallahassee, Florida
-
Harry W. Haverkos, M.D.
-
Acting Director
-
Division of Clinical Research
-
National Institute on Drug Abuse
-
Elizabeth A. Irvin, M.S.W.
-
Director of Service Integration
-
Department of Mental Health
-
Commonwealth of Massachusetts
-
Edward K. Katz, M.D., M.P.H.
-
Mind Science
-
Consultation for Problems in Thinking and Feeling
-
Stow, Ohio
-
Ruth H. Carlsen Kahn, D.N.Sc., R.N.
-
Special Projects Section
-
Division of Medicine
-
Bureau of Health Professions
-
Health Resources and Services Administration
-
George Kolodner, M.D.
-
Kolmac Clinic
-
Silver Spring, Maryland
-
Susan Krupnick, R.N., M.S.N., C.A.R.N., C.S.
-
Psychiatric Consultation Liaison Nurse
-
Department of Psychiatric Nursing
-
Hospital of the University of Pennsylvania
-
Fox Chase Manor, Pennsylvania
-
Robert M. Lichtman, Ph.D., C.A.C.
-
Associate Psychologist/Program Coordinator
-
Richmond Hill Outpatient Division
-
Creedmoor Psychiatric Center
-
Richmond Hill, New York
-
Herbert J. McBride
-
President and Medical Director
-
Re-Enter, Inc.
-
Philadelphia, Pennsylvania
-
Catherine Devaney McKay, M.D.
-
Chief Executive Officer
-
Connections Community Support Programs, Inc.
-
Wilmington, Delaware
-
Norman S. Miller, M.D.
-
Associate Professor of Psychiatry
-
Department of Psychiatry
-
University of Illinois at Chicago
-
Thomas Neslund
-
Executive Director
-
International Commission for the Prevention of Alcoholism and Drug Dependency
-
Silver Spring, Maryland
-
John Nielsen, L.P.C., C.C.D.C., M.S.S.
-
Alcohol and Other Drugs Counselor
-
Threshold Youth Services
-
Sioux Falls, South Dakota
-
Robert E. Nikkel, M.S.W.
-
Coordinator
-
Adult Program Services Team
-
Mental Health and Development Services Division
-
Office of Mental Health Services
-
State of Oregon
-
Fred C. Osher, M.D.
-
Acting Director for Demonstration Programs
-
Center for Mental Health Services
-
William C. Panepinto, A.C. S.W.
-
Assistant Director
-
Homelessness/Housing Unit
-
New York State Office of Alcoholism and Substance Abuse Services
-
T. Allan Pearson, M.S.W.
-
Mental Health, Alcohol, and Other Drug Abuse Counselor
-
Ozaukae County Department of Community Programs
-
Port Washington, Wisconsin
-
Walter E. Penk, Ph.D.
-
Chief
-
Psychology Services
-
Edit Nourse Rogers Memorial Veterans Hospital Bedford, Massachusetts
-
Harold I. Perl, Ph.D.
-
Public Health Analyst
-
Homeless Demonstration and Evaluation Branch
-
National Institute on Alcohol Abuse and Alcoholism
-
Ernest Quimby, Ph.D.
-
Assistant Graduate Professor
-
Department of Sociology and Anthropology
-
Howard University
-
Washington, D.C.
-
Kathleen Reynolds, M.S.W., A.C.S.W.
-
Associate Coordinator
-
Livingston/Washtenaw Substance Abuse Coordinating Agency
-
Washtenaw Community Mental Health
-
Ypsilanti, Michigan
-
Henry Jay Richards, Ph.D.
-
Associate Director for Behavioral Sciences
-
Patuxent Institution
-
Jessup, Maryland
-
Richard K. Ries, M.D.
-
Director of Inpatient Psychiatry and Dual Disorder Programs
-
Harborview Medical Center
-
Seattle, Washington
-
Bruce J. Rounsaville, M.D.
-
Associate Professor of Psychiatry
-
Division of Substance Abuse
-
Yale School of Medicine
-
New Haven, Connecticut
-
Harry Schnibbe
-
Executive Director
-
National Association of State Mental Health Program Directors
-
Bonnie Schorske, M.A.
-
Coordinator
-
Special Populations
-
New Jersey Division of Mental Health and Hospitals
-
Candace Shelton, M.S., C.A.C.
-
Clinical Director
-
Pascua Yaqui Adult Treatment Home
-
Tucson, Arizona
-
Elizabeth C. Shifflette, Ed.D.
-
Staff Development and Training Coordinator
-
South Carolina Commission on Alcohol and Drug Abuse
-
Virginia Stiepock, R.N., A.C.S.W., C.S.
-
Assistant Center Director/Clinical Director
-
Northern Rhode Island Community Mental Health Center, Inc.
-
Woonsocket, Rhode Island
-
Mathias E. Stricherz, Ed.D., C.D.C. III
-
Director
-
Student Counseling Center
-
University of South Dakota
-
Vermillion, South Dakota
-
J. Michael Sullivan, Ph.D.
-
Clinical Director
-
Evans and Sullivan
-
Beaverton, Oregon
-
Johnie L. Underwood, B.S., C.S.W.
-
Assistant Deputy Director
-
Division of Mental Health and Addictions
-
Indiana Family Social Services Administration
-
Mark C. Wallen, M.D.
-
Medical/Clinical Director
-
Livengrin Foundation, Inc.
-
Bensalem, Pennsylvania
-
Linda M. Washington, M.S.N., R.N., C.S.-P.
-
Psychiatric Nurse Clinical Specialist
-
Outpatient Addictions Services
-
Montgomery County Department of Addictions, Victims, and Mental Health
Services
-
Rockville, Maryland
-
Patricia M. Weisser
-
National Association of Psychiatric Survivors
-
Sioux Falls, South Dakota
-
Sonya Cornell Yarmat, M.A.
-
Consultant
-
Division of Alcohol and Drug Abuse Services
-
Department of Social Rehabilitation
-
Topeka, Kansas
-
Doug Ziedonis, M.D.
-
Assistant Professor
-
Department of Psychiatry
-
Medical Director, Substance Abuse Treatment Unit
-
Outpatient Services
-
Yale University
-
New Haven, Connecticut
-
Joan Ellen Zweben, Ph.D.
-
Executive Director
-
East Bay Community Recovery Project
-
14th Street Clinic and Medical Group
-
Berkeley, California
Exhibits
Exhibit 2-1
DSM-III-R and DSM-IV Draft Criteria for AOD Dependence
| DSM-III-R Criterion No. |
DSM-IV Draft Criterion No. |
Diagnostic Criterion (language from DSM-III-R) |
| No. 1 |
No. 3 |
AODs are often taken in larger amounts or over a longer
period of time than the person intended. |
| No. 2 |
No. 4 |
The person has a persistent desire or has made one or more
unsuccessful efforts to cut down or control AOD use. |
| No. 3 |
No. 5 |
The person spends a great deal of time in activities necessary
to obtain, consume, or recover from AOD effect |
| No. 4 |
Deleted |
The person experiences frequent intoxication or withdrawal
symptoms when expected to fulfill major role obligations at work, school,
or home, or when AOD use is physically hazardous. |
| No. 5 |
6 |
Important social, occupational, or recreational activities
are given up or reduced because of AOD use. |
| No. 6 |
7 |
AOD use continues despite knowledge of having a persistent
or recurrent social, psychological, or physical problem that is caused
or exacerbated by AOD use. |
| No. 7 |
1 |
There is evidence of marked tolerance: a need for markedly
increased amounts of AODs to achieve intoxication or a desired effect,
or markedly diminished effect with continued use of the same amount. |
| No. 8 |
2 |
Evidence of characteristic withdrawal symptoms. |
| No. 9 |
2 |
AODs are often taken to relieve or avoid withdrawal symptoms. |
Exhibit 3-1
Treatment Approach Similarities and Differences
|
Mental Health System |
Dual Disorders Approach |
Addiction System |
| Medications |
Central to the management of severe disorders in acute,
subacute, and long-term phases of treatment: antidepressants, antipsychotics,
anxiolytics, mood stabilizers. |
Central to the treatment of many patients with dual disorders.
Caution is used when prescribing psychoactive, mood-altering medications. |
Central for acute detoxification; less common for subacute
phase. Few used during long-term treatment: disulfiram, naltrexone, methadone,
and LAAM. |
| Therapeutic Confrontations |
Minimal to moderate use, depending upon setting, patient,
and problem. Not central to therapy. |
Generally used, but use is modulated according to fragility
of mental status. |
Use by staffand peers is one of the central techniques
in AOD treatment. |
| Group Therapy |
Central to treatment. |
Central to treatment. |
Central to treatment. |
| 12-Step Groups |
Although historically underused, use is growing. Examples
include: Emotions Anonymous, Obsessive-Compulsive Anonymous, and Phobics
Anonymous. |
Dual Disorders Anonymous groups not yet widespread. Use
of 12-step groups for AOD problems is central, but actively psychotic or
paranoid patients may not mix well in meetings. "Double Trouble" AA groups
are becoming more numerous. |
Use of 12-step groups is central to AOD treatment. Great
availability. Examples include: Alcoholics Anonymous, Narcotics Anonymous,
and Cocaine Anonymous. |
| Other Self-Help Groups |
Numerous national organizations. Growing numbers of local
groups. Use depends upon availability and awareness. Examples include:
Anxiety Disorders Association of America, National Depressive & Manic-Depressive
Association, Recovery, Inc., and National Association of Psychiatric Survivors. |
Use of self-help groups regarding AOD and mental health
problems is increasing. |
Numerous organizations and groups, often specialized. Examples
include: Women for Sobriety, Rational Recovery, Secular Organizations for
Sobriety, International Doctors in AA, Recovering Counselors Network, and
Social Workers Helping Social Workers. |
Exhibit 3-2
The CAGE and CAGEAID Questionnaires
The CAGE Questionnaire:
-
Have you ever felt you should cut down on your drinking?
-
Have people annoyed you by criticizing your drinking?
-
Have you felt bad or guilty about your drinking?
-
Have you ever had a drink first thing in the morning to steady your nerves
or get rid of a hangover (eye-opener)?
Source: Mayfield et al., 1974.
The CAGE Questions Adapted to Include Drugs (CAGEAID):
-
Have you felt you ought to cut down on your drinking or drug use?
-
Have people annoyed you by criticizing your drinking or drug use?
-
Have you felt bad or guilty about your drinking or drug use?
-
Have you ever had a drink or used drugs first thing in the morning to steady
your nerves or get rid of a hangover or to get the day started?
Source: Brown, 1992.
Exhibit 5-1
Drugs That Precipitate or Mimic Mood Disorders
| Mood Disorders |
During Use [Intoxication] |
After Use [Withdrawal] |
| Depression and dysthymia |
Alcohol, benzodiazepines, opioids, barbiturates, cannabis,
steroids (chronic), stimulants (chronic) |
Alcohol, benzodiazepines, barbiturates, opiates, steroids
(chronic), stimulants (chronic) |
| Mania and cyclothymia |
Stimulants, alcohol, hallucinogens, inhalants (organic
solvents), steroids (chronic, acute) |
Alcohol, benzodiazepines, barbiturates, opiates, steroids
(chronic) |
Exhibit 7-1
Characteristics of People With Passive-Aggressive, Antisocial,
and Borderline Personality Disorders
| Characteristic |
Passive-Aggressive |
Antisocial |
Borderline |
| Affect |
Overcontrolled hostility |
Angry intimidation |
Angry self-harm |
| World-view |
I do everything right and they still act this way. I don't
deserve this. I'm fine; ignore the tears. |
If you don't do what I want, you'll be sorry. I deserve
it all. They're the ones with the problem. |
I've got to get you, before you get me. I don't deserve
to exist. Help me, help me, but you can't. |
| Presenting problem |
Depression, somatization, sedative dependence, codependency
relationships |
Legal difficultie polysubstance abuse and dependence, parasitic
cold relationships |
Self-harm, impulsive behavior, episodic polysubstance abuse. |
| Social functioning |
Consistent underachievement |
Episodic achievement |
Gross dysfunctioning |
| Motivation |
Belonging |
Self-esteem |
Safety |
| Defenses |
Repression |
Rationalization, projection |
Splitting, projection |
Adapted with permission from Evans, K., and Sullivan,
J.M. Step Study Counseling With the Dual Disordered Client. Center City,
Minnesota: Hazelden Educational Materials, 1990.
Exhibit 7-2
Step Work Handout For Patients With Borderline Personality Disorder
Step One: "We admitted we were powerless over alcohol-that our lives
had become unmanageable."
-
Describe five situations where you suffered negative consequences as a
result of drinking or using other drugs.
-
List at least five "rules" that you have developed in order to try to control
your use of alcohol or other drugs. (Example: "I never drink alone.")
-
Give one example describing how and when you broke each rule.
-
Check the following that apply to you:
-
I sometimes drink or use other drugs more than I plan.
-
I sometimes lie about my use of alcohol or other drugs.
-
I have hidden or stashed away alcohol or other drugs so I could use them
alone or at a later time.
-
I have had memory losses when drinking or using other drugs.
-
I have tried to hurt myself when drinking or using other drugs.
-
I can drink or use more than I used to, without feeling drunk or high.
-
My personality changes when I drink or use other drugs.
-
I have school or work problems related to using alcohol or other drugs.
-
I have family problems related to my use of alcohol or other drugs.
-
I have legal problems related to my use of alcohol or other drugs.
-
Give two examples for each item that you checked.
Step Two: "We came to believe that a Power greater than ourselves could
restore us to sanity."
-
Give three examples of how your drinking or use of other drugs was insane.
(One definition of insanity is to keep repeating the same mistake and expecting
a different outcome.)
-
Check which of the following mistakes or thinking errors that you use:
-
Blaming
-
Lying
-
Manipulating
-
Excuse making
-
Beating up yourself with "I should have" statements
-
Self-mutilation (cutting on yourself when angry)
-
Negative self-talk
-
Using angry behavior to control others
-
Thinking "I'm unique."
-
Explain how each thinking error you checked above is harmful to you and
others.
-
Give two examples of something that has happened since you stopped drinking
or using other drugs that shows you how your situation is improving.
-
Who or what is your Higher Power?
-
Why do you think your Higher Power can be helpful to you?
Step Three: "Made a decision to turn our will and our lives over to
the care of God as we understood Him."
-
Explain how and why you decided to turn your will over to a Higher Power.
-
Give two examples of things or situations you have "turned over" in the
last week.
-
List two current resentments you have, and explain why it is important
for you to turn them over to your Higher Power.
-
How do you go about "turning over" a resentment?
-
What does it mean to turn your will and life over to your Higher Power?
-
Explain how and why you have turned your will and life over to a Power
greater than yourself.
Step Four: "Made a searching and fearless moral inventory of ourselves."
-
List five things you like about yourself.
-
Give five examples of situations where you have been helpful to others.
-
Give three examples of sexual behaviors related to your drinking or use
of other drugs, which have occurred in the last 5 years, about which you
feel bad.
-
Describe how beating yourself up for old drinking and other drug-using
behavior is not helpful to you now.
-
List five current resentments you have, and explain how holding on to these
resentments hurts your recovery.
-
List all laws you have broken related to your drinking and use of other
drugs.
-
List three new behaviors you have learned that are helpful to your recovery.
-
List all current fears you are experiencing, and discuss how working the
first three Steps can help dissolve them.
-
Give an example of a current situation you are handling poorly.
-
Discuss how you plan to handle this situation differently the next time
the situation arises.
Adapted with permission from Evans, K., and Sullivan, J.M. Step Study
Counseling With the Dual Disordered Client. Center City, Minnesota: Hazelden
Educational Materials, 1990.
Exhibit 7-3
Recovery Model for the Treatment Of Borderline Personality Disorder
| Stage |
Indications |
Goal |
Interventions |
| I. Crisis |
Behavior out of control; risk of harm to self or others;
extreme withdrawal or intrusiveness |
Safety and health through structure and support |
-
Inpatient stay
-
Contracts for safety
-
Case manager or support groups
-
Identify triggers for relapse or stress to plan for crisis
-
Make daily or weekly schedule to structure time
|
| II. Building |
Routine attendance at therapeutic sessions, meetings, appointments;
some ability to stay focused on here and now |
Increasing coping skills and self-esteem |
-
Develop an assets or accomplishments list
-
Positive self-talk and affirmations
-
Skills training in time management, assertiveness, and so on
|
| III. Education |
Expresses, exhibits increased self-efficacy |
Reframe self-perceptions and history from victim to survivor |
-
Read or debrief clinician-prescreened ACOA or incest-survivor literature
-
Classes on dysfunctional families, survivor issues
-
Written assignments on strengths and limitations of "survivor behaviors"
|
| IV. Integration |
Able to express feelings |
Integrate past, present, and regulate thinking and actions
behaviors |
-
Art therapy, journal work, current feelings, thoughts, other expressive
modalities
-
Psychodynamic therapy, here-and-now interpretations
-
Grief and child-within work, marital, sex, or family therapy
|
Adapted with permission from Evans, K., and Sullivan,
J.M. Step Study Counseling With the Dual Disordered Client. Center City,
Minnesota: Hazelden Educational Materials, 1990.
Exhibit 7-4
Antisocial Thinking-Error Work
The group facilitator will present thinking errors and then ask each group
member to identify two thinking-error examples that apply to him or her
and to choose one to focus on with group help.
-
Excuse making -- Excuses can be made for anything and everything.
Excuses are a way to justify behavior. For example: "I drink because my
mother nags me," "My family was poor," "My family was rich."
-
Blaming -- Blaming is an excuse to avoid solving a problem and is
used to excuse behavior and build up resentment toward someone else for
"causing" whatever has happened. For example: "They forced me to drink
it!"
-
Justifying -- To justify an antisocial behavior is to find a reason
to support it. For example: "If you can, I can," "I deserve to get high,"
"I've got 30 days clean."
-
Redefining -- Redefining is shifting the focus on an issue to avoid
solving a problem. Redefining is used as a power play to get the focus
off the person in question. For example: "I didn't violate my probation.
The language is confusing and the order is full of typos."
-
Superoptimism -- "I think; therefore it is." Example: "I don't have
to go to AA. I can stay sober on my own."
-
Lying -- There are three basic kinds of lies: (1) lies of commission
-- making things up that are simply not true; (2) lies of omission -- saying
partly what is so, but leaving out major sections, and (3) lies of assent
-- pretending to agree with other people or approving of their ideas despite
disagreement or having no intention of supporting the idea.
-
"I'm Unique" -- Thinking one is special and that rules shouldn't
apply to one.
-
Ingratiating -- Being nice to others, and going out of one's way
to act interested in other people, can be used to try to control situations
or get the focus off a problem. Apple polishing.
-
Fragmented Personality -- Some people may attend church on Sunday,
get drunk or loaded on Tuesday, and then attend church again on Wednesday.
They rarely consider the inconsistency between these behaviors. They may
feel that they have the right to do whatever they want, and that their
behaviors are justified.
-
Minimizing -- Minimizing behavior and action by talking about it
in such a way that it seems insignificant. For example: "I only had one
beer. Does that count as a relapse?"
-
Vagueness -- This strategy is to be unclear and nonspecific to avoid
being pinned down on any particular issue. Vague words are phrases such
as: "I more or less think so," "I guess," "probably," "maybe," "I might,"
"I'm not sure about this," "it possibly was," etc.
-
Power Play -- This strategy is to use power plays whenever one isn't
getting one's way in a situation. Examples include walking out of a room
during a disagreement, threatening to call an attorney or report the group
facilitator to higher-ups.
-
Victim Playing -- The victim player transacts with others to invite
either criticism or rescue from those around him.
-
Grandiosity -- Grandiosity is minimizing or maximizing the significance
of an issue, and it justifies not solving the problem. For example: "I
was too scared to do anything else but sit," "I'm the best there is, so
no one else can get in my way."
-
Intellectualizing -- Using an emotionally detached, data-gathering
approach to avoid responsibility. For example, when faced with a positive
urine drug screen the patient states: "When was the last time the laboratory
had their equipment calibrated?" or "What is the percentage of error in
this testing procedure?"
Adapted with permission from Evans, K., and Sullivan, J.M. Step Study
Counseling With the Dual Disordered Client. Center City, Minnesota: Hazelden
Educational Materials, 1990.
Exhibit 7-5
Step Work Handout For Patients With Antisocial Personality Disorder
Step One: "We admitted we were powerless over alcohol -- that our
lives had become unmanageable."
-
Give five examples of ways you have tried to control your use of chemicals
and failed.
-
Give five examples of people you have tried and failed to control, and
explain why your controlling behavior was unsuccessful (minimum of 150
words each).
-
Give five examples of situations not associated directly with drinking
or using other drugs where you have tried to control things and failed
(minimum of 100 words each).
-
Give two examples of people who currently have control over you, and explain
how that is helpful to you (minimum of 100 words each).
-
Give ten examples of how your drinking and using other drugs caused you
problems (minimum of 25 words each).
-
Give five examples of negative consequences that await you should you continue
using or abusing alcohol or other drugs (minimum of 50 words each).
Step Two:"Came to believe that a Power greater than ourselves could
restore us to sanity."
-
Repeating the same mistake over and over when you continually receive negative
consequences is one definition of insanity. From the list below, identify
your "mistakes" (place a check mark on the line next to each "mistake"
that applies). Then, below the list, explain how each of these mistakes
in your thinking has caused you problems.
-
Excuse making
-
Minimizing
-
Blaming
-
Intentionally being vague
-
Using anger and threats
-
Superoptimism
-
Using power plays
-
Playing the victim
-
Making fools of others
-
Love for drama and excitement
-
Assuming what others think and feel
-
Not listening to others and being closed-minded
-
Thinking "I'm unique"
-
Maintaining an "image"
-
Being ingratiating (kissing up)
-
Being grandiose
-
Lying: commission, omission, assent
-
List three people with whom you are angry and explain how they can be helpful.
-
List five people more powerful than you who can help you stay clean and
sober. Explain why and how each person can help.
-
Who or what is your Higher Power?
-
Describe how this Higher Power can help you with your mistakes in thinking.
Step Three: "Made a decision to turn our will and our lives over to
the care of God as we understood Him."
-
How did you decide that you needed to turn your will over to a Higher Power?
-
Why is it important for you to turn your will and life over to a Higher
Power?
-
Explain how you go about "turning it over."
-
Give three examples of things you have had to "turn over" in the last week.
-
Give three examples of things you have yet to turn over and explain how
and when you plan to do so.
-
What does it mean to "turn your will and life over to your Higher Power"?
-
Without displaying any thinking errors, explain how and why you have turned
your will and life over to a Power greater than yourself.
Step Four: "Made a searching and fearless moral inventory of ourselves."
-
List any and all law violations you have committed regardless of whether
or not you were caught for these crimes.
-
List every person you have a resentment against, and explain how this resentment
is hurting you.
-
Give ten examples of sexual behavior you engaged in that was harmful to
your partner, and explain the negative consequences to you of this behavior.
-
Give five examples of aggressive behavior (either verbal or physical) you
have been involved in, and explain how it was hurtful to the other person
and to you.
-
List five major lies you have told, and explain how that lying was hurtful
to you.
-
List three lies you have told within the last 48 hours, and explain how
this lying hurts your recovery program.
Adapted with permission from Evans, K., and Sullivan, J.M. Step Study
Counseling With the Dual Disordered Client. Center City, Minnesota: Hazelden
Educational Materials, 1990.












Copyright © 2000, Southern Development Group,
S.A. All Rights Reserved.
A Private Non-Profit Agency for the good of all,
published in the UK & Honduras